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Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterised by 
altered stool frequency and/or consistency in addition to abdominal pain. There are four 
bowel pattern subtypes in IBS: diarrhoea predominant IBS (IBS-D), constipation 
predominant IBS (IBS-C), alternating bowel habit IBS (IBS-A) and unclassified IBS 
(IBS-U). IBS is a biopsychosocial syndrome and the predominant psychological 
treatment is cognitive behavioural therapy (CBT). The objectives of this PhD were (1) to 
assess whether cognitive and behavioural factors were mediators of treatment effect on 
the outcomes of symptom severity and work and social adjustment/quality of life, and 
(2) to identify whether cognitive and behavioural factors were associated with IBS 
bowel pattern subtypes. Two studies (studies one and two) were conducted to assess 
objective one, and two studies (studies three and four) were conducted to address 
objective two. Two data samples were used for analyses conducted in this thesis. Data 
set 1 was from a previously conducted randomised controlled trial (RCT) including IBS 
participants meeting Rome I criteria with a GP diagnosis of IBS. Data set 2 was from a 
new RCT including refractory IBS participants meeting Rome III criteria with a GP 
diagnosis of IBS.  
A systematic review (study one) of mediation analysis conducted in the context of 
psychological interventions for IBS returned nine studies. The results suggested that 
illness-related cognitions were important mediators of treatment effect for the outcomes 
of symptom severity and quality of life. Gastrointestinal (GI) specific anxiety was found 
to be a mediator more often than general anxiety was. Only two studies assessed the 
mediating role of behaviours. The study assessing GI related behaviours found them to 
significantly mediate treatment effect, but the other study assessing general all-or-
nothing behaviours did not find significant mediation. Study two utilised data set 1. It 
assessed simple and sequential mediation models in the context of an RCT assessing the 
effect of CBT + mebeverine to mebeverine alone on symptom severity and work and 
social adjustment in IBS participants (n=148). Simple mediation models found that 
general anxiety, GI related cognitions and GI safety behaviours mediated treatment 
effect on both outcomes. GI avoidance behaviour was not found to be a significant 
mediator. Sequential mediation models indicated that change in GI cognitions and GI 
safety behaviours preceded a reduction in general anxiety, and these sequential paths 
significantly mediated treatment effect on both outcomes.   
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Study three and four assessed differences in GI cognitions, GI safety behaviours, GI 
avoidance behaviours, general anxiety, work and social adjustment and symptom 
severity between IBS bowel pattern subtypes (IBS-A, IBS-C and IBS-D) using 
ANOVAs. IBS-U was excluded due to a disproportionately low number of participants 
in both studies classified as IBS-U. There was a significantly higher level of avoidance 
behaviours in the IBS-A and IBS-D subtypes than in IBS-C found in both studies. IBS-
A was also found to have significantly higher levels of safety behaviours than IBS-D in 
both studies. However, in study three those with IBS-A also had significantly higher 
safety behaviours than those with IBS-C, whereas in study four, those with IBS-C (along 
with IBS-A) had significantly higher safety behaviours than those with IBS-D. In study 
three there was a non-significant trend towards a greater level of unhelpful GI related 
cognitions in those with IBS-D compared to the other two subtypes and this was found 
to be a significant difference in study four.   
Together the results of this thesis suggest that cognitive and behavioural factors are 
important treatment mechanisms in IBS as well as potentially modifiable factors to help 
treatment targeting for particular IBS subtypes. Future directions for research should 
involve (1) mediation analysis including all process variables as identified by the CBT 
models of IBS (2) cluster analysis to identify subgroups in IBS classified by 
psychological factors in addition to bowel pattern predominance (3) assessment of 
moderated mediation to assess whether treatment mechanisms vary depending on 
subgroup membership in IBS. 
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1. Introduction to Irritable Bowel Syndrome  
1.1 Definition of IBS  
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder (FGID) 
characterised by both bowel and abdominal symptoms. It falls under the umbrella term 
of “medically unexplained symptoms/long term conditions” (MUS/LTC), which are 
characterised collectively as syndromes consisting of persistent physical symptoms with 
no clear physiological cause (Deary, Chalder, & Sharpe, 2007). Diagnostic criteria have 
been developed to provide definitive criteria for IBS. The Manning Criteria is a 
diagnostic criteria that has largely been superseded by the development of the Rome 
criteria (Drossman, 2016). The Manning Criteria identified six key symptoms that 
identified a diagnosis of IBS as distinct from other potential FGIDs. These included (i) 
visible abdominal distension (ii) pain relieved by a bowel action (iii) more frequent 
stools with the onset of pain (iv) looser stools with the onset of pain (v) rectal passage of 
mucus (vi) sensation of incomplete evacuation (Talley et al., 1990). The more symptoms 
present in an individual, the higher the likelihood of IBS. However the criteria did not 
suggest a threshold number of symptoms necessary for diagnosis and therefore 
diagnoses of IBS have been made with as little as two of the six symptoms present 
across research studies (Saito et al., 2000). 
 A more rigorous criterion for diagnosis in IBS called the “Rome criteria” was 
developed by a working group of clinical experts (Saito et al., 2000). Such criteria have 
been subsequently refined in numerous iterations based on continuing research and 
expert observations (Drossman et al., 2011). The most recent set of criteria is the Rome 
IV (Drossman, 2016). These stipulate that the experience of abdominal symptoms such 
as pain and/or bloating must be associated with altered bowel movements or stool 
consistency. These symptoms have to have been experienced a minimum of once a week 
consistently for at least six months, to constitute a diagnosis of IBS. There are three 
notable changes in the definition and characterisation of IBS in Rome IV compared to 
Rome III (Drossman, 2016). The first change relates to the removal of the term 
‘discomfort’ in application to abdominal pain. The Rome III stipulated that individuals 
must experience “abdominal pain or discomfort”. It was presumed that these terms 
described a continuum of abdominal pain severity, with ‘discomfort’ describing less 
severe pain. It has been shown however, that individuals interpret pain and discomfort as 
qualitatively different constructs, with discomfort potentially incorporating a range of 
symptoms (Shah, Bhatia, & Mistry, 2001). The Rome IV has therefore reduced 
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ambiguity, by using the term “pain” only, to describe the question regarding abdominal 
pain severity.  
The Rome III classification identified four IBS subtypes according to the proportion of 
stools that were hard/lumpy compared to those that were loose/watery (table 1.1). The 
four subtypes are constipation predominant IBS (IBS-C) (loose/watery stools <25%, 
hard/lumpy stools >25%), diarrhoea predominant IBS (IBS-D) (loose/watery stools 
>25%, hard/lumpy stools <25%), alternating/mixed pattern IBS (IBS-A) (loose/watery 
stools >25%, hard/lumpy stools >25%) and unclassified (IBS-U) (loose/watery stools 
<25%, hard/lumpy stools <25%). The Rome IV maintains these classifications of bowel 
pattern subtypes, however makes the important distinction that classifications are based 
on the proportion of symptomatic stools rather than all stools (i.e. stools when a-
symptomatic).  
The next change to the criteria was with specific regard to the relationship between IBS 
and other functional bowel disorders. Instead of identifying IBS, with its composite 
bowel pattern subtypes as distinct disorders, the Rome IV considers IBS to exist on a 
spectrum of symptom presentations. This change acknowledges that there are linked 
pathophysiological features of differing functional bowel disorders and that symptoms 
may overlap between different diagnostic criteria. The Rome IV explicitly states 
therefore that patients may transition across diagnoses or have combinations of 
diagnoses that could require overarching treatment approaches.  
A key limitation of the Rome criteria across all of the iterations is that it is not generally 
adopted in clinical practice to diagnose IBS (Moayyedi et al., 2017; Chang et al., 2018). 
A recent study found that only about a third of GPs in primary care across European 
countries regularly used the criteria for diagnosis of IBS (Mujagic et al., 2017). The 
result of this is often that patients with IBS receive a diagnosis by exclusion. This is 
described and discussed further in section 1.8.  
Table 1.1: ROME III classifications of IBS bowel subtypes 
 Stool Type 
Bowel Subtype Loose/Watery Hard/Lumpy 
IBS-D >25% <25% 
IBS-C <25% >25% 
IBS-A >25% >25% 




1.2 Physiology of the Digestive Process and IBS  
1.2.1 Normal gut digestion and motility  
Figure 1.1 depicts the gastrointestinal (GI) tract, which includes the key areas involved 
in digestion and GI motility. At the top of the figure is the oesophagus, which transports 
food from the mouth to the stomach. After each swallow, peristaltic (synchronised) 
contractions allow the sphincter between the oesophagus and the stomach to open, 
enabling the food to travel from one to the other. Once in the stomach, the food is 
ground down and mixed with digestive juices to allow later absorption when it reaches 
the small intestine. To achieve this, there are rhythmic synchronized contractions in the 
lower part of the stomach, which push waves of food and digestive juices against a 
closed pyloric sphincter muscle. The stomach then empties by moving the food into the 
small intestine at a controlled rate facilitated by further slow contractions.  Between 
meals, when the digestible content has left the stomach, further contractions occur, 
known as the migrating motor complex. These are occasional bursts of synchronised 
contractions that occur in conjunction with the opening of the pyloric sphincter muscle. 
They have the function of ridding the stomach of indigestible content. More, largely 
irregular, contractions occur in the small intestine, intended to move the food back and 
forth to mix it with digestive enzymes allowing absorption of the food. The contractions 
also move the contents of the small intestine to the large intestine (colon). It will usually 
take between 90 and 120 minutes to move the first portion of the meal that has been 
eaten, to reach the colon. The last portion of the meal may not reach the colon for five 
hours. Between meals the small intestine repeats a cycle of contractions every 90-120 
minutes. This cycle consists of a period without contractions, a period of 
unsynchronised contractions similar to those that appear after eating and then a period of 
strong peristaltic contractions.  
Discrete clustered peristaltic contractions may also occur at infrequent intervals in the 
upper small intestine. In addition to these, there are also giant migrating contractions, 
which are peristaltic over a long span of the intestine and may be part of a reflex that 
sweeps bacteria and food debris out of the intestine. In healthy people neither of these 
contractions cause substantial sensation or pain (Johnson et al., 2012). Contractions in 
the colon can be subdivided into non-peristaltic contractions, designed to move the 
contents of the colon back and forth to allow ultimate reabsorption of liquids, and high 
amplitude propagating contractions (HAPC), intended to move the contents forward. It 
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is these contractions that begin at the top of the colon and sweep round, down to the 
rectum producing a stool or urge to pass a stool.  
The enteric nervous system (ENS) is part of the autonomic nervous system (ANS). It is 
made up of 500 million neurons and located in the walls of the gastrointestinal tract, 
reaching from the oesophagus to the anus (Fichna & Storr, 2012). Although the general 
structure of the ENS is similar whether it is located in the oesophagus or the colon, it is 
not necessarily the case that it operates similarly in the different parts of the GI tract 
(Furness, 2008). The role of the ENS in IBS is presented in further detail below (1.4.1), 
however generally in healthy gut function the ENS is the mechanism by which 
contractions and gut function are coordinated with the central nervous system (CNS). 
“Efferent pathways” refer to the signalling channel from the CNS (brain) to the ENS 
(gut), whilst “afferent pathways” are the channels in reverse from the gut to the brain.  
1.2.2 Digestion and gut motility in IBS 
Gut function has been observed to differ in IBS compared to normal functioning in 
healthy controls (Tanaka, Kanazawa, Fukudo, & Drossman, 2011). There are two main 
ways that gut function is different in those with IBS: altered motility and altered 
perceptions/ experiences of gut sensations (Mach, 2004; Tanaka et al., 2011). In IBS, 
motility can be observed to differ from that of healthy controls, as there appears to be a 
disruption in peristaltic contractions, which have become desynchronized (Garnett, 
1999). Individuals with IBS-C have a decreased number of colonic contractions slowing 
gut transit, whereas individuals with IBS-D have a greater number of fast colonic 
contractions accelerating gut transit (Garnett, 1999; Mach, 2004). However, the exact 
patterns of motility responsible for IBS-D and IBS-C have not been established 
(Drossman, Camilleri, Mayer, & Whitehead, 2002).  
Abnormal contractions in the GI tract can also account, at least in part, for the 
abdominal pain experienced in IBS (Kellow & Phillips, 1987; Chey, Jin, Lee, Sun, & 
Lee, 2001; Drossman et al., 2002). Individuals with IBS who experience abdominal pain 
and diarrhoea have been shown to have significantly more clustered peristaltic 
contractions in the small intestine, which are of higher amplitude than those observed in 
healthy controls (Drossman et al., 2002). These types of contractions are thought to be 
associated with abdominal pain (Drossman et al., 2002) however there is little empirical 
evidence to support this assertion (Delvaux, 2002). The motility abnormalities may 
interact with low sensory thresholds to produce IBS symptoms. For example, the 
delayed transit of gas has been shown to increase abdominal perception in IBS (Serra, 
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Azpiroz, & Malagelada, 2001). Furthermore those with IBS perceive the occurrence of 
normal migrating motor complex significantly more than controls (Kellow, Eckersley, & 
Jones, 1991). An area of research in IBS, which is fast growing relates to the apparent 
visceral hypersensitivity within the bowels in IBS (Delvaux, 2002; Poitras, Poitras, 
Plourde, Boivin, & Verrier, 2002). Visceral hypersensitivity refers to the tendency to 
experience pain within the inner organs – in IBS, the GI tract – at a more intense level 
than the average individual (Delvaux, 2002; Drossman et al., 2002). Research has shown 
that individuals with IBS have enhanced visceral perception in various regions of the GI 
tract including the oesophagus, stomach and small intestine (Delvaux, 2002; Drossman 
et al., 2002). The potential mechanics and pathophysiology of visceral hypersensitivity 









1.3 Prevalence of IBS  
IBS is a particularly prevalent syndrome, estimated to affect between 10 and 22% of the 
UK population (Hellier, Sanderson, Morris, Elias, & De Caestecker, 2006) with a 
similar prevalence in the US (Hungin et al., 2008) and Europe (Quigley, Bytzer, Jones, 
& Mearin, 2006). Previously research has indicated that IBS has a higher prevalence in 
Western countries as opposed to non-Western countries (Husain et al., 2008). However, 
more recently it appears that the prevalence is increasing amongst these countries as 
individuals adopt a more ‘Western lifestyle’ (Gwee, 2005; Kang, 2005). This could 
suggest that cultural or dietary factors impact on the incidence of IBS. The role of social 
influences are considered in section 1.6.1. Variation in reported prevalence rates may 
also be in part due to the use of different diagnostic criteria (Hungin, Whorwell, Tack, & 
Mearin, 2003). In addition to the present and previous iterations of the Rome criteria, 
some studies utilise the Manning Criteria or rely on the use of self-identified IBS 
(Lovell & Ford, 2012b) and therefore estimations of prevalence can contrast quite 
substantially. A meta analyses of prevalence studies found that studies utilising the 
Manning Criteria had higher calculations of prevalence (Lovell & Ford, 2012b). This 
equated to a 14% prevalence rate as compared to 8.8% (Rome I) and 9.4% (Rome II). 
The study was conducted prior to the development of the Rome III or IV.  
1.3.1 Bowel pattern subtypes 
Studies assessing the prevalence using iterations of the Rome criteria have also varied in 
terms of the estimation of the prevalence of the specific bowel pattern subtypes. Until 
the Rome III criteria, IBS-A and IBS-U were not explicitly defined (Dorn et al., 2009), 
which may be another factor affecting estimates of subtype prevalence. However, a 
comparison of subtype prevalence across Rome I and II criteria found high agreement in 
terms of subtype classifications and stability (Dorn et al., 2009). Since the development 
of the Rome III criteria, research has generally demonstrated that IBS-A is the most 
prevalent subtype with IBS-U being the least common subtype (Guilera, Balboa, & 
Mearin, 2005; Longstreth et al., 2006; Su, Shih, Presson, & Chang, 2014). This is 
however highly variable across studies, with some finding that IBS-A is the least 
prevalent subtype (Engsbro, Simren, & Bytzer, 2012). The variability in IBS subtype 
distribution is said to be affected by geographical location, the particular population 
being sampled (e.g. female only, particular age, etc.) and the criteria employed to 
classify subtypes (Guilera et al., 2005). The validity of the bowel subtypes as identified 
by the Rome criteria has also been questioned. This is due to an inconsistency between 
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subtypes identified according to the Rome criteria and self-reported experience of 
subtypes (Hungin et al., 2003). For example, the rate of IBS-A was found to be much 
higher using Rome II (63%) when compared to self-report (21%) (Hungin et al., 2003). 
This perhaps questions the utility of the Rome criteria in classifications of bowel pattern 
subtypes. There may also be inconsistency in bowel pattern subtypes within individuals 
as studies have demonstrated that individuals can transition across the different bowel 
pattern subtypes (Mearin et al., 2004; Guilera et al., 2005). It has been predicted that the 
Rome IV criteria may further change the distributions of the classifications, potentially 
reducing the amount of individuals identifying as IBS-U (Drossman, 2016).  
1.3.2 Female predominance  
There appears to be consistency across studies utilising different diagnostic criteria, in 
identifying a female predominance in IBS (Kang, 2005; Lovell & Ford, 2012a, 2012b).  
A gender difference in prevalence across the IBS subtypes has also been shown in a 
meta-analysis assessing gender differences in IBS (Lovell & Ford, 2012a). IBS-C was 
more common in women and IBS-D was more common in men (Lovell & Ford, 2012a), 
while IBS-A was generally equally distributed across genders. The pooled prevalence of 
IBS-C was 40% for women, compared to 21% in men. In contrast the prevalence of 
IBS-D in women was 31% compared to 50% in men. Whilst some studies have 
indicated that geography does not affect the female predominance in IBS (Kang, 2005), 
other research has suggested that prevalence of IBS in women was not significantly 
higher in studies conducted in South Asia, South America or Africa (Lovell & Ford, 
2012a). Nevertheless, the authors concluded that a modestly higher prevalence in 
women than men is generally stable according to geography.  
1.3.3 Age 
In addition to gender, age is another factor found to affect the prevalence of IBS. In most 
studies the IBS prevalence rate declines with age (Kang, 2005). The odds of IBS in 
those aged 50 years or older was significantly lower than in those younger than 50 years 
(OR, 0.75; 95% CI, 0.62-0.92) (Lovell & Ford, 2012b). Although IBS has been found to 
occur in all age groups including children, adolescents and the elderly, it has been found 
that 50% of individuals with IBS report first experiencing symptoms before the age of 
35 years old (Canavan, West, & Card, 2014).  
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1.3.4 Socioeconomic status 
Unlike age, there is limited research reporting the prevalence of IBS according to 
socioeconomic status. In the 2012 meta-analysis, pooled data from the only four studies 
reporting on socioeconomic status in IBS, suggested that there was no significant 
difference in prevalence in high compared to low socioeconomic groups (Lovell & Ford, 
2012b). Since the review, however, there have been further studies reporting on this 
with contradictory findings (Canavan et al., 2014). While one study suggested IBS was 
associated with low socioeconomic status, two other studies suggested the opposite, 
showing a higher prevalence of IBS amongst those who have a higher socioeconomic 
group during childhood (Canavan et al., 2014). Although the evidence is limited, the 
authors postulate that the results could indicate that greater internalisation of stress that 
comes with a particular kind of work and role in higher earning groups, has a role in the 
onset and/or maintenance of IBS symptoms. Identifying groups and areas in which IBS 
is more or less prevalent is important for building an understanding of aetiology in IBS.    
1.4 Biopsychosocial Aetiological Understanding of IBS  
The aetiology of IBS is largely accepted to be of biopsychosocial origin (Drossman, 
2016). This conceptualises the pathogenesis and clinical experience of IBS as an 
interacting mixture of biological, psychological and social factors. Figure 1.2 depicts the 
biopsychosocial model of IBS. It illustrates how individuals may have a number of 
factors predisposing them to developing IBS. These factors may be biological (genetics), 
psychological (personality factors, trauma) or social (culture and environment). 
Predisposing factors interact with precipitating factors, which may also be biological, 
psychological or social, in nature (figure 1.2). For example a bout of gastroenteritis may 
trigger the initial onset of IBS in an individual who has grown up in an environment that 
regards bowel symptoms as shameful or overly focuses on bowel movements. IBS 
symptoms are then perpetuated by a cycle of biopsychosocial factors, such as increased 
sensitivity, altered immune function, unhelpful cognitions regarding symptoms, anxiety, 
unhelpful behavioural responses and perceived social support.  
The framework of understanding IBS has been important in establishing 
interdisciplinary treatment approaches for IBS (Drossman, 2016). The model 
demonstrates how there can be substantial variability of the different factors involved in 
onset and maintenance of IBS across individuals. This is better understood through 
consideration of the separate spheres of aetiology: biological, psychological and social, 
which are considered in more detail below. A physiological system by which interaction 
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of these three spheres may occur is referred to as the “brain-gut axis” (BGA) (Jones, 




Figure 1.2: Biopsychosocial Model of IBS (Halpert & Drossman, 2005)  
1.4.1 Brain-gut axis  
The Brain-Gut Axis (BGA) is a term used to refer to the bidirectional communication 
network between the central nervous system (CNS) and the enteric nervous system 
(ENS). The CNS comprises the brain and spinal chord, and neuronal signalling allows 
communication between structures within the network. The CNS coordinates and 
controls most functions of the body and the mind. The ENS has been called the ‘second 
brain’ as it has the ability to act autonomously from the other arms of the nervous 
system (Furness, 2008). It is also able to integrate information in the same way as the 
brain does, without CNS input, due to the fact that it includes efferent neurons, afferent 
neurons and interneurons (Mayer, 2011). Efferent neurons carry information from the 
CNS to organs and muscles throughout the body, while afferent neurons carry 
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information from organs and muscles to the CNS. Interneurons transmit impulses 
between neurons allowing decisions on whether incoming signals warrant response 
(Mulak & Bonaz, 2004). As such the ENS can receive and send information to the CNS 
as well as integrating different information and adapting signalling accordingly.  
The two key brain regions of importance in the CNS with regards to IBS, are the limbic 
system and the prefrontal cortex (PFC) (Jones, Dilley, Drossman, & Crowell, 2006). The 
limbic system is also referred to as the ‘emotional motor system’, ‘emotional brain’ and, 
prior to that, the ‘visceral brain’ due to its role in emotion formation and regulation 
(Mach, 2004). The limbic system is anatomically comprised of the amygdala, 
hypothalamus, medial thalamus and anterior cingulate cortex (Jones et al., 2006). The 
amygdala is heavily involved in emotional processing including the formation of 
emotionally conditioned responses (e.g. fearful avoidance), the consolidation of 
emotional memories and the processing of social signalling of emotions (e.g. facial 
expressions or posture) (LeDoux, 2000; Dalgleish, 2004). Together with the amygdala 
the thalamus processes information about incoming sensory signals to determine 
perception of threat (Jones et al., 2006).  
The hypothalamus provides a link between the CNS and the ANS, which is the part of 
the nervous system that orchestrates the automatic stress response. In addition to the 
ENS, there are two other branches of the ANS. These are the sympathetic nervous 
system (SNS) and the parasympathetic nervous system (PNS). The SNS prepares the 
body for intense physical activity as in the ‘fight or flight’ stress response, while the 
PNS regulates general autonomic functioning (e.g. digestion, defecation, urination and 
heart rate) to keep the body operational. The PNS is responsible for inhibiting high-
energy processes triggered by the SNS. During the stress response, the SNS is activated 
by the amygdala registering a threat and sending signals to the hypothalamus. It is the 
hypothalamus that allows communication with the rest of the body as it fires neurons to 
activate the adrenal glands. The adrenal glands respond by releasing the hormone 
epinephrine (also known as adrenaline) into the blood stream. This causes a number of 
physiological changes, such as increased heart rate and blood pressure, increasing blood 
flow to particular organs and muscles including the bowels. Epinephrine also triggers 
the release of blood sugar and fats from temporary storage into the blood stream 
allowing increased energy to all parts of the body. This initial ‘fight or flight’ process in 
response to stress is known as the sympathetic adrenal medullary (SAM) system. The 
initial stress response can therefore have a direct effect on gastric motility, which can be 
disrupted in the process of altered autonomic processes.   
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The second component of the stress response system is also activated by the 
hypothalamus. This is known as the Hypothalamic-Pituitary-Adrenal (HPA) axis, and is 
activated as the initial surge of epinephrine subsides. If the amygdala continues to 
register a threat after the initial response, the hypothalamus will release corticotropin-
releasing hormone (CRH), which travels to the pituitary gland and triggers the release of 
adrenocorticotropic hormone (ACTH). In turn this travels to the adrenal glands and 
prompts the release of the stress hormone cortisol. This has the effect of keeping the 
body on high alert and vigilant to potential perceived threats. Together, the amygdala 
and the hypothalamus therefore have a key role in threat perception and stress response 
activation.  
The anterior cingulate cortex (ACC) is the other key brain area within the limbic system 
that has been implicated as an important component of the BGA in IBS (Morgan, 
Pickens, Gautam, Kessler, & Mertz, 2005; Jones et al., 2006; Hall et al., 2010; Tillisch 
& Labus, 2011; Kennedy et al., 2012). The ACC is said to have a ‘cognitive’ dorsal 
subdivision and an ‘affective’ ventral subdivision, which is also called the perigenual 
ACC (pACC) (Jones et al., 2006). Increasingly research suggests that the ACC monitors 
the functional state of the body and detects any new information that may cause conflict 
and give rise to affective or emotional consequences (Bush, Luu, & Posner, 2000; 
Dalgleish, 2004). It therefore integrates visceral, attentional and affective information, 
and when potential conflicts are detected, the ACC signals to the PFC (Jones et al., 
2006). 
The PFC has a wide variety of functions and is often termed the ‘executive control 
centre’. This is because it is responsible for integrating together multiple sources of 
informational input from different areas of the brain. It uses the integrated information 
as a basis for decision-making processes and planning (Jones et al., 2006). In the context 
of the BGA, the PFC’s role is to form integrated multisensory representations about gut 
function homeostasis, food intake and visceral pain (Mayer, 2011). The BGA therefore 
is an important network to maintain the healthy regulation of food intake, digestion, 
motility and gut sensations (Fichna & Storr, 2012).  
Disruptions within the BGA at any level, whether structural or functional can therefore 
result in FGIDs such as IBS (Mach, 2004; Jones et al., 2006; Mayer, 2011; Fichna & 
Storr, 2012; Kennedy et al., 2012). In IBS both gut motility and abdominal 
pain/hypersensitivity may be due to dysfunction in the BGA. Researchers have 
suggested that disruption in the BGA may be the result of alterations in the ENS (bottom 
up model) or the result of alterations affecting the CNS (top down model) (Mulak & 
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Bonaz, 2004). It is also possible that IBS symptoms are produced by a combination of 
both. The ENS, when functioning correctly, is programmed to provide local reflexes 
such as the migrating motor complex and the peristaltic reflex (section 1.2, physiology 
of IBS). A disruptive stimulus in the gut such as an infectious event, or the presence of 
food or bile acids, can therefore trigger an alarm signal to the CNS (Mach, 2004; Mulak 
& Bonaz, 2004). This would be an instance of bottom up BGA disruption. As such 
physiological factors can have a causative role in IBS. These are considered further 
below. Top down processing involves the CNS transmitting inhibitory efferent signals to 
inhibit the afferent pain signals (i.e. pain signals coming from the gut). The CNS’s 
prioritization of the amplification or diminishment of pain signals is dependent on 
relevant environmental and internal perceptions (Jones et al., 2006). As such it is likely 
that the bidirectionality of transmissions along the BGA allow both the CNS and ENS to 
work in tandem in order to determine both pain sensations and motility in IBS (Mayer, 
2011; Mayer & Tillisch, 2011; Tillisch & Labus, 2011; Fichna & Storr, 2012). 
Furthermore, as the limbic system is implicated in the integration of emotional, visceral 
and attentional information, cognitive, behavioural and emotional factors are likely to 
impact on the dispersal of inhibitory efferent pain signals determined by these brain 
regions (Jones et al., 2006). 
1.5 Biological/Physiological Aetiological Factors 
1.5.1 Visceral hypersensitivity 
Visceral hypersensitivity has been identified as a characteristic amongst individuals with 
IBS, and one that may be involved in the pathogenesis of abdominal pain that is 
experienced in IBS. To date the exact cause of visceral hypersensitivity in IBS is 
unknown (Delvaux, 2002). A method of assessing pain thresholds in the bowels is called 
‘barostat distension’ in which a balloon is inserted into the colon and slowly inflated to 
different pressure levels. The exercise is known to cause abdominal pain, which is 
thought to be the result of the direct impact of the balloon on the internal walls of the 
colon. One seminal study introduced this technique in the context of IBS, finding that 
individuals with IBS reported pain when the balloon was at a lower volume than healthy 
controls (Ritchie, 1973). This study has since been replicated in a number of studies that 
corroborate these findings showing that in 50-70% of IBS patients the threshold for 
reporting pain is below that of healthy controls (Drossman et al., 2002).  
This observable sensitisation may be caused by peripheral mechanisms localised to the 
bowels involving afferent signalling from the ENS to the CNS (Halpert & Drossman, 
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2005; Azpiroz et al., 2007). It may also be the result of central sensitisation in the CNS 
whereby signalling between the brain and the gut becomes hyperactive and abdominal 
activity and sensation is inappropriately exaggerated (Halpert & Drossman, 2005; 
Azpiroz et al., 2007). Support for peripheral sensitisation as opposed to central 
sensitisation comes from the fact that visceral pain hypersensitivity is generally limited 
to sensitivity in the viscera (i.e. the organs) and not extended to the somatic system (i.e. 
tissue pain) in IBS (Cook, van Eeden, & Collins, 1987; Accarino, Azpiroz, & 
Malagelada, 1995). This may suggest that the mechanism is localised rather than 
centralised (Azpiroz et al., 2007). Furthermore IBS is known to occur after irritation of 
the gut by infectious agents (Gwee et al., 1999; Mearin et al., 2005). Establishing that 
exaggerated signals from the gut cause the visceral sensitivity demonstrated in IBS, is 
difficult due to the fact that there are no valid instruments able to assess the signal at the 
level of the gut or spinal chord (Azpiroz et al., 2007). 
The alternative hypothesis that disruption in particular brain circuits involving the limbic 
system and prefrontal cortex are involved in the central modulation of visceral 
hypersensitivity in IBS, is informed by the field of somatic pain research (Verne & 
Price, 2002; Azpiroz et al., 2007; Zhou & Verne, 2011). There appear to be two main 
neural networks that have been shown to function abnormally in brain imaging studies 
of visceral pain in IBS (Kennedy et al., 2012). These include the emotional-arousal 
network, which is heavily implicated in the BGA and the lateral prefrontal regions of the 
descending pain inhibitory network (limbic system and PFC, amongst other regions 
beyond the scope of this thesis), which also interact with the BGA (Tillisch & Labus, 
2011). Both of these networks are impacted by and involved in affective responses such 
as threat processing, fear (Halpert & Drossman, 2005; Azpiroz et al., 2007; Tillisch & 
Labus, 2011; Kennedy et al., 2012) and cognitions, such as anticipatory processes, 
attentional control and reappraisal (Tillisch & Labus, 2011; Kennedy et al., 2012). 
Psychosocial factors are therefore pertinent to the development of visceral 
hypersensitivity.  
There is also the likely possibility that both peripheral and central sensitisation can have 
a role in the pathophysiology of IBS, rather than the two hypotheses being mutually 
exclusive. It is important to acknowledge that visceral hypersensitivity is but one aspect 
of IBS and not one that is universal to everyone who has IBS (Azpiroz et al., 2007; Zhou 
& Verne, 2011). Furthermore, the experience of visceral hypersensitivity itself, within 
IBS, is also heterogeneous. While for some individuals it is localised to a particular part 
of the GI tract, for others it may be distributed across the entire GI area. Consequently, 
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the extent to which understanding the pathophysiology of visceral sensitivity can inform 
our aetiological understanding of IBS is limited. What the evidence for both peripheral 
and central sensitisation shows, is that both physical (e.g. infectious event) and 
psychological factors (e.g. affective arousal) can trigger such sensitisation (Halpert & 
Drossman, 2005; Azpiroz et al., 2007; Tillisch & Labus, 2011; Kennedy et al., 2012)   
1.5.2 Gut microbiota 
In the last ten years there has been an increase of research into the role of gut 
microbiota, with particular focus on its potential aetiological role in IBS (Cryan & 
Dinan, 2012). Gut microbiota is the term given to a dense microbial ecosystem 
consisting of bacterial cells. In healthy individuals there is estimated to be around 195 
bacterial strains (Collins, 2014). Healthy gut microbiota are characterised by diversity in 
strains and stability in the balance across them. “Dysbiosis” refers to the loss of 
microbial diversity and temporal instability, which is advocated as a potential cause of 
bowel dysfunction (Collins, 2014; Ringel & Ringel-Kulka, 2015). However it is 
acknowledged in a recent review of the role of microbiota in IBS, that dysbiosis is 
unlikely to account for all instances of IBS (Collins, 2014). This is because not all 
individuals with IBS have abnormal bacterial counts compared to healthy controls 
(Posserud, Stotzer, Björnsson, Abrahamsson, & Simrén, 2007; Öhman & Simrén, 2010).  
Evidence that gut microbiota may have a role in the expression of IBS primarily comes 
from animal studies. These have demonstrated that antibiotic-induced dysbiosis resulted 
in changes to gut motility (Collins & Bercik, 2009; Anitha, Vijay–Kumar, Sitaraman, 
Gewirtz, & Srinivasan, 2012; Chassard et al., 2012) as well as increases in visceral pain 
responses in barostat distension (Verne & Price, 2002; Verdu et al., 2006). Microbiota 
have been shown to exert effects on gut motility and sensitivity at different levels within 
the BGA with bidirectional effect (Moloney et al., 2016). This means that as well as 
impacting on gut physiology, the microbiota can also affect mood and cognition (Cryan 
& Dinan, 2012; Collins, 2014; Moloney et al., 2016). Rat and mice studies compare 
germ-free rodents with abnormally low levels of gut microbiota to control counterparts 
with normal gut microbiota levels. Such studies have found that germ-free mice have an 
exaggerated release of ACTH (stress hormone) when exposed to mild stress (Cryan & 
Dinan, 2012), display changes in emotive behaviour (Cryan & Sweeney, 2011; Collins, 
2014) and display deficits in non-spatial and working memory tasks (Gareau et al., 
2010). As such microbiota may not only contribute to changes in gut functioning and 
sensations but also contribute to changes in anxiety, cognitions and behaviour (Collins, 
2014). Importantly, there are multiple physiological and psychological factors that affect 
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gut microbiota levels. These include psychological stress, diet and the administration of 
antibiotics (Cryan & Dinan, 2012; Collins, 2014; Distrutti, Monaldi, Ricci, & Fiorucci, 
2016; Moloney et al., 2016). 
1.5.3 Genetics 
It has been suggested that there is a hereditary component to IBS. Studies have found 
that there is a concordance rate of 17.3% in monozygotic (identical) twins and 8.4% in 
dizygotic twins (Levy et al., 2001). Whist this would support the assertion that there 
may be a predisposing genetic role in IBS, it would also suggest that there are other 
factors involved. This is because the concordance rate is not 100% or even close, 
demonstrating a variability in the onset of IBS that is unaccounted for. The literature 
examining the extent of genetics in the aetiology of IBS, generally accepts that whilst 
there may be a contribution of genes to the development of IBS, complex 
biopsychosocial interactions are also involved (Saito, 2011) 
1.6 Social Aetiological Factors 
1.6.1 Social learning & environmental influences 
The study by Levy et al compared the probability of having a mother with IBS with the 
probability of having a co-twin with IBS for monozygotic (MZ) twins with IBS (Levy et 
al., 2001). Monozygotic twins have 100% the same genetics, whereas mothers share 
approximately 50% of genes with their children. Therefore, from a genetic point of view 
the probability that the mother of an MZ twin has IBS should be lower than the 
probability that the MZ co-twin has IBS. However, the findings indicated that having a 
mother with IBS accounted for as much variance as having an identical set of genes with 
an MZ co-twin who has IBS. This would indicate that the contribution of social learning 
to IBS is at least as great as the contribution of heredity. Social learning in this context 
includes both the likelihood for children to observe and display parental behaviours 
(modelling) and the conditioning of behaviours by parental reinforcement. There is 
evidence for both types of learning in IBS (Van Oudenhove et al., 2016).  
Evidence for modelling comes from studies showing a strong association between 
parental anxiety and somatization and children’s abdominal symptoms (Walker, Garber, 
& Greene, 1991; Campo et al., 2007; Seino et al., 2012). Research in the wider context 
of functional illness and somatic complaints examining the social learning hypothesis 
that illness behaviour can be learned, lends support to the notion that this can occur in 
IBS (Scharff, 1997). An example of social learning IBS illness behaviours would be if a 
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child observed their mother or father’s tendency to pay close attention to their 
abdominal sensations. The child would learn that monitoring such sensations is 
important and the consequent behaviour (such as going to the toilet for long periods) 
may also be learned.  
The basic principle of positive reinforcement is the rewarding of a behaviour that 
increases the likelihood of the same behaviour to occur again. Behavioural 
reinforcement in IBS may occur where a child expresses worry about a particular 
symptom and the parent/s may reward this with increased attention, sympathy or 
indulgence. In an experimental study, parents were asked to either show positive and 
sympathetic responses to their children’s pain or to ignore it (Walker et al., 2006). The 
frequency of pain complaints were higher in the positive/sympathetic group than the 
group instructed to ignore the children. This demonstrated that when the complaining 
behaviour was rewarded, it was reproduced. Outside of experimental settings, it has also 
been shown that children whose mothers reinforce illness behaviour, experience more 
severe stomach aches and more school absences than other children (Levy et al., 2001). 
1.6.2 Early adverse life events  
Early adverse life events are traumatic experiences during childhood that encompass 
physical, emotional or sexual abuse as well as conflicting relationships with the primary 
care giver or loss of a parent (Bradford et al., 2012). In comparison to controls, 
individuals with IBS have a significantly higher reported prevalence of early adverse life 
events than healthy controls (Bradford et al, 2012). In particular the instances of 
physical, emotional and sexual abuse are much higher than reported in healthy control 
groups (Bradford et al, 2012). Other studies have similarly demonstrated that there is a 
high prevalence of sexual abuse history within the IBS population (Drossman, Talley, 
Leserman, Olden, & Barreiro, 1995; Ross, 2005). The mechanism by which such events 
may have a role in the onset of IBS is likely to involve the BGA and stress response 
systems (Halpert & Drossman, 2005). The onset of IBS is likely associated with the 
increased psychological stress that occurs in the face of these traumatic events (Van 
Oudenhove et al., 2016) 
1.7 Psychological Aetiological Factors   
1.7.1 Stress and psychological distress 
Psychological stress is commonly identified within the literature (Drossman et al., 2002; 
Drossman, 2016) and by patients (Håkanson, 2014) as a probable trigger of IBS. 
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Psychological stress occurs when an individual perceives that environmental demands 
exceed their capacity to cope with them (Cohen, Janicki-Deverts, & Miller, 2007). 
Psychological stress and psychological distress are rarely teased apart conceptually, as 
they are highly interconnected (Ridner, 2004). Psychological distress can be understood 
as the emotional reaction that accompanies the experience of perceived stress (Cohen, 
Kamarck, & Mermelstein, 1994). For the purposes of discussing the aetiological role of 
stress in IBS, the term “stress” will be used to refer to the experience of psychological 
stress that is psychologically distressing.  The hypothesis is that both intense periods of 
acute stress and chronic levels of stress can cause abnormal functioning in the bowel 
because of the close connection between the brain and the gut (Tanaka et al., 2011; 
Lovell & Ford, 2012b; Drossman, 2016; Van Oudenhove et al., 2016).  While the effects 
of stress on gut function is not specific to those with IBS and are observable in healthy 
controls (Murray et al., 2004), research suggests that individuals with IBS may have a 
greater reactivity to stress (Drossman, 2005; Chang, 2011). This has been investigated 
using brain-imaging studies (Drossman, 2005), measures of CNS functioning (Fukudo 
& Suzuki, 1987; Patacchioli, Angelucci, Dell’Erba, Monnazzi, & Leri, 2001; Berman et 
al., 2002; Posserud et al., 2004) such as the comparison of salivary cortisol of IBS 
patients compared with healthy controls (Patacchioli et al., 2001) and psychological self 
report measures (Whitehead, Crowell, Robinson, Heller, & Schuster, 1992). 
Furthermore stress has been associated with the onset of IBS symptoms (Drossman et 
al., 2002; Chang, 2011) with high levels of perceived stress identified as a risk factor for 
those with gastroenteritis to develop IBS (Spence & Moss-Morris, 2007).  
1.7.2 Precipitating affective disorders  
While it is established that there is a high co-morbidity of anxiety and depression in IBS 
(presented in section 1.10.2), it has also been postulated that these affective disorders 
may have a predictive role. Along with high levels of perceived stress, anxiety was also 
found to be a significant risk factor for developing IBS after a bout of acute 
gastroenteritis (Spence & Moss-Morris, 2007). A recent meta-analysis combined the 
results of studies assessing anxiety and depression as risk factors for the onset of IBS 
and found that self-reported anxiety and depression provided a twofold risk for IBS 
onset (Sibelli et al., 2016). Both anxiety and depression appeared to play a stronger role 
in IBS onset for individuals with a gastrointestinal infection rather than individuals 
assessed in the general population. However, this difference could be attributed to 
differences in methodologies between these two types of study.  
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1.8 Diagnostic Procedures of Exclusion  
The NICE guidance on the diagnosis of IBS recommends that individuals meeting the 
Rome criteria, also undergo some further tests to exclude other potential diagnoses such 
as inflammatory bowel disease or coeliac disease (Dalrymple & Bullock, 2008).  These 
tests of exclusion are blood tests, which include a full blood count, c reactive protein 
(CRP), erythrocyte sedimentation rate (ESR) or plasma viscosity (PV) and antibody 
testing such as tissue transglutaminase (TTGA) or endomysial antibodies (Dalrymple & 
Bullock, 2008). A full blood count test is conducted to check for anaemia or other 
potential abnormalities that may account for symptom experience. CRP tests and ESR or 
PV tests are conducted to detect inflammation, which could be indicative of 
inflammatory bowel disease, while antibody testing such as TTGA is used to detect a 
potential diagnosis of coeliac disease. Should all of the blood tests be within the normal 
ranges, clinicians are advised to provide a diagnosis of IBS (Dalrymple & Bullock, 
2008). It is however not uncommon for one of the tests to fall out of the normal ranges 
and require retesting (Spiegel, Farid, Esrailian, Talley, & Chang, 2010). If the individual 
is suffering with a virus, cold or other infection, they may have elevated CRP levels, for 
example. This would mean that individuals are required to have a retest to assess 
whether this was the cause of the elevation or whether further investigation is necessary.  
Nice guidance also recommends that clinicians assess for ‘red flag’ symptoms that may 
be indicative of a serious organic disease (Dalrymple & Bullock, 2008). These red flag 
symptoms include unintentional and unexplained weight loss, rectal bleeding, a family 
history of bowel cancer or ovarian cancer or, for patients aged 60 or over, a sudden 
change in bowel habit to looser and/or more frequent stools that have persisted for more 
than 6 weeks. In addition to the suggested tests, individuals may opt to pay for further 
tests privately. Such tests may include ultrasonography, colonoscopy, thyroid function 
test, microscopy and culture for faecal ova and parasite or hydrogen breath tests for 
lactose intolerance and bacterial overgrowth. These tests are said not to be necessary for 
a diagnosis for IBS (Dalrymple & Bullock, 2008) however, patients frustrated with 
symptoms may pursue alternative methods of diagnosis and treatment (Bertram, 
Kurland, Lydick, Locke, & Yawn, 2001; Dhaliwal & Hunt, 2004; Quigley et al., 2006; 
Håkanson, 2014). 
Actual patient experience of diagnosis is rarely as straight forward as the 
recommendations by NICE (Spiegel et al., 2010). Physicians may be anxious about 
providing a diagnosis that overlooks alternative diagnosis and consequently suggest 
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more tests, favouring a diagnosis of IBS by exclusion (Spiegel et al., 2010). It can 
therefore take a long time for individuals to receive a formal diagnosis of IBS, which 
can be upwards of 10 years in some cases (Meadows, Lackner, & Belic, 1997).  In some 
cases individuals experiencing IBS may never receive a formal diagnosis from the 
doctor whereby they are definitively told that their symptoms are due to IBS (Hungin, 
Chang, Locke, Dennis, & Barghout, 2005). In these cases, individuals may have on their 
medical records a label of IBS, which may not have been adequately communicated to 
them (Owens, Nelson, & Talley, 1995; Chang et al., 2006).  
One of the effects of having a diagnosis by exclusion is that individuals with an organic 
bowel disease such as inflammatory bowel disease (IBD) are unlikely to be diagnosed 
with IBS. There is both merit and disadvantages to this. Patients with IBD, who are not 
yet aware of their diagnosis are safeguarded by the process of diagnosis by exclusion. 
However, where patients are aware of their organic bowel conditions, it may be 
beneficial to receive an additional diagnosis of IBS. This would apply when the 
experience of particular symptoms such as persisting pain and urgency are not purely 
attributable to their primary diagnosis (Grover, Herfarth, & Drossman, 2009). Receiving 
an additional diagnosis of IBS may provide additional opportunity for symptom 
management outside of pharmacological treatments, utilising psychological techniques 
shown to be effective in IBS. In the long-term conditions literature, it is has been argued 
that the extent to which a symptom has an organic or ‘non-organic’ cause is irrelevant 
beyond the point of the likelihood of progressing physical damage (Grover et al., 2009). 
Persisting physical symptoms with known organic cause, can be managed in the same 
way as physical symptoms with unknown organic origins. Both involve the use of 
techniques to minimize the impact of such symptoms on everyday functioning and 
quality of life (Grover et al., 2009; Chacko, 2013; Coventry et al., 2015; Valovska, 
2016).   
1.8.1 The Necessity of a Diagnostic Criteria Specifically for IBS 
Although it may be argued that IBS could be diagnosed using the Diagnostic and 
Statistical Manual 5 (DSM-5) under the criterion specified for ‘Somatic Symptom 
Disorder’, which no longer distinguishes between medically unexplained symptoms and 
organic disorder,  (American Psychiatric Association, 2013; Regier, Kuhl, & Kupfer, 
2013), . The diagnostic criteria for Somatic Symptom Disorder include: 
A. One or more somatic symptoms that are distressing or result in a significant 
disruptions of daily life.  
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B. Excessive thoughts, feelings or behaviours related to the somatic symptoms  
C. A persistent state of being symptomatic, even though the symptom may not be 
continuously present 
While patients with IBS are likely to meet this criteria, there are important advantages to 
instead applying a more tailored criteria to diagnose IBS. A primary advantage being the 
perception of the syndrome by healthcare professionals. As the Rome criteria is 
biopsychosocially informed, it establishes a role for pharmacological treatment methods 
in IBS as well as psychological methods (Drossman., 2016). This is important because 
evidence suggests that the symptoms of IBS can be managed with medications such as 
antispasmodics or low dose antidepressants (Ford et al., 2009; Spiller et al., 2007). 
Should this guidance not be in place, it may limit effective treatment options for patients 
and increase the burden on already stretched resources for psychological treatments.  
The Rome criteria therefore makes primary care treatment more accessible for patients, 
which is important given the high prevalence of IBS symptoms.  
An additional consideration is the stigma that may come with a diagnosis that is 
determined by a manual for ‘mental disorders’. This may inhibit healthcare 
practitioners’ tendencies to provide a diagnosis of ‘somatic symptom disorder’ in place 
of irritable bowel syndrome. Reluctance of healthcare providers to provide such a 
diagnosis can be seen elsewhere in the literature (Dimsdale et al., 2013; Rief & Martin, 
2014). The consequence of this would be to create more uncertainty in patient prognosis 
and treatment journeys, which would likely impact on symptoms detrimentally.  
A final issue with using the DSM-5 criteria in place of the Rome Criteria for IBS, is that 
such criteria are not sufficiently tailored to the symptoms and experience of IBS 
(Klemm et al., 2018). As such, the procedures for diagnosis do not guide clinicians to 
check for ‘red flag’ symptoms, to guard for risk of a more serious bowel disease. 
1.9 Patient Experience  
The result of potentially lengthy and perceivably unhelpful diagnostic procedures and 
healthcare consultations, is that individuals with IBS can often feel frustrated with 
healthcare services and professionals (Håkanson, 2014) as well as uncertain about their 
symptoms and health (Owens et al., 1995; Rønnevig, Vandvik, & Bergbom, 2009).  It is 
not currently understood what distinguishes those that seek healthcare from those who 
do not. However one review postulated that psychosocial factors are important (Koloski, 
Talley, & Boyce, 2001). The authors suggested that healthcare seeking behaviour in IBS 
could be divided into three categories (1) non-consulters (2) sporadic consulters (3) 
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frequent consulters. Non-consulters were characterised as having greater coping 
abilities, but also potentially greater embarrassment and abnormal illness attitudes. 
Sporadic consulters were said to experience greater levels of distress and life events 
whilst those frequently consulting healthcare services had potential psychiatric co-
morbidities, history of abuse and poor social support. The proposed model, although 
based on the results of a comprehensive review, has not been prospectively tested. 
Nevertheless, the importance of psychosocial factors in the context of healthcare 
professionals has been well advocated in the context of IBS (Drossman et al., 2002; 
Tanaka et al., 2011; Drossman, 2016). Integral to good clinician-patient interaction are 
five identified features: (1) empathy to patients’ experience of illness (2) obtaining 
illness history and acknowledging the role of the patients’ psychological factors (3) 
clarifying misunderstandings of the patient with regards to the illness (e.g. constipation 
is harmful) (4) educating the patient on self-management of the illness, including 
psychosocial factors (5) agreeing collaboratively a plan of treatment with the patient 
(Tanaka et al., 2011; Drossman, 2016). 
Part of the problem encountered with healthcare professionals (HCPs) is the lack of 
knowledge possessed by general practitioners and nurses regarding the diagnostic 
criteria and symptoms of IBS (Longstreth & Burchette, 2003; Charapata & Mertz, 2006; 
Van Tilburg, Squires, Blois‐Martin, Leiby, & Langseder, 2013). An integrated review of 
qualitative studies assessed the experience of IBS, including experiences with HCPS. 
Common themes emerging from a total of 144 participants were lack of information and 
support, unrecognised illness experiences and humiliating encounters (Håkanson, 2014). 
Humiliation appeared to primarily be the result of feeling that HCPs trivialised or 
dismissed symptoms being experienced. A key frustration and indeed apparent barrier to 
perceived ability to self-manage symptoms, was lack of clear diagnosis from physicians 
(Owens et al., 1995; Mira et al., 2015).  
Uncertainty is an emergent theme in IBS qualitative studies. Unclear or confusing 
diagnoses are likely a key contributor to this and the lack of perceived control reported 
(Håkanson, 2014). Individuals with IBS report worrying not only about the experience 
of symptoms but about the potential threatening nature of them and the overarching 
effect that symptoms have on every day functioning (Rønnevig et al., 2009). The quality 
of life (QoL) of individuals with IBS is often much lower than healthy controls (El‐
Serag, Olden, & Bjorkman, 2002), and the everyday ability to engage in desired work 
and social activities is impeded (Casiday, Hungin, Cornford, de Wit, & Blell, 2008; 
Rønnevig et al., 2009; Farndale & Roberts, 2011). Patients cite having to sacrifice 
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elements of life to counteract the impact of symptoms as a cause of impaired functioning 
and QoL (Rønnevig et al., 2009). For example in one qualitative study a participant 
spoke of missing “spontaneously getting together with other people. Because of my IBS, 
I don’t dare follow sudden impulses to see other people anymore” (Rønnevig et al., 
2009). It seems that the more severe symptoms being experienced, the worse QoL 
individuals with IBS experience (Coffin, Dapoigny, Cloarec, Comet, & Dyard, 2004). If 
left untreated, symptoms of IBS fluctuate over time, but appear to persist rather than 
remit completely (Drossman et al., 2002; Canavan et al., 2014). 
1.10 IBS Subtypes & Psychological Factors 
1.10.1 Bowel pattern subtypes and psychological factors 
As described above, IBS subtypes are predominantly characterised by bowel patterns 
(Drossman, 2016). The rationale for this is that there are different pharmacological 
treatments that can be prescribed according to the predominant bowel symptom patterns. 
The clinical merits of subtyping IBS by bowel pattern appear to end here and the 
tradition of doing so is one of contention (Talley, Zinsmeister, & Melton III, 1995; 
Whitehead, Palsson, & Jones, 2002; Marquis et al., 2014). Arguably, subtypes in IBS 
might be more clinically meaningful if they were found to either be associated with 
other clinical factors (such as symptoms, co-morbidities, psychological profiles) or 
impact upon clinical outcomes differentially. In terms of impacting on clinical 
outcomes, there is no compelling evidence to suggest that outcomes are worse in any 
particular IBS subtype (Muscatello et al., 2010). Qualitative research can however 
provide an insight into how differential bowel pattern subtypes in IBS may impact on 
psychological factors. Such research has found that while IBS-D is associated with 
feelings of urgency, IBS-C is associated with feeling incomplete evacuation and 
tendencies to strain on the toilet (Casiday et al., 2008; Rønnevig et al., 2009; Marquis et 
al., 2014; Fehnel et al., 2017). IBS-A is associated with both types of bowel sensations 
and all of the subtypes are associated with abdominal pain (Fehnel et al., 2017). The 
impact that urgency in IBS-A and IBS-D has is one of a sense of unpredictability and 
uncertainty, which can cause considerable stress and anxiety (Casiday et al., 2008; 
Rønnevig et al., 2009; Fehnel et al., 2017). For individuals with IBS-C, researchers have 
suggested that it is a sense of fear regarding the long-term damage of both constipation 
and the medications used to counteract it that is the issue (Casiday et al., 2008). Those 
with IBS-A have the potential to be affected by issues arising in both IBS-C and IBS-D. 
Qualitative research describes the different types of behaviours that the different 
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subtypes might engage in. Those with IBS-D may be prone to avoiding travel or social 
events due to fear of accidents (Casiday et al., 2008) as well as abstain from certain 
foods (Rønnevig et al., 2009). Furthermore they reported preparing for potential 
symptoms by taking anti-diarrhoea medications or wearing protection in their underwear 
(Rønnevig et al., 2009). Those with IBS-C also took precautions such as taking laxatives 
to prevent constipation. However the decision of whether they should was reported to be 
a difficult one with additional considerations (Rønnevig et al., 2009). 
Some researchers have started to quantitatively address the question as to whether these 
bowel pattern subtypes are differentially associated with psychological factors (Prior, 
Maxton, & Whorwell, 1990; Farnam, Somi, Sarami, Farhang, & Yasrebinia, 2007; 
Eriksson, Andrén, Eriksson, & Kurlberg, 2008; Sugaya & Nomura, 2008; Muscatello et 
al., 2010; Stengel et al., 2010; Thijssen et al., 2010; Fond et al., 2014; Rey de Castro, 
Miller, Carruthers, & Whorwell, 2015; Kibune-Nagasako, Garcia-Montes, Silva-Lorena, 
& Aparecida-Mesquita, 2016; Polster et al., 2017). Relatively speaking, there are not 
many studies investigating this and the findings are contradictory. Most studies have 
focused on affective differences such as differences in anxiety or depression (Prior et al., 
1990; Farnam et al., 2007; Eriksson et al., 2008; Sugaya & Nomura, 2008; Muscatello et 
al., 2010; Thijssen et al., 2010; Fond et al., 2014; Rey de Castro et al., 2015; Kibune-
Nagasako et al., 2016). A meta-analysis of anxiety and depression comorbidities in IBS 
concluded that there were inconsistent findings as to whether the subtypes are 
differentially associated with anxiety and depression (Fond et al., 2014). This is likely to 
be because while some studies find that anxiety and/or depression is higher in one 
particular subtype, other studies find the opposite. Furthermore some studies 
investigating this reported no significant differences between groups (Rey de Castro et 
al., 2015).  
There are even fewer studies assessing the difference in illness-related cognitions. All 
studies that have assessed these differences, have found no significant differences 
between subtypes (Sugaya & Nomura, 2008; Stengel et al., 2010; Thijssen et al., 2010). 
There appear to be even fewer studies assessing behavioural differences between 
subtypes, with one study finding that those with IBS-D reported more avoidant 
behaviour and agoraphobic symptoms than those with other IBS subtypes (Sugaya & 
Nomura, 2008). Another study assessed whether healthcare seeking behaviour differed 
across subtypes and found that it did not (Talley et al., 1995). These studies however 
were limited by small sample sizes, reducing the potential power to detect significant 
differences. Furthermore different studies utilised different tools for classification of 
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bowel symptom subtypes and not all studies included comparison of IBS-A in addition 
to IBS-C and IBS-D (Sugaya & Nomura, 2008). This therefore makes meaningful 
consolidation and comparison of such studies difficult.  
Some researchers have progressed a step further than looking at existing subtypes and 
singular associations with various outcomes and psychological factors. Instead, they 
have assessed whether more encompassing subgroups exist within IBS, characterised by 
a range of symptomatic and psychological factors (Guthrie et al., 2003; Polster et al., 
2017). Different statistical approaches were used to assess the existence of subgroups in 
IBS, and different measures were included to identify subgroup classification. Both 
studies identified that bowel patterns were still distinguishing features, but that these 
were differentially associated with psychological profiles and severity of symptoms. The 
first study identified three groups (1) high rectal sensitivity, high rates of sexual abuse 
history, psychiatric history, interpersonal problems and doctors visits (2) high rectal 
sensitivity, low rates of sexual abuse history and moderate psychiatric history (3) low 
rectal sensitivity, IBS-A or IBS-C, and low rates of doctor consultations and sexual 
abuse (Guthrie, et al., 2003). In contrast the other study found six subgroups that were 
more heavily characterised by bowel pattern subtypes. These included IBS-A, IBS-C 
and IBS-D with either high or low comorbidities of extra-intestinal somatic and 
psychological symptoms (Polster et al., 2017). These studies indicated that the 
characterisation of IBS subgroups may be more clinically meaningful with the inclusion 
of psychosocial factors.  
1.10.2 Co-morbidities in IBS 
It is well established that there is a higher rate of anxiety and depression amongst those 
with IBS (Drossman et al., 2002; Whitehead et al., 2002; Tanaka et al., 2011; Van 
Oudenhove et al., 2016). It was estimated that in up to 94% of IBS cases, psychiatric 
disorders such as major depression, anxiety and somatoform disorder also occurred 
(Whitehead et al., 2002). This review, along with others (Fond et al., 2014; Lee et al., 
2017) found that the levels of anxiety and depression were particularly high in IBS when 
compared to healthy controls. The prevalence of anxiety and depression in FGIDs is 
between 30% - 50% and around 30% respectively (Van Oudenhove et al., 2016). It is 
not clear the extent to which such comorbidities have a causative role in IBS, or are the 
result of the symptoms and impaired functioning experienced in IBS. However, the 
coexistence of these comorbidities has been shown to negatively impact on illness 
trajectories, treatment outcomes GI symptom burden and health related quality of life 
(Lackner et al., 2014; Vu, Kushnir, Cassell, Gyawali, & Sayuk, 2014; Creed, 1999; 
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Drossman, 1999; Creed et al., 2005). The experience of psychological distress can lower 
pain threshold (Drossman et al., 2002; Drossman, 2005), exacerbate the experience of 
symptoms (Van Oudenhove et al., 2016) and increase healthcare seeking (Addolorato et 
al., 1998; Hu et al., 2002). Indeed such is the clinical importance of these psychiatric 
comorbidities, that researchers are increasingly suggesting that they should be factored 
into the classification of subgroups in IBS (Whitehead et al., 2002). 
It has also been suggested that somatic comorbidities are considered in the subgrouping 
of IBS, as these can have important bearing on therapeutic formulation and processes 
(Reidl et al., 2008). Individuals with IBS who have one or more somatic comorbidity 
also report higher levels of anxiety and depression (Walker, Gelfand, Gelfand, Green, & 
Katon, 1996; Novi et al., 2005). This represents a significant proportion of those with 
IBS, as a systemic analysis of studies identifying the presence of somatic comorbidities 
in IBS found a twofold increase of these in IBS compared to controls (Riedl et al., 
2008). Almost half of individuals with IBS were found to experience additional GI 
disorders such as gastroesophagul reflux disease or functional dyspepsia (Reidl et al., 
2008). A broad range of extraintestinal comorbidities were also found to occur in up to 
65% of IBS patients. These included fibromyalgia, chronic pelvic pain and chronic 
fatigue syndrome. The occurrence of one or more comorbidities was associated with 
increased health care utilisation (Whitehead et al., 2002; Riedl et al., 2008; Tanaka et al., 
2011) 
1.11 Economic Burden of IBS 
IBS is estimated to cost the UK National Health Service (NHS) £45.6 million per year 
(Inadomi, Fennerty, & Bjorkman, 2003). There are a number of factors impacting on the 
health care costs of IBS. The first of which is the over reliance of diagnosis by exclusion 
(Yawn et al., 2001), with only 19% of those formally diagnosed with IBS having been 
given a diagnosis on their first visit (Hungin et al., 2003). Individuals with IBS also tend 
to visit physicians more than the general population (Talley et al., 1995; Camilleri & 
Williams, 2000; Inadomi et al., 2003). One study found that in a sample of 257 patients 
with severe IBS, the average amount of visits in a 6 month period was 6.9 (Creed et al., 
2001). Furthermore, as briefly acknowledged earlier, the presence of comorbidities in 
IBS increases the utilisation of healthcare services (Whitehead et al., 2002; Riedl et al., 
2008; Tanaka et al., 2011). Aside from the cost to health services, there is also an 
economic cost of IBS due to the number of sickness days taken by those with IBS 
(Hungin et al., 2003; Inadomi et al., 2003). In an assessment of the impact of IBS using 
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a community sample of over 40,000 participants it was found that on average 
individuals with IBS had 5.5 sick days compared with 3.1 days for those without IBS 
(Hungin et al., 2003). Individuals with IBS also averaged 10.2 days when work had to 
be cut short compared to 4.8 days without IBS (Hungin et al., 2003). The exact indirect 
costs arising from IBS in the UK are not clear but the total indirect costs for the US were 
estimated to be $205 million annually (Inadomi et al., 2003).  
Consideration of the factors contributing to the economic cost of IBS is therefore 
important to identify ways to reduce it. A key area for reducing cost lies within the 
diagnostic procedures for IBS as increasing positive diagnosis and decreasing the use of 
diagnosis by exclusion can reduce healthcare costs. Improvement of diagnostic criteria 
to include more clinical markers in addition to bowel pattern classifications (e.g. somatic 
and psychological comorbidities) may increase GPs’ confidence in providing diagnoses 
of IBS (Whitehead et al., 2002; Spiegel et al., 2010; Polster et al., 2017). Poor diagnostic 
procedures and subsequent communication HCPs provide to individuals with IBS has an 
economic impact due to the effect it has on health trajectories. Providing patients with a 
thorough understanding of their diagnosis and self-management options is important for 
improving illness trajectory (Owens et al., 1995; Casiday et al., 2008; Mira et al., 2015). 
Furthermore, thoroughly exploring the impact and role of comorbidities can reduce the 
future reliance on health care services (Johansson, Farup, Bracco, & Vandvik, 2010). 
One of the key frustrations of patients with IBS is the lack of “expertise” in IBS of 
physicians and the lack of information given to the patient (Owens et al., 1995; Casiday 
et al., 2008; Mira et al., 2015). 
1.12 Treatment Approaches to IBS 
There are different available approaches to treating IBS, both pharmacotherapeutically 
and psychologically (Drossman et al., 2002; Ford, Talley, Schoenfeld, Quigley, & 
Moayyedi, 2009). Individuals may also seek to treat IBS through a change in diet 
(Heizer, Southern, & McGovern, 2009) or with the use of probiotics (Hoveyda et al., 
2009), discussion of which is beyond the scope of this thesis. Generally individuals with 
IBS who have milder symptoms (Drossman et al., 2002) or are in the early onset of 
symptoms (Yawn et al., 2001) treat their symptoms with pharmacological agents 
directly targeting the gut. These include the use of laxative agents and antidiarrheals. 
Long term use of these are not recommended due to the disruption to colonic motility if 
taken repeatedly (Saha, 2014). Antispasmodics are used in IBS to alleviate abdominal 
pain and have been shown to have good efficacy in doing so (Spiller et al., 2007; Ford et 
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al., 2008). The rationale for using such agents is to attenuate the increased contractions 
within the bowels seen in IBS, especially postprandially (Spiller et al., 2007). 
Antispasmodics do not however have an effect on bowel symptoms such as constipation 
or diarrhoea. In the UK only two of the antispasmodics shown to have efficacy are 
licensed. These are mebeverine and hyoscine (Spiller et al., 2007).  
For individuals with more persistent and severe symptoms, additional symptoms may be 
prescribed or suggested by healthcare professionals. These include the use of 
psychopharmacology and psychological therapies, which are described below with 
consideration of the potential mechanisms of treatment effect.  
1.12.1 Pharmacological treatment 
1.12.1.1 Tricyclic Antidepressants (TCAs) 
The use of TCAs in IBS has more established benefit than the use of SSRIs (Drossman 
et al., 2002; Ford et al., 2009; Ford et al., 2014). When prescribed for IBS, the dose is 
lower than when prescribed for depression or mood disorders. The lower dosage works 
quicker as a central analgesic, than when prescribed for depression in higher dosages 
(Drossman et al., 2002). Even with low doses however, side effects include constipation 
along with dry mouth, drowsiness and fatigue. As such it has been suggested that TCAs 
may be more beneficial to individuals with IBS-D as opposed to those with IBS-C 
(Spiller et al., 2007). As TCAs have a cumulative effect, healthcare practitioners are 
advised to communicate with patients that at least four weeks of taking the medication is 
needed to establish potential benefit (Spiller et al, 2007).  
Exactly how TCAs exert analgesic effects in IBS is not currently understood. It is 
speculated that TCAs may work peripherally, by reducing visceral afferent activity 
directly in the GI tract, or centrally by facilitating inhibitory pain pathways (Chen, 
Ilham, & Feng, 2017). The alteration of pain perception is observed independently of 
their antidepressant and antianxiety effects (Clouse & Lustman, 2005).  
1.12.1.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 
In contrast to TCAs, SSRIs accelerate intestinal transit (Clouse & Lustman, 2005) and 
therefore may be better used in the treatment of those with IBS-C. SSRIs are prescribed 
in their full psychiatric dose (Clouse, 2003) and therefore are superior to TCAs in 
treating the associated emotional symptoms of anxiety and depression (Drossman et al., 
2002; Creed, 2006). It is the efficacy in decreasing psychological distress that is 
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hypothesised to be the predominant mechanism by which SSRIs have effect on 
enhancing global outcomes in IBS (Drossman et al., 2002; Clouse, 2003; Creed, 2006; 
Spiller et al., 2007). This is particularly so as although global improvements in over all 
health related quality of life are reported, generally bowel symptoms are unchanged 
(Spiller et al, 2007). There is less evidence that SSRIs have analgesic effects particularly 
in comparison to the evidence showing the analgesic effects of TCAs (Creed, 2006).  
1.12.1.3 Anxiolytics  
Anxiolytic medications such as benzodiazepines are sometimes prescribed in IBS where 
there is comorbidity of anxiety disorders, due to the recognition that acute psychological 
distress can make bowel symptoms worse (Drossman et al, 2002). Evidence of the 
efficacy of such drugs however is limited and it is not understood if the effects are 
centrally or peripherally mediated (Drossman et al., 2002; Salari & Abdollahi, 2011).  
There is also the potential problem of dependence and abuse of such medications, which 
can have strong physical withdrawal syndrome effects (Lader, 1994). 
1.12.2 Psychological treatment  
A number of psychological approaches to treating IBS have been reviewed in recent 
years showing a beneficial effect of hypnotherapy, psychodynamic interpersonal 
therapy, mindfulness and cognitive behavioural therapy (Ford et al., 2009; Ford et al., 
2014). The treatments, evidence and potential mechanisms are described below.  
1.12.2.1 Hypnotherapy  
Hypnotherapy used in IBS is called “gut-directed hypnotherapy” (GDH). It involves the 
use of muscular and mental relaxation techniques and hypnotic suggestions to focus on 
symptoms or to distract from them (Webb, Kukuruzovic, Catto‐Smith, & Sawyer, 2007). 
The hypnotherapist utilises feedback from the individual to further adapt suggestions to 
allow the individual a greater feeling of influence over symptoms (Whorwell, Prior, & 
Faragher, 1984; Moser et al., 2013). For example individuals may be asked to imagine 
the normalisation of GI function, using imagery of a blocked river clearing or flowing 
smoothly. Sessions are designed to provide individuals with a sense of control over 
external stimuli (such as the pressure of the chair, sounds, lights) and internal 
physiological experiences such as breathing and eventually bowel symptoms. 
Hypnotherapy in IBS is found to generally be effective in reducing pain and enhancing 
QoL (Wilson, Maddison, Roberts, Greenfield, & Singh, 2006; Webb et al., 2007; Miller 
et al., 2015). The quality of such studies has however been described as inadequate, with 
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a need for more high quality trials (Wilson et al., 2006; Webb et al., 2007; Rutten, 
Reitsma, Vlieger, & Benninga, 2013).  
The precise mechanism/s of action in GDH has not been established, yet a number of 
possibilities have been proposed (Tan, Hammond, & Gurrala, 2005; Spiller et al., 2007; 
Rutten et al., 2013). It has been observed by researchers that hypnotic suggestion can 
change gastric motility (Whorwell, Houghton, Taylor, & Maxton, 1992; Houghton, 
Calvert, Jackson, Cooper, & Whorwell, 2002). However it is not clear whether this 
effect persists once an individual is no longer in a hypnotic state. In addition there is 
limited evidence showing other physiological change such as CNS/ANS activity or 
altered pain thresholds as a result of GDH (Tan et al., 2005; Spiller et al., 2007; Rutten 
et al., 2013). There is comparatively more evidence for the effect of GDH on potential 
psychological mediators (Rutten et al, 2013). Somatisation, psychological stress and 
negative cognitions have all been shown to reduce after GDH (Spiller et al., 2007; 
Rutten et al., 2013). The authors of one particular study that found symptom 
improvement after GDH was associated with a reduction in negative cognitions, 
suggested that the hypnotherapeutic approach to IBS may be considered a form of 
cognitive restructuring (Gonsalkorale, Toner, & Whorwell, 2004). 
1.12.2.2 Psychodynamic interpersonal therapy 
Psychodynamic therapy for IBS is referred to as “psychodynamic interpersonal therapy” 
(PIT) as it targets distress arising from interpersonal relationships, which are said to be 
the underlying cause of somatic symptoms (Guthrie, 2002). The treatment model asserts 
that individuals with IBS are submissive and seek reassurance from others (Hyphantis, 
Guthrie, Tomenson, & Creed, 2009). However, there is little evidence to suggest that 
these are qualities that characterise the entire heterogeneous IBS population.  There is 
limited evidence coming from RCTs of PIT or the efficacy of PIT in IBS (Altayar, 
Sharma, Prokop, Sood, & Murad, 2015). The one RCT of PIT in IBS included 
participants with severe IBS and compared the efficacy of PIT to administration of an 
SSRI, paroxetine or treatment as usual (TAU) (Creed et al., 2003). Although superior to 
TAU, there were no significant differences between the efficacy of paroxetine and PIT 
in improving symptom severity or QoL. However, in the year follow up individuals who 
received PIT had a lower associated heath care cost than those in the SSRI group. 
Although this demonstrates a potential benefit of treatment, it is not clear whether this is 
the result of PIT specifically, or the opportunity for individuals to discuss their 
symptoms and feel heard. This has previously been shown to reduce the utility on 
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healthcare services (Owens et al., 1995; Inadomi et al., 2003; Johansson et al., 2010; 
Mira et al., 2015).  
1.12.2.3 Mindfulness  
There is increasing RCT-based evidence for the efficacy of mindfulness in IBS (Lakhan 
& Schofield, 2013; Zernicke et al., 2013). It is suggested that mindfulness may improve 
symptoms in IBS through the reduction of hypervigilance as individuals increase 
attentional control and reduce GI related anxiety (Garland et al., 2012). Studies 
assessing the efficacy on symptom severity and quality of life have found significant 
improvements compared to active and wait list controls (Ljótsson et al., 2010; Gaylord 
et al., 2011; Zernicke et al., 2013). 
Mindfulness used in IBS is adapted from the traditional 8-week mindfulness based stress 
reduction programme (Kabat-Zinn, 1982) and delivered in groups. The mindfulness 
protocols tend to include a psycho-education component specifically regarding the 
physiology of IBS and the brain-gut connection. Guided meditations are used to alter 
individuals’ relationships with their body and symptoms. Individuals are required to 
complete home practice, which consists of a meditative practice 6/7 days and/or an 
activity designed to increase awareness and break unhelpful cycles (e.g. a pleasant 
events diary, where individuals are asked to log 10 daily pleasant events). Adherence to 
home practice is hard to verify (Zernicke et al., 2013) but class attendance was generally 
good (Lakhan & Scholfield, 2013).  
1.12.2.4 Acceptance and Commitment Therapy in IBS 
Acceptance and Commitment Therapy (ACT) is a ‘third wave’ behavioural therapy, 
which conceptualises psychological inflexibility as a key factor in the maintenance and 
perpetuation of psychopathology (Hayes & Strosahl, 2004; Bravo Ferreira, Eugenicos, 
Graham Morris, & Gillanders, 2011). Psychological inflexibility is defined as the 
‘inability to modulate behaviour in response to how helpful it is’ (Hayes & Strosahl, 
2004). Increasing psychological flexibility therefore increases the capacity of clients to 
stay with experiences within the present moment and their ability to choose courses of 
action that are in line with their core values (Arch & Craske, 2008; Bravo Ferreira et al., 
2011).  The use of ACT in IBS is relatively new, with only two small pilot studies 
conducted to date (Ferreira, Gillanders, Morris, & Eugenicos, 2017). Although these 
showed positive changes in acceptance and symptom severity, both studies were limited 
by low power. Furthermore, the treatments assessed were not full courses of ACT 
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tailored for IBS, but rather a one-day group workshop with a self-help manual (Ferreira 
et al., 2017) and an ACT based psychoeducation self-management programme without 
therapeutic support (Ferreira et al., 2017). As such conclusions about the efficacy of 
ACT in IBS cannot be made at this stage.  
1.12.2.5 Cognitive behavioural therapy  
There is a substantial amount of good quality evidence coming from RCTs showing that 
CBT is effective for reducing symptom severity and enhancing QoL in IBS (Ford et al., 
2009; Ford et al., 2014). CBT treatments for IBS involve cognitive restructuring, 
behavioural activation and exposure and psycho-education into the link between 
cognitions, behaviours, emotions and bowel symptoms (Toner et al., 2000). There are 
some differences in the treatments provided across different studies, which are described 
further below. These are considered in terms of the potential mechanisms involved in 
the different CBT treatment models.  
1.13 Cognitive Behavioural Models of IBS 
There are a number of cognitive behavioural models, which have slightly different 
formulations (Windgassen et al., 2017). All models share the hypothesis that 
biopsychosocial factors as described previously, have predisposing, precipitating and 
perpetuating role in IBS (Toner, Segal, Emmott, & Myran, 2000). More specifically the 
models focus on the perpetuating factors, all of which identify the role of cognitions and 
behaviours. Furthermore, all models suggest that it is GI-related cognitions and 
behaviours that are important in IBS (Toner et al., 2000), as opposed to more generic 
tendencies to catastrophise or act in response to emotion.  The general goal of CBT for 
IBS is to allow individuals to reconceptualise their symptoms, shifting perceptions of 
lack of control to more optimistic controllable views of their symptoms (Toner et al., 
2000). What distinguishes the models from each other is the differential focuses they 
place on particular perpetuating factors that are considered important for changing 
outcomes (i.e. symptom severity and QoL) in IBS. Each model is considered further 
below.  
1.13.1 Three systems model  
The three systems model was first proposed by Lang in relation to fear responses (Lang, 
1968). The theory identified three response systems to fear: physiological reaction, 
overt-behaviour and cognitions. This three systems approach to IBS therefore focuses on 
the interplay between unhelpful illness-related cognitions, behavioural responses to 
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symptoms and physical sensations, which may pertain to the bowel symptoms 
themselves or the physical sensations of anxiety that may be associated with the 
experience of such bowel symptoms (Kennedy et al., 2005; Everitt et al., 2015). The 
model depicted in figure 1.3 shows how when an individual experiences bowel 
symptoms, they also experience anxious thoughts about the symptoms. Thoughts such as 
“it will be embarrassing if I have an accident”, or “I can’t cope with these symptoms” 
cause and are exacerbated by behavioural responses to symptoms (Beesdo‐Baum et al., 
2012). These behavioural responses may be avoidant (avoiding certain foods or 
activities to prevent or deal with symptoms). They may also reflect efforts to control 
symptoms. These are termed “safety behaviours” by clinicians and may include 
tendencies to take preventative medications, strain to pass a stool or wear protective 
underwear/loose clothing. Both cognitive and behavioural responses can have the effect 
of exacerbating or prolonging symptoms (Drossman et al., 2000; Rutter & Rutter, 2002; 
Lackner, 2005; Spence & Moss-Morris, 2007; Weinland et al., 2010). The key mediators 
of treatment effect proposed by this model are therefore GI related cognitions and 
behaviours. These have been shown to directly affect gut motility via the CNS (Kennedy 
et al., 2012) and indirectly. For example safety behaviours such as over-reliance on 
antimotility or laxatives to prevent feared symptoms can indirectly impact gut motility. 
This is because prolonged use can disrupting normal motility further or cause abdominal 
pain (Quigley et al., 2006; Rønnevig et al., 2009; Saha, 2014). Further consideration of 
mechanisms of psychological treatment in IBS is provided in chapters 3 - 5.   
 
Figure 1.3: Three systems CBT model of IBS 
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1.13.2 Four factor model 
The four factor CBT model of IBS includes the additional factor of emotion (Jones, 
Koloski, Boyce, & Talley, 2011). Figure 1.4 depicts how emotions such as anger and 
frustration impact on cognitions, behaviours and symptoms. The premise of the four 
factor model is that psychological treatments work by reducing the impact of disturbed 
emotional processing in the CNS, on gut function through management of stress and 
anxiety (Jones et al., 2011). The primary target for change in such therapy is therefore a 
reduction in anxiety/psychological stress. It is also important to distinguish the fact that 
the cognitions and behaviours targeted are therefore not always necessarily symptom 
related and may pertain to general responses to stress and anxiety.  
 
 
Figure 1.4: Four factor CBT model of IBS 
1.13.3 Interoceptive exposure CBT model  
More recently an interoceptive exposure CBT model (CBT-IE) was proposed to 
specifically target GI specific anxiety in IBS (Craske et al., 2011). GI specific anxiety 
(also called ‘visceral anxiety’) refers to the anxiety individuals have with regards to the 
anticipation and experience of GI symptoms (Mayer, Craske, & Naliboff, 2001). It has 
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been proposed that IBS symptoms are primarily affective in nature and risk factors such 
as general anxiety, neuroticism and worry/stress have an effect on symptom severity 
(Labus et al., 2005). The CBT models informing treatment target GI specific anxiety. 
This is based on the model of CBT used in panic disorder (Craske & Barlow, 2006). The 
model is depicted in figure 1.5, which shows that fear of gut sensations contributes 
directly to the intensity of such symptoms via the BGA. In addition GSA results in 
people with IBS trying to avoid gut sensations (e.g. by avoiding certain foods or tight 
clothing) and situations in which bowel symptoms may cause embarrassment or 
inconvenience (e.g. long journeys, restaurants with long delay/route to the bathroom). 
GI specific anxiety, avoidance behaviours and cognitions interact to maintain symptoms. 
Treatment involves exposure to visceral sensations (e.g. by tightening the stomach 
muscles) and feared situations, cognitive restructuring, attentional control training to 
reduce hypervigilance and psycho-education about the brain and the gut. As such, 
although the model differs slightly with a highly specific target of reducing GI specific 
anxiety, the treatment is very similar to that of the three systems approach.  
 




IBS is a highly prevalent functional gastrointestinal disorder characterised by abdominal 
pain and altered bowel patterns. Four subtypes with IBS exist, characterised only by 
predominant bowel pattern: constipation predominant IBS (IBS-C), diarrhoea 
predominant IBS (IBS-D), alternating IBS (IBS-A) and unclassified IBS (IBS-U). There 
is limited and contrasting evidence that particular subtypes are associated with certain 
psychological characteristics. Researchers have called for more clinically meaningful 
subgroup classifications in IBS, which take into account levels of symptom severity, co-
morbidities and other psychological characteristics.  
IBS is a biopsychosocial disorder, with a clear pathophysiological mechanism by which 
psychosocial factors can affect bowel symptoms and gastrointestinal pain. Psychological 
treatments have been shown to be effective in reducing symptoms and enhancing QoL in 
IBS. CBT is the psychological approach with the most high quality empirical support. 
The mechanisms of treatment effect may vary depending on the specific CBT model 
being applied. Generally, cognitions, behaviours and affective factors such as 
anxiety/gastrointestinal related anxiety are identified as key targets for change. 
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2. Methodological Overview  
2.1 Chapter Overview  
The previous chapter introduced the importance of cognitive and behavioural factors in 
irritable bowel syndrome (IBS). The present thesis had two main objectives: (1) to 
assess whether cognitive and behavioural factors were mediators of treatment effect on 
the outcomes of symptom severity and work and social adjustment/quality of life (2) to 
identify cognitive and behavioural factors associated with IBS bowel pattern subtypes. 
To meet objective one, two studies were conducted consisting of a systematic review 
(study one) and a mediation analysis (study two) using data from a previously conducted 
randomised controlled trial comparing the antispasmodic, mebeverine, alone to 
cognitive behavioural therapy (CBT) plus mebeverine. To meet objective two, two 
further studies were conducted to assess differences in psychological factors between 
IBS bowel subtypes (study three and study four). Study three used the same data as 
study two, and study four used prospectively collected data from a randomised 
controlled trial assessing CBT in IBS.  
This chapter will provide details of the study design of the two trials, before providing 
an outline of the methodology employed to complete the studies included in the thesis. 









2.2 The Cognitive Behavioural Therapy in Addition to 
Antispasmodic Treatment for Irritable Bowel Syndrome in 
Primary Care Trial  
The Cognitive Behavioural Therapy (CBT) in Addition to Antispasmodic Treatment for 
Irritable Bowel Syndrome in Primary Care Trial was conducted prior to the beginning of 
this thesis, the results of which are reported comprehensively elsewhere (Kennedy et al., 
2005; Kennedy et al., 2006). The data from this trial were used for secondary analysis in 
two studies contained in this thesis (2.4). An outline of the study design, intervention 
and measures utilised for the purposes of this thesis only, are detailed below.  This data 
set shall be referred to as ‘data set 1’.  
2.2.1 Design 
The study was a randomised controlled trial (RCT) comparing the effect of CBT in 
addition to the antispasmodic medication, mebeverine, to mebeverine alone on the 
outcomes of symptom severity and work and social adjustment in irritable bowel 
syndrome (Kennedy et al., 2005). Figure 2.1 depicts the CONSORT study flow diagram 
detailing the steps of recruitment and follow up assessments included in the study.  
2.2.2 Participants and procedure 
Individuals aged between 16 and 50, diagnosed with IBS and meeting the Rome I 
criteria (Thomson, Doleval, Drossman, & Heaton, 1989) were recruited from 10 London 
general practices. A total of 235 participants completed the initial assessment measures 
utilised in study three; 149 participants were randomised to either receive mebeverine 
alone (77) or to receive CBT in addition to mebeverine (72). The data for one participant 
was lost, leaving 148 participants to be included in analysis in study two. 
Questionnaire measures were taken at 7 time points (figure 2.1), two of which occurred 
prior to randomisation (visit 1 and visit 2). The first assessment was conducted at 
screening and the second assessment was taken after two weeks of treatment as usual, 
once participants had consented to participate in the study. The baseline (start of RCT) 
measure was taken at visit 3 and the first follow up at 1.5 months post randomisation at 
visit 4. The second follow up was at 3 months (visit 5) and the ultimate follow up at 12 
months (visit 7).  
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2.2.3 CBT intervention 
The therapy was delivered in face-to-face sessions by four general practice nurses who 
had received training in CBT and were under the close supervision of an experienced 
therapist. Participants received six 50 minute sessions at weekly intervals. The CBT 
intervention was based on Lang’s three systems model (Lang, Melamed, & Hart, 1970) 
as adapted for IBS, which posits that GI related cognitions and behaviours interact to 
maintain and exacerbate the experience of symptoms. To target GI cognitions and 
behaviours the intervention included psychoeducation, cognitive restructuring and 
behavioural techniques. The psychoeducation provided information about the 
physiology of the bowel and the brain-gut connection. Cognitive restructuring was 
aimed at making individuals aware of unhelpful gastrointestinal (GI) related thoughts, 
recognising how these affected their behaviours and GI symptoms.  Patients were 
encouraged to challenge these thoughts and identify alternative thoughts. Behavioural 
techniques involved goal setting to increase helpful behaviours such as eating regular 
meals, regular exercise and drinking water, whilst reducing unhelpful behaviours. 
Behaviours identified as unhelpful could be avoidance behaviours such as avoiding 
situations that may be impacted by bowel symptoms, or safety (also termed ‘control’) 
behaviours such as taking precautionary measures like trying to force the bowels to 
empty before leaving the house. Techniques to manage stress and prevent relapse were 
also included. The treatment aimed to improve participants’ ability to participate in life 
despite their IBS symptoms. It was anticipated that IBS symptoms may also reduce as a 
result of treatment. A summary of sessions is contained in appendix F.  
2.2.4 Antispasmodic treatment 
Individuals in both the CBT treatment arm and antispasmodic alone arm took 270mg of 
the antispasmodic, mebeverine, three times daily. Antispasmodics have been shown to 
be effective in reducing the global effect of IBS (Ford et al., 2008; Ruepert et al., 2011). 
2.2.5 Measures 
Primary outcome measures  
The Irritable Bowel Severity Scoring System (IBS-SSS) (Francis, Morris, & Whorwell, 
1997) measures symptom severity specific to IBS and is sensitive to change over time. 
The maximum score is 500, with scores <75 indicating normal bowel function. Scores 
between 75-174 indicate mild IBS, 175-299 moderate IBS and scores between 300-500 
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indicate severe IBS. A 50 point change from baseline is regarded as clinically significant 
(Francis et al., 1997).  
The Work and Social Adjustment Scale (WSAS) (Mundt, Marks, Shear, & Greist, 2002) 
is a measure of work and social functioning. It contains 5 items each rated 0 - 8, with a 
total potential score of 40. The items assess individuals’ ability to engage in day-to-day 
tasks at work, at home, socially, with family and in relationships. It was found to be a 
reliable and valid measure of impaired functioning with an internal scale consistency 
ranging from α 0.70 to 0.94 for the 5 subscales (Mundt et al., 2002). 
‘Illness Identity symptom’ item from the Adapted Illness Perception Questionnaire 
(IPQ) to assess Bowel Pattern Subtype (Moss-Morris et al., 2002) 
Predominant bowel pattern was identified through recoding of the adapted ‘Illness 
Identity symptom’ items of the Illness Perception Questionnaire (IPQ), which asked 
participants how often they experienced diarrhoea and constipation. Responses were 
rated as “never = 0”, “occasionally = 1”, “frequently = 2” or “all of the time = 3”. 
Constipation predominant IBS was defined as individuals who never experienced 
diarrhoea and scored ≥1 for constipation. Diarrhoea predominant was defined as 
individuals who never experienced constipation and scored ≥1 for diarrhoea. Individuals 
who scored ≥1 for constipation and diarrhoea were classified as having alternating 
bowel pattern. Those who scored 0 for both diarrhoea and constipation were classified as 
IBS-U.  
Secondary outcome measures  
The Cognitive Scale for Functional Bowel Disorders (CSFBD) (Toner et al., 1998) 
contains items that assess thoughts specific to the experience of functional bowel 
disorders such as “my bowel symptoms make me feel out of control”. The scale consists 
of 25 items, with a possible total score of 25 to 175 with higher scores indicating more 
illness-related cognitions. The measure has been demonstrated to have good reliability 
and validity α=0.93 (Toner et al., 1998).  
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) contains 
two subscales measuring anxiety and depression and is well validated in different patient 
populations (Bjelland, Dahl, Haug, & Neckelmann, 2002). The anxiety and depression 
subscale of the HADS are each made up of 7 items scored from 0 to 3, with a total 
possible score of 21. Scores of 8 and above are said to indicate anxiety and depression 
(Bjelland et al., 2002). The anxiety subscale assesses general anxiety rather than anxiety 
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specific to IBS, with items such as “I feel tense or wound up” or “worrying thoughts go 
through my mind”. The depression subscale includes items such as “I feel as if I am 
slowed down”.  
The IBS Behavioural Responses Questionnaire (IBS-BRQ) (Reme, Darnley, Kennedy, & 
Chalder, 2010) consists of two subscales. The first measures avoidance behaviour such 
as “I avoid going out in case I have problems with my IBS” (15 items). The second 
subscale assesses safety behaviours (11 items), which are referred to as ‘control 
behaviours’ in the scale. An example safety behaviour item is “I spend more time on the 
toilet than I would ideally like”. Each item is scored on a scale of 1-7, and the two 
subscales are scored by summing the total of the items. Higher scores indicate higher 
levels of unhelpful behaviours. The scale has been shown to have good reliability and 
validity α=0.86 (Reme et al., 2010).  
2.2.6 Power calculation   
Power was calculated a priori to detect differences between the CBT + mebeverine 
group and the control group. The calculation assumed that the mean score (SD) on the 
IBS-SSS at six months’ follow up would be 133 (80) in the CBT + mebeverine group 
and 180 (80) in the control group. To give the power 90% power, with 95% confidence 







Figure 2.1: CONSORT diagram of the study design and data collection for The Cognitive 
Behavioural Therapy in Addition to Antispasmodic Treatment for Irritable Bowel Syndrome in 
Primary Care Trial 
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2.3 Assessing Cognitive Therapy in Irritable Bowel (ACTIB) 
Trial  
The ACTIB Trial began concurrently with the beginning of the present thesis, allowing 
prospective data collection. The completion of data collection up until the 12 month 
follow ups occurred approximately nine months prior to the doctorate submission 
deadline and therefore it was only possible to utilise the baseline data in analysis 
conducted for the present thesis (2.4). The results of the study are pending, however the 
trial protocol has been published for further detail of the study design (Everitt et al., 
2015). This data set shall be referred to as ‘data set 2’. 
2.3.1 Design 
The ACTIB Trial was a RCT comparing three arms, consisting of two treatment arms 
and a treatment as usual (TAU) arm. The two treatment arms both included the same 
CBT intervention content, but delivered in different formats with different therapist time 
allocations. The ‘Therapy CBT’ (TCBT) arm was the high intensity group consisting of 
six x 60 minute phone sessions over a three month period, with two further follow up 
sessions in addition to TAU. In this arm participants were provided with a CBT booklet 
with eight chapters and homework exercises. In the ‘Website Based CBT’ (WBCBT) 
arm, participants received a low intensity CBT intervention, receiving three x 30 minute 
phone sessions over a three month period with two further follow up sessions in addition 
to TAU. Participants in this group predominantly worked through the CBT programme 
utilising an interactive online self-management programme, which contained the same 
information and exercises as the booklet provided in the TCBT arm. Those participants 
allocated to TAU were instructed to continue with their current medication and GP 
consultation follow ups, but asked not to engage in psychological therapy for IBS and to 
refrain from partaking in any other interventions for IBS. All treatment arms received a 
standard information sheet on lifestyle and diet in IBS, based on NICE guidelines 
(appendix E). The TAU participants had access to the WBCBT without the additional 
telephone support after completion of the 12 month follow up. Figure 2.2 shows the 
CONSORT flow diagram detailing the progression of participants through the trial.  
2.3.2 Participants and procedures 
Individuals aged 18 + with refractory IBS were recruited from primary and secondary 
care sites in South London and Hampshire. To meet the inclusion criteria participants 
had to meet the Rome III criteria for IBS (Drossman & Dumitrascu, 2006), have a 
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diagnosis of IBS for at least 1 year and score at least 75 on the IBS-SSS (Everitt et al., 
2015). Participants had to have been offered first line IBS medications with persisting 
symptoms for at least 12 months. Participants of 60+ had to have had a review of their 
symptoms with a consultant in the last two years to confirm that their symptoms were 
related to IBS and to exclude the possibility of other more serious bowel conditions. 
This was due to the recommendations of NICE guidelines advising further investigation 
of new change in bowel habit in those 60 years and over due to the increased risk of 
bowel cancer in this age group (Hookway, Buckner, Crosland, & Longson, 2015).   
Once participants were deemed to be eligible at the screening stage, they were asked to 
provide informed consent online. When consent was provided, potential participants 
were given instructions to get a blood test or retrieve results of blood tests completed 
within the last three months. The purpose of the blood tests was to exclude alternative 
diagnoses to IBS. The blood tests included a full blood count (FBC) for anaemia, 
transglutaminase antibodies (TTG) for Coeliac disease and C Reactive Protein (CRP) for 
inflammation, which can be a marker for inflammatory bowel disease. The Chief 
Investigator (CI) checked the blood results to determine eligibility. For patients with 
abnormal FBC or TTG results, participants were excluded from the study and referred 
back to their GP. CRP can be raised temporarily due to minor illness or infection 
therefore participants with an abnormal CRP were offered a second test after 4 weeks. 
Potential participants with a second high CRP result were excluded from the trial and 
their GP was informed of the test result.  
Once potential participants received confirmation of normal blood tests, they completed 
baseline questionnaires online. After these were completed, participants were 
randomised to a treatment arm. 558 participants were successfully randomised and 
allocated to TCBT (n =186), WBCBT (n=186) or TAU (n=187). Questionnaire 
measures were assessed at 4 time points, which was then extended to an additional time 
point of 24 month follow up. The 24 month follow up data collection is due to be 
completed in June 2019.  
2.3.2 CBT interventions  
The content of the CBT included in both treatment conditions was the same and drew on 
therapy content from the previous trial (Kennedy et al, 2005; Kennedy et al, 2006), a 
self-management CBT programme designed for IBS (Moss-Morris, McAlpine, 
Didsbury, & Spence, 2010) and adapted parts of the CBT manuals used in a trial of 
therapies for chronic fatigue syndrome (White, Sharpe, Chalder, DeCesare, & Walwyn, 
 
56 
2007). The intervention utilised more of a four-factor approach than a three systems 
approach, identifying cognitions, behaviours and emotions as key maintaining factors of 
IBS symptoms (Everitt et al., 2015). The therapy consisted of psychoeducation about the 
physiology of the bowels and the connection with the brain. Cognitive and behavioural 
techniques were used to improve bowel habits and eating patterns, address unhelpful 
thoughts, manage stress, reduce symptom focusing and prevent relapse. A summary of 
the sessions is contained in appendix F. Ten therapists experienced in delivering CBT in 
medically unexplained and long-term conditions delivered the therapy in both treatment 
arms. All therapists received additional training in the CBT model for IBS and 
supervision was tailored specifically for IBS delivered via the telephone or through the 
internet.  
2.3.2.1 Therapist cognitive behavioural therapy (TCBT) 
Individuals randomised to TCBT were provided with a hard copy paper manual of the 
CBT programme consisting of eight chapters with allocated homework tasks (appendix 
F). Participants received six one-hour telephone sessions with their allocated therapist 
over a 9-12 week period and were encouraged to work through the manual in between 
sessions. Two one-hour ‘booster’ telephone sessions were arranged at around the four 
and eight month post randomisation point. Although based on the content of the sessions 
in the patient manual, the TCBT telephone sessions were formulation driven so that the 
order and extent to which all sessions were covered was individualised.  
2.3.2.2 Website based cognitive behavioural therapy (WBCBT)  
Individuals randomised to WBCBT were provided with a login to the online CBT 
intervention and advised to start working sequentially through the eight online weekly 
sessions and homework tasks. The formulation was completed online by participants 
using the interactive tools of the website to map out their own CBT model of IBS. 
Participants received weekly reminders to log in and complete sessions. In addition, they 
received three 30-minute telephone therapy support calls over 9-12 weeks and two more 
30-minute booster sessions at around the four and eight month post randomisation point. 
These phone support sessions were deemed necessary to aid participant engagement 
with the programme. Limited therapist input has shown promising results in previous 
similar remote CBT based interventions for IBS (Hunt, Moshier, & Milonova, 2009; 
Ljótsson et al., 2010). When appropriate, therapists could use the phone calls to suggest 
that participants focus on particular sessions rather than others.  
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2.3.4 Treatment as usual (TAU) 
Participants in all three arms received TAU, with TAU alone constituting the control 
arm of the trial. TAU was defined as the continuation of current medications and usual 
general practitioner (GP) or consultant follow-up with the exclusion of any 
psychological therapy for IBS. All GPs and consultants involved in the study received a 
copy of the NICE Guidance (appendix E) at the start of the study to ensure that they all 
had the best standard practice information on IBS management. Those participants that 
were allocated to TAU alone were provided with access to the WBCBT website at the 
end of the 12 month follow up period.  
2.3.5 Measures  
The measures used for the present thesis from the ACTIB data collection (data set 2) 
were the same as the ones used in data set 1 (Kennedy et al., 2005) with one exception. 
In data set 1, the adapted IPQ was used to classify bowel pattern subtypes, whereas in 
data set 2, the Rome III criteria was used. The Rome III was assessed at screening only 
and no at baseline or subsequent follow ups. All copies of the questionnaires used for 
the thesis can be found in appendix D. 
Rome III Criteria (Drossman & Dumitrascu, 2006) to assess bowel pattern subtypes 
The Rome III is a diagnostic tool for assessing IBS and identifying bowel pattern 
subtypes. Individuals were classified as IBS-D if they had lose/watery stools ≥ 25% of 
the time and had hard/lumpy stools < 25% of the time. IBS-C was defined as those with 
lose stools <25% of the time and hard stools ≥25%. IBS-A was categorised as those with 
both hard and loose stools ≥25% of the time, while IBS-U experienced hard and loose 
stools <25% 
2.3.6 Power calculation  
Power calculations were conducted a priori to determine necessary sample size for each 
condition to detect differences in the primary outcome. To achieve power of 90%, taking 
into account the number of therapists providing therapy and attrition rate, it was 
calculated that 165 participants were needed for each group, totalling 495 participants. 
This was increased to 189 per group as the attrition rate was found to be closer to 30% 




Figure 2.2: CONSORT diagram of the study design and data collection for The Assessing 
Cognitive Therapy in Irritable Bowel Syndrome 
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2.4 Study Sequence  
2.4.1 Study aims and objectives 
The two main objectives of the thesis were: (1) to assess whether cognitive and 
behavioural factors were mediators of treatment effect on the outcomes of symptom 
severity and work and social adjustment/quality of life, and (2) to identify cognitive and 
behavioural factors associated with IBS bowel pattern subtypes. Two studies (studies 
one and two) were conducted to assess aim one, and two studies (studies three and four) 
were conducted to address aim two (table 2.1, figure 2.3).  
The more specific aim of study one was to systematically identify psychological factors 
found to mediate the effect of psychological interventions in IBS on the outcomes of 
symptom severity and/or quality of life. It was hypothesised that cognitions, behaviours 
and anxiety would significantly mediate treatment effect, in line with cognitive 
behavioural models of IBS (Kennedy et al., 2005; Craske & Barlow, 2006; Moss-Morris 
et al., 2010). 
Study two had two more specific aims: (1) to assess whether GI related avoidance 
behaviours, GI related safety behaviours, GI related cognitions, and general anxiety 
mediated the effect of CBT on symptom severity and work and social adjustment, and 
(2) to identify which mediating variables changed first in sequential mediator models. It 
was hypothesized that all four variables would significantly mediate the effect of CBT 
on both symptom severity and work and social adjustment based on the theoretical 
treatment model and findings from previous studies (Windgassen et al., 2017). It was 
also hypothesized that cognitive and behavioural change would precede change in 
anxiety, as these were the targets for change in the treatment protocol informed by the 
three systems model. Furthermore, in the previous mediation study based on the same 
data, cognitive and behavioural change was found to precede changes in anxiety (Reme, 
Stahl et al, 2011).  
Study three and four both aimed to assess whether there were differences in cognitive 
and behavioural factors in addition to levels of anxiety, depression, symptom severity 
and work and social adjustment across IBS subtypes. Study three had the additional aim 
of assessing whether abdominal pain was associated with specific bowel pattern 
subtypes. It was hypothesised that due to the nature of symptoms and the additional 
burden created by the experience of diarrhoea, those with IBS-A and IBS-D would have 
more extreme symptoms, disability and cognitive, behavioural responses compared to 
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those with IBS-C. This is due to the unpredictability and uncertainty of diarrhoea as 
opposed to constipation. With regard to the relationship between bowel pattern subtypes 
and abdominal pain, it was hypothesised that individuals with IBS-A and IBS-D would 
have higher levels of abdominal pain compared to IBS-C, based on previous findings 
assessing this association (Heitkemper et al., 2011).  
Study four aimed to validate the findings from study three in a larger sample with bigger 
power to detect differences. It was hypothesised that cognitions and behaviours would 
differ between subtypes. Based on previous results, the three specific hypotheses were 
that (1) unhelpful cognitions would be greater in those with IBS-D than IBS-C, (2) 
unhelpful avoidance behaviours would be greater in those with IBS-D and IBS-A 
compared to IBS-C, and (3) control behaviours would not significantly differ across 
subtypes. 
2.4.2 Study methodology  
Precise details of the statistical analyses utilised in each study are provided in the 
respective chapters. This section will instead provide a rationale for the methods used in 
each study and how they fit the aims of the study.  
2.4.2.1 Study one 
This study aimed to assess psychological mediators of treatment effect in the context of 
psychological interventions for IBS. In order to systematically collate findings from 
previous research assessing mediation in such a context, it was decided that a systematic 
review should be used. Systematic reviews identify, appraise and synthesise findings 
from empirical studies conducted in a specified area of research (Littell, Corcoran, & 
Pillai, 2008). In contrast to narrative reviews, they reduce bias by identifying all 
available studies meeting a stipulated inclusion criteria, and systematically assessing the 
quality of the studies (Higgins & Green, 2011). This allows consideration of the results 
balanced against the relative quality of the study. The PRISMA guidelines ensure 
standardised reporting of the methodology and results of systematic reviews (Moher et 
al., 2015). These guidelines were adhered to in the systematic review presented in this 
thesis.  
The alternative approach to a systematic review would have been a meta-analysis. A 
meta-analysis involves the use of statistical techniques to synthesize the data from 
several studies into an effect size (Littell et al., 2008). This approach was considered but 
determined to be inappropriate in the context of the mediation analysis studies returned 
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from the systematic review, for a number of reasons. The measures of indirect effects 
(mediated effects) were inconsistently reported, some papers only reported the effect 
sizes of the overall path model and not the composite mediating pathways, whether 
these were singular (i.e. one mediator pathways) or sequential (i.e. multiple mediators in 
a pathway). Furthermore, of those studies presenting the indirect effects, different 
measures of effect size were used, preventing the data from being pooled. In four out of 
eight studies, the data necessary to conduct a meta-analysis was not available. In 
addition, not all studies assessed the same mediators, resulting in very small pools of 
mediator variables to compare. On balance, the small number of studies returned 
allowed a meaningful review of the results without an additional meta-analysis, 
providing a good basis for informing and improving future studies.  
2.4.2.2 Study two 
Study two aimed to assess both simple mediation models (i.e. one mediator) and 
sequential mediation models. It was determined that structural equation modelling 
(SEM) was the best method available to conduct mediation analysis. SEM is sometimes 
referred to as path analysis when it is conducted using observed variables rather than 
latent variables (Mackinnon, 2008). Path analysis (or SEM) allows the modelling of 
multiple outcomes simultaneously (Mackinnon, Fairchild, & Fritz, 2007; MacKinnon, 
2008; Bollen & Pearl, 2013). This means that longitudinal modelling of multiple 
measures of mediators and outcomes can be conducted, which enables the assessment of 
sequential mediation models as was required in the present study. For example, it allows 
the assessment of whether change in one mediator (mediator one) causes change in 
another mediator (mediator two), or whether this path is best explained in reverse; i.e. 
change in mediator two causes change in mediator one instead. This method of analysis 
also allows the inclusion of potential confounding variables in the analysis, controlling 
for the effects such variables may have on the relationships between other variables of 
interest (MacKinnon, 2008; Emsley, Dunn, & White, 2010). For this reason path 
analysis is superior to the traditional but somewhat out-dated alternative method of 
Baron & Kenny’s causal steps framework (Baron & Kenny, 1986). This approach 
specifies that a number of regressions need to be conducted to establish whether 
mediation exists. These regressions are used to establish whether (1) the effect of the 
independent variable on the dependent variable is statistically significant, (2) the effect 
of the independent variable on the mediator is significant, (3) the effect of the mediator 
on the dependent variable is significant, and (4) the relationship between the 
independent variable and the dependent variable is no longer significant when 
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controlling for the mediator. It was postulated that this would indicate that the 
relationship between the independent and dependent variable was fully explained by the 
mediator variable. This approach does not allow for the modelling of sequential 
mediation models. This methodological approach to mediation is compared to path 
analysis further in chapter 6.  
The original trial was not powered for mediation analysis and there is no existing 
literature that provides sufficient information on how to calculate power for more 
complex meditational models as were conducted in study four (Thoemmes, MacKinnon, 
& Reiser, 2010). However guidelines have been developed for suggested sample sizes to 
achieve 80% power for simple mediation models based on small, medium and large 
effect sizes of the α and β paths (Fritz & MacKinnon, 2007). The α path is the path from 
independent variable to the mediator and the β path is the path from the mediator to the 
dependent variable. For medium effect sizes (0.39) of both paths, a sample of 71 is 
necessary to detect mediated effects when applying the bias-corrected bootstrap as was 
done in study two (Fritz & MacKinnon, 2007). For an effect size halfway between small 
and medium (0.26) a sample size of 148 is needed (Fritz & MacKinnon, 2007).  
2.4.2.3 Studies three and four. 
Studies three and four both used one-way ANOVAs to assess differences in 
psychological variables and outcome measures between three IBS subtypes (IBS-A, 
IBS-C and IBS-D). IBS-U was excluded in both analyses because of the 
disproportionately low numbers of participants classified in this subtype. One-way 
ANOVAs were used to detect differences between groups as this analytical approach is 
the most commonly used technique for comparing group means (McDonald, 2009). In a 
one-way ANOVA there is one independent variable (e.g. group) and one dependent 
variable (outcome of interest). The analysis calculates the mean of the observations 
within each group then compares the variance across the group means to the average 
variance within each group. As the means get further apart, the variance among the 
means increases. The test statistic (F statistic) is therefore a ratio of the variance across 
the means divided by the average variance within the groups (McDonald, 2009; Pagano, 
2012).  
The two samples of data were analysed separately as they could not be pooled due to the 
use of different measurements of IBS bowel pattern subtypes. Furthermore it is good 
practice to assess patterns or associations in one data set and replicate in another to 
validate results (Mishler, 1990; Agrillo & Petrazzini, 2012). 
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A priori power calculations were not possible for study three or four, however post hoc 
power calculations were conducted for each study (chapter 7 and 8)
Table 2.1: Overview of studies 
Study 
Number 
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2.5 Chapter Summary 
This chapter provided an overview of the two RCTs that produced the data used in this 
thesis. Both RCTs assessed the efficacy CBT-based interventions in improving symptom 
severity and work and social adjustment in irritable bowel syndrome. There were 
distinctions between data set 1 and data set 2 in trial design, the samples recruited and 
the interventions delivered. The sample in data set 1 was smaller (n=148) than data set 2 
(n=557). Individuals recruited in data set 2 had refractory IBS, whereas this was not an 
inclusion requirement in dataset 1. Furthermore participants in dataset 2 met the Rome 
III criteria for IBS diagnosis, whereas participants in data set 1 met the earlier iteration 
of the Rome I criteria. The key differences in the interventions delivered were that in 
data set 1, CBT was delivered face to face by a trained nurse but in data set 2, all therapy 
delivered was over the phone (in TCBT and WBCBT). The therapy in data set 2 was 
delivered by highly experienced CBT therapists and clinicians specialising in the 
delivery of CBT to LTC/MUS patient populations. The models of CBT used in both 
studies differed slightly. In data set 1, the protocol used a three system’s CBT model of 
IBS whereas in data set 2 the intervention followed a more four-factor approach 
(appendix F).  
All data collection was complete for data set 1, however data set 2 data collection is still 
in progress, allowing only baseline data available to use for analysis in the present 
thesis. This chapter outlined the aims and methods of four studies conducted using both 
data sets and a systematic review of the existing literature. The objectives of these 
studies were (1) to assess whether cognitive and behavioural factors were mediators of 
treatment effect on the outcomes of symptom severity and work and social 
adjustment/quality of life, and (2) to identify cognitive and behavioural factors 
associated with IBS bowel pattern subtypes.
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3. Importance of Mediation Analysis  
3.1 Chapter Overview  
The introduction (chapter one) provided some background to the efficacy of 
psychological treatments in improving symptom severity and quality of life in irritable 
bowel syndrome (IBS). The concept of treatment mechanisms was introduced with the 
assertion that establishing how psychological therapies exert positive effects on 
outcomes is important for the modification and enhancement of future treatments. 
Chapter two detailed (1) a systematic review of mediation studies conducted in the 
context of IBS (study one) (2) a mediation analysis assessing simple and sequential 
mediation models including cognitive, behavioural and affective process variables as 
mediators (study two).  
This chapter explores the concept of treatment mechanisms further, presenting the 
statistical approach of mediation analysis to provide a methodological background for 
studies one and two. The basic principles of mediation analysis, an overview of different 
potential ways to conduct the analysis and the advantages and limitations of such 
approaches are considered. The utility of mediation analysis in furthering the theoretical 
understanding and clinical benefit of psychological treatments is presented with 
examples from studies in IBS.  
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Establishing how psychological therapies work: the importance of mediation 
analysis. 
Abstract 
This editorial reviews the literature regarding psychological studies that are designed to 
address the question of not just whether, psychological interventions effect change, but 
how.  The practicalities and implications of assessing mechanisms of treatments are 
considered with examples from the fields of Cognitive Behavioural Therapy (CBT) and 
Mindfulness. The potential for elucidating theoretical mechanisms, developing new 
theoretical models and modifying treatment approaches are described. In addition an 
overview of different types of statistical methods available to researchers for assessing 
mediation is given.  Structural Equation Modelling (SEM) is a recommended approach. 
The review concludes with a summary of optimum study conditions adopted by 
researchers for establishing mediating effects.
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What is mediation? 
Psychological studies generally focus on measuring whether an intervention works or 
not through the use of specific patient reported outcome measures (Neale & Strang, 
2015). It is less often that researchers investigate how interventions exert their effects on 
an outcome. The investigation into ‘‘how’’ is an investigation into mediation, which 
seeks to understand the mechanisms in process to produce outcomes. 
When the effect of one variable, often an intervention, has its effect on an outcome 
through change in a third variable, mediation is said to occur. This third variable is 
called the mediator. Mediators of treatment effects are sometimes described as the 
treatment effect mechanisms. 
Investigating mediation is important both for the advancement of psychological theory 
and refinement of clinical practice. The study of psychological mediators can allow us to 
capitalise upon key processes involved in generating positive outcomes. This editorial 
aims at providing a basic understanding of mediation, giving a sense of its scope, and to 
illustrate that despite this sort of analysis potentially requiring some specialist 
knowledge, it is critical to advance understanding of psychological therapies. Critical 
evaluation of current research into mediational processes from psychological 
intervention studies are provided, to demonstrate the importance and value of the study 
of mediation as well as potential limitations that may arise in such analysis. 
Study design considerations 
Randomised Controlled Trials (RCTs) are considered to be the gold standard of 
assessing therapeutic change (Evans, 2003) and they are also the optimum study design 
for establishing mediation. Randomisation allows researchers to assume that there are 
no variables confounding the relationship between intervention and mediator, or 
between intervention and outcome. However, this design does not preclude the 
possibility that there may be unmeasured variables confounding the relationship 
between mediator and outcome, as generally the mediator is not randomised 
(MacKinnon & Pirlott, 2015). Confounders are discussed further in the section below. 
Ideally the design of RCTs would incorporate mediation analysis as an integral part of 
the design phase. As such this would involve considered inclusion of mechanism 
measures as well as outcome measures, with stipulation of how many times and at what 
time points these are assessed. The variables to be included in mediation analysis 
should be informed by theory and/or empirical studies, to avoid ‘‘fishing’’ which may 
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cloud theoretical understanding (Johansson & Høglend, 2007). 
 How is Mediation Established? 
The literature regarding mediation in psychology is growing, as evidenced by the 
increasing number of citations of Baron & Kenny’s seminal paper published in 1986 
(Baron & Kenny, 1986). The Baron and Kenny article presents mediation in a three 
variable path model. The three variables are: 
● R= randomisation 
● M= mediator 
● Y= outcome variable (an appropriate measure of therapeutic change) 
The model is demonstrated in Figure 1, which illustrates the path after R on Y ‘‘(path 
c)’’, representing the overall treatment effect of R on Y. Panel B includes a depiction 
of both the direct effect of R on Y through path c’ and also the indirect effect of R on 
Y through M involving paths a and b. The potential unmeasured confounding variables 
– as mentioned in the previous section – are represented by U. 
Baron and Kenny’s methodology asserts that a series of regressions be conducted to 
establish the statistical significance of relationships between the variables in the 
different paths. The series of regressions seeks to infer the mechanistic process of M 
by ascertaining whether: (1) in a regression of Y on R (path c), the effect of the 
intervention variable is statistically significant (2) in a regression of M on the R (path 
a), the effect of the intervention variable is statistically significant (3) in a regression of 
Y on R (path c’), and M (path b) the effect of the mediator is statistically significant (4) 
in the regression in (3), the intervention effect is no longer statistically significant 
when controlling for the mediator. 
Baron and Kenny assert that the strongest evidence for mediation is when the effect of 
the intervention in regression (3) is reduced to zero, which is generally referred to as 
‘‘full mediation’’. If the effect of the mediator and intervention are significant in (3), 
or if the effect of the mediator is significant and the effect of the intervention is not 
zero, but is lessened when controlling for the mediator, this is generally referred to as 
partial mediation, and the assumption is that there are other mediators influencing the 
effect of the intervention on the outcome that haven’t been included. This method is 




Although this method of testing mediation is now widespread in the literature, there 
are limitations associated with the method that have been discussed elsewhere (Emsley 










Figure 1:  Simple mediation model.  Panel A depicts R →Y model and panel B depicts R → M 
→Y mediation model. 
 
One issue with the method is the requirement for a significant intervention effect as 
stated in (1). Along with others (Emsley et al., 2010; MacKinnon, 2008), we do not 
agree that mediation should only be investigated when there is a significant intervention 
effect. It may be even more important to study mediation where this is not the case; in 
order to determine if the intervention does not have the desired effect on the mediator, 
the mediator does not have an effect on the outcome, or if there is evidence of 
suppression (MacKinnon et al., 2000; MacKinnon, 2008). Suppression occurs when the 
indirect and direct effects oppose one another. 
Another difficulty with the causal steps method is that it does not directly quantify the 
indirect effect through the mediator. Instead it relies on a number of hypothesis tests to 
make inferences about mediation. In addition, this method has been shown to have low 
power to detect mediated effects. In other words, researchers using this method may 
miss effects even when they are present (Hayes, 2009; MacKinnon et al., 2002, 2007; 
Preacher & Hayes, 2008). Finally, Baron & Kenny did not address the possibility of 
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biased results due to unmeasured confounding variables i.e. variables which may 
influence both the mediator and the outcome. The omission of such confounding 
variables could bias the results of mediation analysis (Emsley et al., 2010; MacKinnon, 
2008). This issue was presented in the earlier and less referenced paper by Judd & 
Kenny (1981), and can be at least partially dealt with by measuring potential 
confounders and including them in the regression models. 
Another issue that was brought to the fore in both the Baron & Kenny and Judd & 
Kenny papers (Baron & Kenny, 1986; Judd & Kenny, 1981) was measurement error in 
variables, which could also lead to biased effect estimates. Measurement error is likely 
to be of particular concern in psychology and psychiatry, where we are often interested 
in unobservable or latent traits. Structural Equation Modelling (SEM) allows modelling 
of relationships between underlying latent trait variables, each quantified by several 
scale items or measures. For example maladaptive cognitions may be measured using a 
questionnaire, which includes several items that could be indicative of such cognitions 
(‘‘I am no good’’, ‘‘they probably think I can’t do this’’). In this example the latent trait 
is maladaptive cognitions. By utilising multiple items or measures and modelling latent 
variables, SEM account for measurement error and elucidate relationships between 
latent traits (Bollen & Pearl, 2013; MacKinnon, 2008). SEM utilising only observed 
variables is referred to as Path Analysis Models (MacKinnon, 2008). 
Like the use of Baron & Kenny’s Framework, the use of SEM for investigating 
mediation has also been criticised. However, it has been noted that rather than an issue 
with the method itself (Bollen & Pearl, 2013; Emsley et al., 2010; MacKinnon, 2008), 
this is more to do with improper or non- specification of theoretical models and 
disregarding assumptions in interpreting results  (Bollen  & Pearl, 2013; Emsley et al., 
2010; MacKinnon, 2008). An important advantage to the SEM approach to mediation 
is that SEM can simultaneously model multiple outcomes/regressions as well as 
multiple mediators (MacKinnon, 2008). To summarise, two main benefits of SEM are: 
the ability to allow for measurement error (Little et al., 2007), and the ability to 
investigate more complex models of mediation. 
  Mediation in psychological research 
As already identified, one benefit of mediation research in psychological studies is the 
potential for therapeutic approaches to be enhanced. By pinpointing mediating 
mechanisms, therapeutic processes may be refined to focus on specific aspects of 
therapy that lead to improvements in outcomes, with the possibility of discarding 
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aspects that are less relevant (Kazdin, 2007). This could lead to more efficient and 
effective delivery of therapy. Uncovering mechanistic processes can also be useful for 
development and enhancement of treatments that can be used transdiagnostically 
across different conditions, tackling a range of outcomes simultaneously. An advantage 
to the development of transdiagnostic treatments is to potentially streamline the 
approach to treatment of individuals with multiple symptoms or comorbidities (Clark 
& Taylor, 2009; Newby et al., 2015). 
Investigations of the mechanistic processes of psychotherapies are increasing, although 
currently the literature remains limited. Psychotherapies that have been more widely 
subjected to mediation analysis include cognitive behavioural therapy (CBT) (Maric et 
al., 2013; Odondi et al., 2013; Turner et al., 2007; Whisman, 1993) and mindfulness 
based therapies (MBTs)  (Bra¨nstro¨m  et  al.,  2010;  Coffey  &  Hartman,  2008; Sears & 
Kraus, 2009). 
  Investigating proposed theoretical mechanisms 
One practical use of mediation analysis is to evaluate theoretically implicated process 
variables. This can advance both theory and therapeutic practices. Given that it is now 
widely used transdiagnostically, CBT is an example of a therapy where mechanism 
evaluation is particularly import- ant. CBT is designed to alter negative patterns of 
thinking and behaving that are considered to cause and/or maintain symptoms and 
disability across a wide variety of conditions. The proposed mechanisms of change at a 
broad level are cognitions and behaviours. Investigation into whether these processes 
are indeed responsible for improved outcomes as a result of CBT have been conducted 
in the context of chronic pain (Turner et al., 2007), panic disorder (Hofmann et al., 
2007), chronic fatigue syndrome (Chalder et al., 2015; Moss- Morris et al., 2005; Stahl 
et al., 2014) and irritable bowel syndrome (IBS) (Lackner et al., 2007; Miklowitz & 
Scott, 2009; Reme et al., 2011) amongst other disorders (Hofmann et al., 2012). 
Specific CBT models have been developed to explain certain conditions such as 
depression (Beck et al., 1987), medically unexplained symptoms (Deary et al., 2007), 
and IBS (Toner et al., 2000). Such models provide a basis for empirical investigation, 
which in turn allow the validation and development of the models. In the context of 
IBS for example, the CBT model postulates that reduction in symptom severity and 
impact on life is due to treatment-induced changes in conceptualisation of bowel 
symptoms (Toner et al., 2000). This reconceptualization should involve changes in 
beliefs about IBS being an uncontrollable medical problem and increases in 
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behavioural strategies that can be employed in the face of symptoms. One particular 
study examining cognitive and behavioural mechanisms in IBS found evidence 
supportive of this (Reme et al., 2011). The mediator variables tested included the 
Cognitive Scale for Functional Bowel Disorders (CS-FBD) (Toner et al., 1998) and 
the Behavioural Responses Questionnaire for IBS (IBS-BRQ) (Reme et al., 2010). The 
CS-FBD includes items relating to specific beliefs about functional bowel disorders 
such as ‘‘It is embarrassing to keep going to the toilet’’. The IBS-BRQ includes 
specific items for behaviour implicated in IBS such as ‘‘I avoid exercise when I have 
stomach pains’’. 
The analysis found that change in both cognitions and behaviours mediated the 
reduction in symptom severity and impact on life. SEM was used to apply a 
sequential mediator model indicating that behaviours changed prior to cognitions 
(Reme et al., 2011). In this study, the mediator variables included in the analysis were 
taken from the same time point as the outcome variables. Mediation implies a causal 
process, where treatment is applied first, followed by a change in the mediator, which 
is then followed in turn by a change in the outcome. Studies with mediator and 
outcome measures taken at the same time may provide weaker evidence for treatment 
mechanisms as the implied temporal ordering has not been incorporated in the study 
design. The rationale in this case was that there was no significant further change in 
mediator variables assessed at later time points and therefore it made little difference 
to use scores from later time points in analysis. Nevertheless, it is more theoretically 
sound to design studies that respect this implied temporal ordering. Therefore, studies 
should aim at including mediators measured at time points prior to the outcome 
variable. This is given further consideration later. 
Where the focus of interventions differ within the same school of psychotherapy, 
mediation can be used to clarify the extent to which different processes produce 
change in outcomes. For example, within CBT as applied to IBS, different researchers 
postulate the importance of different mechanistic processes, namely a change in 
cognitions and/or behaviour versus a reduction in distress/anxiety. To date, findings 
supporting one key process over the other have been inconsistent. This is demonstrated 
by the differing results in two particular mediation studies investigating CBT for IBS, 
conducted by Lackner et al. (2007) and Jones et al. (2011). Both studies investigated 
the potential mediating roles of psychological distress on outcome after CBT for IBS, 
with conflicting findings. There were, however, some distinct limitations within both 
studies and also arising from the comparison between them. First of all, both studies 
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used different measures of psychological distress: Jones et al., used the Hospital 
Anxiety and Depression Scale measure of anxiety and depression (Snaith, 2003) and 
Lackner et al., used the Brief Symptom Inventory measure of psychological distress 
(Derogatis & Spencer, 1993). Whilst Jones et al. provided a clear mediation model 
informed by theory, Lackner et al., assessed a model of mediation that did not appear 
to be informed by theory. The path model of Jones et al., arranged variables into a 
sequence informed by an interpretation of the Biopsychosocial model (Drossman, 
1998), in which CBT alters mood (anxiety and depression) positively, which then 
reduces bowel symptoms. In contrast, Lackner et al., assessed a complex path model 
with no clear theoretically informed structure, in which there were three direct paths 
from CBT to all three outcomes (quality of life, global symptom improvement and 
distress) as well as multiple indirect paths between the different outcome measures. 
Jones et al. found that anxiety and to a lesser extent depression had a mediating effect, 
whereby decreases in both led to a reduction in symptom severity. On the other hand, 
Lackner et al. did not find psychological distress to be a significant mediator. They 
instead found that CBT had a direct effect on symptom severity independent of 
distress. Lackner et al.’s findings are supported by more recent mediation analysis, 
which also found that distress was not a significant mediator (Chilcot & Moss-Morris, 
2013). This study included a measure of cognitions and behaviours, finding that 
cognitions significantly mediated the effect of treatment on symptom severity. This 
strengthens support for a cognitive behavioural model for IBS in which change in 
outcome is mediated by cognitions rather than distress. 
The example of the Jones and Lackner studies illustrates a number of limitations 
within the current mediation literature: (a) Results will be dependent on which 
mediation variables are entered in the analysis. It is important for mediation studies to 
be fully informed by theory to allow for examination of all possible mediators as 
dictated by the theoretical model. (b) Different measures may be utilised to measure 
concepts that are the same or similar, which can limit interpretation across studies e.g. 
a measure of anxiety vs. a measure of psychological distress. (c) Different approaches 
to mediation analysis may affect findings. This will be considered later in the article 
and (d) It may be that there is a longer mediation chain that involves more than one 
mediator variable in the causal path where one mediator may serve     to mediate the 
effects of another mediator (Taylor et al., 2008). In this  example,  this  would  occur  
where  change  in cognitions mediates change in psychological distress, which then 
accounts for change in the outcome of symptom severity. 
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  Developing theory 
The previous section described the use of mediation studies to examine processes 
guided by psychological theory. Here we consider how mediation analysis can provide 
opportunities to build theory, which we refer to as ‘‘back translation’’. Mindfulness 
research provides an opportunity in which to consider the application of back 
translation. The provision of MBT is growing across different clinical populations, yet 
the theoretical underpinnings of such practice remains scarce. An initial theory, by 
which mindfulness was proposed to exert clinical effects, was published in 2006 
(Shapiro et al., 2006). The theory asserted that four variables identified as changes in 
self-regulation, values, flexibility (cognitive, emotional and behavioural) and exposure 
to internal processes, may act as mechanisms responsible for outcomes such as 
reduction in symptoms or distress. These processes were asserted to be achieved 
through increased ‘‘re-perceiving’’ and ‘‘de-centering’’. These pertain to the ability to 
maintain objectivity towards experience. 
This theory was tested by Carmody et al. (2009), using the causal steps approach to 
mediation. There were some methodological issues associated with this study that 
should be considered. First, participants were not randomly allocated to different 
groups so analysis was conducted without the use of a comparator control group. 
Secondly, some of the measures lacked established reliability and validity. Some of 
these measures were then altered further before being entered into the mediation 
analysis, as the authors created a composite unitary measure of mindfulness, re-
perceiving and de-centering; variables that were identified as distinct in the theoretical 
model described by Shapiro et al. (2006). The analysis utilised the Baron & Kenny 
causal steps approach, with the limitations detailed earlier in this paper. Finally, the 
authors did not include measures assessed at differing time points further reducing 
causal inference. 
The results of the analysis found that the effects of composite mindfulness/re-
perceiving on psychological symptoms, were found to be partially mediated by two of 
the four processes identified in the model: Cognitive, emotional and behavioural 
flexibility and values clarification. Rather than providing conclusive evidence for the 
hypotheses proposed by Shapiro et al. the results served as a basis upon which to focus 
further investigations, also highlighting the possibility that there may be other 
mediating processes unaccounted for in the model. 
Both theory and empirical study have been a basis for further investigations into 
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important processes of mindful- ness, such as cognitive and behavioural flexibility 
(Baer, 2010; Heeren et al., 2009; Ho¨lzel et al., 2011; Kuyken et al., 2010). Elements 
closely associated with mindfulness and nested within the model, such as self-
compassion (Baer et al., 2012; Hayes et al., 2004; McCracken & Velleman, 2010; 
Neff, 2003; Petrocchi et al., 2014), have continued to attract research focused on the 
examination of mechanisms of MBTs (Baer, 2010; Ho¨lzel et al., 2011; Kuyken et al., 
2010). Most recently, a systematic review of empirical studies investigating proposed 
mechanisms of MBTs on a range of clinical outcomes identified some key processes 
(Chiesa et al., 2014). These included cognitive reactivity, experiential avoidance, 
emotion regulation and self-compassion. The accrual of empirical evidence of such 
processes will continue to provide cumulative insights informing more 
comprehensive and developed models (Bullock et al., 2010). 
  Shared mechanisms in psychotherapy 
Another reason for investigating mediation in the context of psychotherapy is to 
elucidate mechanisms that are shared across different psychotherapeutic practices. 
There is an increasing shift towards transdiagnostic conceptualisation of conditions 
and treatment approaches (Newby et al., 2015), which is beyond the scope of this 
article. Nevertheless, it is clear that increasing discovery of efficacious mechanistic 
processes across treatment approaches and diagnoses, could allow for more unified 
treatments that are effective for a wide range of outcomes. 
In a systematic review of psychosocial treatments for bipolar disorder, common 
mechanisms across treatments were identified. These included enhancement of 
interpersonal functioning and teaching self-monitoring to allow early self- intervention 
during relapses (Miklowitz & Scott, 2009). Such processes have also been implicated 
in interpersonal therapy (IPT) (Lipsitz & Markowitz, 2013) and can be seen to be 
present in other therapies such as CBT (Livesley, 2007; Steever, 1999), MBT (Epstein 
et al., 2008) and counselling (Howey & Ormrod, 2002). It was particularly noteworthy 
that effective therapies shared a number of common characteristics with regards to 
how the model of therapy was shared with the patient, how the therapy was delivered 
and the structuring of treatment (Miklowitz & Scott, 2009). Shared characteristics 
included individualized formulation (tailoring approaches to meet the patients’ needs 
and understanding), openly sharing the therapy model with the patient, a clear 
rationale for techniques used that were logical to the patient, an emphasis on 
psychoeducation and skill development, attributing change to the patient’s efforts and 
the encouragement of the continued use of illness management techniques for the 
 
78 
patient post therapy. 
Other disease specific systematic reviews conducted have further demonstrated the 
existence of shared mechanisms across different therapeutic approaches. In a recent 
review of mechanisms in psychosocial interventions for cancer, self- efficacy in the 
use of coping strategies and changes in cognitions mediated treatment outcomes in 
CBT, psycho- education and relaxation training (Stanton et al., 2013). However, it 
should be noted that the outcomes across studies varied. The outcomes were broadly 
classified into the following domains: psychosocial adjustment, self-reported physical 
health indicators and biological health indicators. Future reviews establishing 
mediation across the same or similar outcomes would provide an opportunity to test 
the hypothesis that the effects of mediators on such outcomes are the same across 
therapies. 
  Scope of mediation analysis 
Mediation can be a complex process to conceptualise theoretically as well as to 
approach statistically. Some particular areas for researchers to focus on are discussed 
below. 
  Different approaches to mediation 
The ‘‘product of coefficients’’ approach (MacKinnon, 2001; MacKinnon & Dwyer, 
1993) is an extension of the Baron & Kenny causal steps approach, which can be 
applied using the SEM framework. This approach is preferred (Hayes, 2009; 
MacKinnon et al., 2007) over causal steps. Product of coefficients calculates the 
indirect (mediated) effect by multiplying the intervention regression coefficient in path 
a, by the mediation regression coefficient in path b (Figure 1). 
 Temporal precedence 
The design of RCTs can allow for the theoretically implied temporal ordering of the 
mediation model, and ascertain the effects of an intervention (R) that occurs prior to 
the mediator (M) and outcome (Y) (Figure 1). This may not be as readily possible in 
observational studies, in part due to the potential for more sources of confounding. 
However, simply studying mediation in the context of an RCT is not sufficient to 
establish    causal    relationships    (Emsley et al., 2010, MacKinnon, 2008; 
VanderWeele, 2015). One helpful approach to gaining understanding of mediational 
processes is to explore the timeline of mediator and outcome change (Cole & 
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Maxwell, 2003). Assessing both mediator and outcome measures before, during and 
after treatment, with assessment at multiple time points is ideal and can provide 
information about optimal measurement timelines for future studies. 
  Moderation 
The intensity of mediated effects could be dependent on other variables called 
moderators (MacKinnon, 2008). Moderators are variables that alter the form or 
strength of the relationship between an independent variable and a dependent variable 
i.e. R and Y. In other words, when there is moderation, the effect of R on Y varies by 
a third variable, the moderator X, Moderation is explored in models using interaction 
terms, so in this case, we would explore the effect of an R by X interaction in a 
regression model for Y. A moderator may be a variable that is not manipulated such as 
gender or age. For example it is possible that CBT for depression is more or less 
effective for different age groups (Jayasekara et al., 2015) as age may change the 
efficacy of CBT. Moderators may also be experimentally manipulated. For example, 
participants may be randomly assigned to the same treatment with different levels of 
therapist warmth and empathy, to ascertain whether therapist warmth and empathy 
moderates outcome (Harper Romeo et al., 2014). Moderation is important to assess 
the generalizability of research findings. It is also useful in psychological research for 
identifying participant subgroups for whom treatment may be more or less effective. 
 Moderated mediation 
Moderated mediation occurs when the strength of an indirect effect (mediation) 
depends on another variable (moderator) (MacKinnon et al., 2007). As such the 
meditational mechanism differs for different subgroups (e.g. age, gender, levels of 
distress). For example CBT (R) may reduce symptom severity in IBS (Y) through a 
change in cognitions (M). Age (X) may moderate the change in cognitions, for 
example, older participants may experience less change in cognitions. Discovering 
such a relationship would highlight the need to investigate why age may act as a 
barrier to cognitive change, resulting in empirical testing of possible solutions. Such 
analysis into these underlying processes can provide greater potential for tailoring 
treatments to subsets of patients within heterogeneous populations (Bullock et al., 
2010). 
 Summary 
The full complexity of investigating mediation, moderation and moderated mediation 
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is beyond the scope of this article, however some possible reasons for differing 
findings across mediation studies within the same area have been put forward. These 
include the use of different statistical approaches to mediation, different measurements 
of similar variables, inclusion or non-inclusion of variables as dictated  (or not) by 
theoretical models and the inclusion or non-inclusion of confounding variables in 
analysis. Furthermore, considering the intuitive and comparatively simplistic nature of 
the causal steps approach, it also makes sense that this has been the predominant 
method of establishing whether mediation occurs. This being so, it would be useful if 
researchers undertaking mediation analysis would adopt more sophisticated methods 
where appropriate (Hayes, 2009; MacKinnon et al., 2002, 2007; Zhao et al., 2010). 
The widely prevalent use of the causal steps approach to mediation has resulted in a 
number of misconceptions, including the idea that a statistically significant effect of an 
intervention is necessary before it is advisable to test for mediation; and that a decrease 
in variance accounted for in the R – Y relationship after inclusion of a mediator is 
sufficient to conclude there is mediation (Stanton et al., 2013). Happily, researchers 
interested in mediation analysis can now refer to a burgeoning literature on best 
practices in the modern study of mediation (Dunn et al., 2013; Hayes, 2009; 
MacKinnon, 2008; VanderWeele, 2015). 
In the context of psychological studies, the study of mediation is critical if we are to 
understand how therapies exert their effects, test psychological models of therapeutic 
mechanisms, and most importantly, improve outcomes for our patients. The more 
mediation studies that are conducted in a more rigorous fashion, the more insight can 
be gathered into therapeutic mechanisms, which may be transdiagnostic, such as in the 
case of CBT (Murphy et al., 2009; Newby et al., 2015). Future randomised studies of 
psychological therapies should therefore include mediation analysis in their design 
wherever possible, with the inclusion of potential mediator measures informed by 
theory. Measurements should be taken early and at multiple time points, with 
concomitant measurement of potential confounders in order to allow for detailed and 
robust assessments of mediational processes. A recent innovation launched by the UK 
National Institute of Health Research (NIHR) has provided opportunities for funding 
specifically for Efficacy and Mechanisms Evaluation (EME) studies (Dunn et al., 
2013; Walley & Thakker, 2008), with mediation studies being one aspect of the remit. 
This, and the growing interest in, and literature focused on mediation are positive steps 
that have and will continue to increase the use of robust methodological approaches for 
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4. Systematic Review of Mediators in Psychological 
Therapies for IBS 
4.1 Chapter Overview  
Previous chapters have identified the importance in assessing mechanisms by which 
psychological therapies may have an effect on outcomes. To fulfil objective one of this 
thesis, a systematic review was conducted. The aim of this review was to identify 
psychological factors that mediated the effect of psychological interventions in IBS on 
the outcomes of symptom severity and or/quality of life. It was hypothesised that 
cognitions, behaviours and anxiety would significantly mediate treatment effect, in line 
with cognitive behavioural models of IBS (Kennedy et al., 2005; Craske & Barlow, 
2006; Moss-Morris et al., 2010). The results of the review are important for informing 
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The  journey between  brain and gut: A systematic review of psychological 
mechanisms of treatment effect in irritable bowel syndrome 
Purpose: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder 
characterized by abdominal pain and altered bowel habits. It is estimated to affect 10–22% 
of the UK population. The use of psychological interventions in IBS is increasingly 
empirically supported, but little is known about the mechanism of psychological 
treatment approaches. The present systematic review aimed to investigate the 
mechanisms of psychological treatment approaches applied to IBS. 
Methods: The systematic review included studies conducting mediation analysis in the 
context of psychological interventions for IBS, focusing on the outcomes of symptom 
severity and/or quality of life (QoL). 
Results: Nine studies in total were included in the review. Eight of the studies assessed 
mediation in the context of cognitive behavioural-based interventions, and one study 
assessed mediation in a mindfulness-based stress reduction intervention. Results indicate 
that change in illness-specific cognitions is a key process by which psychological 
treatments may have an effect on the outcomes of symptom severity and QoL. 
Furthermore, results suggest that whilst GI-specific anxiety may also be a key mechanism 
of treatment effect, it would appear that general or state anxiety is not. Although less 
commonly included in mediation analysis, illness-specific behaviours may also have a 
mediating role. 
Conclusions: A mediational model amalgamating the results of studies is proposed to 
illustrate the findings of the review. The model depicts the process by which 
psychotherapy changes illness-specific cognitions, behaviours, and anxiety to achieve 




Irritable bowel syndrome: definition, aetiology, and prevalence 
Irritable bowel syndrome (IBS) is a chronic disorder that usually involves 
periods of remittance in between flare-ups that may vary in severity. The 
diagnosis of IBS is based on the absence of any other physiological 
markers that explain the experience of symptoms. For this reason, many 
people with a diagnosis of IBS may have undergone several investigative 
procedures prior to diagnosis. The prevalence of IBS in the general 
population is estimated to be 10.5% (Wilson, Roberts, Roalfe, Bridge, & 
Singh, 2004). This varies across ages and gender, with women aged 
between 30 and 39 being twice as likely to experience it than men of the 
same age range (Dalrymple & Bullock, 2008). IBS is associated with 
impaired quality of life (QoL) and distress (Athanasakos & Emmanuel, 
2013; Wu, 2012) as well as high rates of comorbidity of anxiety (Fond et 
al., 2014). 
The ROME criteria were developed to classify functional gastrointestinal 
disorders that were not otherwise explained by structural or tissue 
abnormalities. The most recent ROME IV criteria asserts that the prevalent 
symptom of IBS is abdominal pain, which must be associated with changes 
in bowel movements or stool consistency (Drossman, 2016). The criteria 
identify four bowel subtypes: constipation predominant (IBS-C), 
diarrhoea predominant (IBS-D), alternating bowel pattern (IBS-A), and 
unclassified (IBS-U). These subtypes are categorized based on the 
proportion of symptomatic stools that are loose/watery or hard/lumpy. 
Brain–gut axis 
Although the cause of IBS remains unclear, increasing credence is given to the 
biopsychosocial aetiological model of IBS (Engel, 1981). This proposes that 
symptoms occur due to an interaction between biological, psychological, and social 
mechanisms (Mayer, Labus, Tillisch, Cole, & Baldi, 2015; Quinton & Keefer, 
2014; Van Oudenhove et al., 2016). A physiological system by which this 
interaction may occur is referred to as the ‘brain–gut axis’ (BGA; Jones, Dilley, 
Drossman, & Crowell, 2006). The BGA is a bidirectional communication between 
the enteric nervous system (ENS) located in the walls of the gastrointestinal (GI) 
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tract, and the autonomic and central nervous systems (Fichna & Storr, 2012). The 
mechanism of communication involves the autonomic stress response and the 
endocrine, neuroimmune, and neural pathways (Wu, 2012; Kennedy et al., 2012) 
utilizing the hypothalamic–pituitary–adrenal axis (HPA axis). A recent review 
comprehensively explains how the BGA underpins the psychological, social, and 
physiological interactions to contribute to the experience of symptoms in 
functional bowel disorders (Van Oudenhove et al., 2016). The BGA is therefore 
the proposed physiological mechanism by which psychological factors can 
exert effect on physical outcomes such as symptom severity (Van Tilburg, 
Palsson, & Whitehead, 2013). 
Psychological treatments in IBS 
It is well established that psychological factors affect both QoL and symptom 
severity in IBS (Van Tilburg et al., 2013), and psychological treatments have 
been developed over the years to target such factors. Meta-analyses and 
systematic reviews have established the efficacy of psychological treatments in 
reducing symptom severity in IBS (Ford, Talley, Schoenfeld, Quigley, & 
Moayyedi, 2009; Kennedy et al., 2012; Lackner, Mesmer, Morley, Dowzer, & 
Hamilton, 2004; Li, Xiong, Zhang, Yu, & Chen, 2014). The most commonly 
utilized psychological treatments in IBS are considered below in terms of the 
underlying theoretical model, mechanisms, and empirical support. 
Cognitive behavioural therapy (CBT) 
To date, the majority of psychological interventions conducted in IBS are CBT-
based, with strong empirical support demonstrating its efficacy in reducing 
symptom severity and enhancing QoL/impact on life (Ford et al., 2009, 2014; Li 
et al., 2014). This being said, there is not one agreed CBT protocol for IBS and 
different studies use different models and treatment techniques (Henrich et al., 
2015). 
Some protocols may put more emphasis on targeting general or state anxiety, 
as opposed to gastrointestinal-specific anxiety (GSA; Blanchard et al., 2007; 
Lackner et al., 2007). Protocols, focusing on GSA, tend to more heavily utilize 
exposure-based techniques  (Craske et al., 2011; Hunt,  Moshier,  &  Milonova,  
2009;  Ljo´tsson  et  al., 2010). It has also become common for CBT protocols to 
include mindfulness (Ljo´tsson et al., 2010; Wolitzky-Taylor, Craske, Labus, 
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Mayer, & Naliboff, 2012). Other protocols follow a three-systems model, 
specifically focusing on the change of illness-related cognitions and behaviours 
(Kennedy et al., 2005, 2006), as opposed to the targeting of thoughts and 
behaviours more commonly related to general anxiety. Although there may be 
shared mechanisms of change across protocol approaches, the way in which 
treatment works may differ between studies depending on the model and 
interventions used. 
Hypnotherapy 
Hypnotherapy (HT) as applied to IBS is called ‘gut-directed’ or ‘gut-focused’ HT. 
The process involves the use of hypnotic techniques that are designed to relax the 
automatic reaction to symptoms and allows individuals more control in their 
cognitive and physical response to them (Gonsalkorale, Toner, & Whorwell, 2004). 
Sessions consist of induction of a hypnotic state and hypnotic suggestions to 
reduce threat perception of symptoms. Evidence suggests that this approach is 
effective in improving both physical symptoms of IBS and enhancing QoL (Miller 
et al., 2015; Wilson, Maddison, Roberts, Greenfield, & Singh, 2006). 
There has been substantial interest in the mechanisms of HT in IBS 
(Simre´n, 2006; Spiller et al., 2007; Tan, Hammond, & Gurrala, 2005). 
One of the key mechanisms consistently implicated in the literature 
seems to be the role of cognitions. One particular study found that 
after HT, IBS improvement was associated with a reduction in IBS-
related cognitions (Gonsalkorale et al., 2004). The authors suggested 
that the hypnotherapeutic approach used could be regarded as a form 
of cognitive restructuring as it involved techniques to increase 
individuals’ perceived control over symptoms. 
Psychodynamic psychotherapy 
Psychodynamic psychotherapy for IBS aims to reduce symptoms 
through enhancing interpersonal relationships, which are purported to be 
the underlying source of symptomatic complaints (Guthrie, 2002). This 
approach is called ‘psychodynamic interpersonal therapy’ (PIT). Sessions 
are designed to provide individuals with insight into the link between 
interpersonal difficulties and symptoms, and between emotions and 
bowel symptoms. A limited number of studies have assessed the efficacy 
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of PIT for IBS with some support for its efficacy in reducing symptom 
severity (Creed et al., 2003; Guthrie, Creed, Dawson, & Tomenson, 
1991; Svedlund, Ottosson, Sjo€din, & Dotevall, 1983). 
There is not an established model by which PIT is proposed to improve 
IBS symptoms; however, Hyphantis, Guthrie, Tomenson, and Creed 
(2009) hypothesized that PIT would lead to a reduction in IBS 
symptoms, by reducing psychological distress associated with 
interpersonal conflict. This study assessed the mediating effect of 
psychological distress on interpersonal distress, finding significant 
mediation.  It did not however assess the relationship between treatment, 
these processes, and the outcome of symptom severity. 
Establishing mechanisms of psychological treatments for IBS 
The primary way to elucidate mechanistic processes in psychological research is by 
conducting mediation analysis (Baron & Kenny, 1986; MacKinnon, 2008; 
Windgassen, Goldsmith, Moss-Morris, & Chalder, 2016). This allows potential 
mechanistic variables to be assessed in the context of the proposed pathway between 
treatment and outcome (Kazdin, 2007). A simplistic model of mediation is 
illustrated in Figure 1. This demonstrates how a treatment may cause change in an 
outcome, by first eliciting change in a mediating variable. An early approach to 
conducting mediation analysis was proposed by Baron and Kenny (Baron & Kenny, 
1986), utilizing a series of regressions. Mediation is said to occur where I is shown 
to no longer influence (or have less of an influence on) O when M is controlled 
for. This approach is sometimes referred to as the ‘Causal Steps’ approach to 
mediation (MacKinnon, Fairchild, & Fritz, 2007; MacKinnon, Lockwood, 
Hoffman, West, & Sheets, 2002). 
Structural equation modelling (SEM) is another statistical method to assess 
mediation. SEM is sometimes referred to as ‘path analysis’ when it is 
conducted utilizing observed variables (MacKinnon, 2008). SEM can also 
allow the modelling of relationships between variables utilizing underlying 
latent traits and allow models to account for measurement error (Bollen & 
Pearl, 2013; MacKinnon, 2008). An advantage to the SEM/path analysis 
approach to mediation is that it can model multiple outcomes/regressions 
simultaneously, which allows for longitudinal modelling of multiple measures 
of mediators and outcomes. In practical terms, this means that numerous 
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Figure 1: Simplistic Mediation Model: I is the treatment or intervention, M the mediating 
variable through which I has an effect on O the outcome. 
Although the number of studies empirically investigating the efficacy of 
psychological therapies for IBS has increased, little is known about how 
psychological treatments work (Murphy, Cooper, Hollon, & Fairburn, 2009). 
Investigating the key processes involved in creating change in outcome is 
important to identify components of therapy that are necessary for achieving 
desired outcomes. It therefore also provides opportunity for treatment 
modification and enhancement. The present review aimed to systematically 
assess psychological variables shown to significantly mediate treatment effect 
on the outcomes of symptom severity and QoL. 
Methodology 
The systematic review methods adhered to PRISMA guidelines to ensure the 
standardized reporting of systematic reviews (Moher, Liberati, Tetzlaff, & 
Altman, 2009). 
Literature search 
The search was conducted using electronic databases Ovid, PsycInfo, Embase, 
MEDLINE, PsycArticles, and Global Health. The search was conducted three 
times in the months April 2014, June 2014, July 2015, and May 2016 (Appendix 






In accordance with the recommendations of the Centre for Reviews and 
Dissemination (Tacconelli, 2010), the search strategy was developed using a 
PICOS format. The acronym refers to (P) population (I) intervention (C) 
comparator group (O) the outcome or endpoint interested in (S) study 
design. This shaped the inclusion criteria (Appendix S2). To be included 
studies had to have conducted mediation analysis on an intervention 
delivered prospectively. This was to ensure that mediation was designed 
to test mechanisms of efficacy for delivered interventions rather than to 
explore potential mechanisms of outcome in the absence of an intervention. 
Assessing study bias 
The Cochrane Handbook stipulates that systematic reviews should assess 
a risk of bias in included studies (Higgins & Green, 2008). In this 
systematic review, two separate tools were used. One was designed to 
assess the overall quality of randomized controlled trials (RCTs) using the 
original RCT publication, and the other was developed to assess the 
quality of mediation analysis. The RCT quality assessment (QA) tool 
(Appendix S3) used was the Cochrane Guide for QA s (Van Tulder, Furlan, 
Bombardier, & Bouter, 2003). Only two criteria were not included in the 
present review. These related to (1) blinding of the participants and (2) 
blinding of the care provider, which were not practical to use due to the 
nature of the interventions being studied. Papers were rated as ‘yes’, ‘no’, or 
‘unclear’ against each criteria. Papers were scored out of a total of 9. Answers 
of ‘no’ or ‘unclear’ scored 0 and answers ‘yes’ scored 1. This rating is 
adherent to the recommendations by Cochrane (Higgins & Green, 2008). 
The papers were rated by the first author and AS. 
Two approaches were used to develop the mediation QA tool (Appendix 
S4). Items were based on a previously developed tool (Lubans, Foster, & 
Biddle, 2008). Some items were altered to reflect the aims of the present 
review. Additional items were added to reflect the range in quality across 
the studies included in review and against standards stipulated in the 
mediation literature (MacKinnon, 2008). 
The additional items were as follows: (1) Was  more than one model fit 
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criteria reported where path models were used in analysis? (2) Was the 
mediator variable/s assessed for change? (3) Was temporal precedence 
accounted for in the analysis? (4) Did the study report confidence 
intervals of the mediated effect? When the Baron and Kenny framework 
was used, it was stipulated that confidence intervals should be used for 
paths a and b. Where SEM or path analysis was used, confidence 
intervals for the indirect path/s were stipulated. 
The additional criteria are detailed in order of their listing: (1) It is 
recommended that more than one model fit criteria should be used in 
SEM because each criteria are affected by different factors (such as 
sample size, model complexity, and data normality; Hair, Anderson, 
Tatham, & Black, 1992; McDonald & Ho, 2002). (2) It was deemed 
important to establish whether the mediator was assessed for change, 
to ascertain whether the interventions were effective in producing 
change in proposed mediating variables. (3) Studies were rated on the 
inclusion of design accommodating temporal precedence as this is an 
important design consideration to allow inferences regarding causality. 
(4) Confidence intervals were deemed necessary to indicate the 
magnitude of the path coefficient. 
Papers using Baron and Kenny’s Causal Steps approach were scored out 
of 7, whilst other approaches to measuring mediation were scored out of 8. 
This was because the item regarding assessment of fit criteria was not 
relevant to the causal steps approach to mediation. 
Quality assessment for mediation was conducted by two of the authors, 
the first author and the fourth author. The third author was used to rate 
the quality of one paper to minimize the risk of bias as the fourth 
author was also an author of this study. Any disparities were discussed 




Figure 2. PRISMA flow diagram. The figure details how many papers were excluded at each 




Three hundred and thirty-seven search results were returned in the initial 
search. Three hundred and seventeen were excluded after screening titles 
and abstracts, and removing duplicates (Figure 2). The full text of 20 
articles were screened, and nine were left to review (Chilcot & Moss-
Morris, 2013; Garland et al., 2012; Hunt et al., 2009; Jones, Koloski, 
Boyce, & Talley, 2011; Labus et al., 2013; Lackner et al., 2007; Ljo´tsson et  
al., 2013; Reme et al., 2011; Wolitzky-Taylor et al., 2012). The most 
common reasons for exclusion at the full-text screening phase were 
studies not performing mediation analysis or not conducting an 
intervention (Figure 2). Two studies that conducted mediation were 
excluded as they either did not assess mediation of treatment effect on 
the outcome of symptom severity or QoL (Hyphantis et al., 2009) or 
they conducted mediation in the absence of an intervention cross-
sectionally (Rutter & Rutter, 2002). 
Study characteristics  
All of the studies included were RCTs. Control groups included wait list control 
(WL; Hunt et al., 2009; Labus et al., 2013; Lackner et al., 2007), treatment as 
usual (TAU; Chilcot & Moss-Morris, 2013; Jones et al., 2011), provision of 
medication (Reme et al., 2011), and alternative psychological or psycho-
education interventions (Garland et al., 2012; Jones et  al., 2011; Lackner  et  al., 
2007; Ljo´tsson et  al., 2013; Wolitzky-Taylor et  al., 2012). Three studies 
compared the active treatment with two control groups (Jones et al., 2011; 
Lackner et al., 2007; Wolitzky-Taylor et al., 2012), and the rest utilized a single 
control group. 
Participants were recruited from primary care (Chilcot & Moss-Morris, 
2013; Reme et al., 2011), secondary care alone (Labus et al., 2013), a 
mixture of secondary care and wider community advertising (Garland et 
al., 2012; Jones et al., 2011; Lackner et al., 2007; Ljo´tsson et  al., 2013; 
Wolitzky-Taylor et  al., 2012) and from online IBS support resources 
(Hunt et al., 2009). Sample sizes ranged from 54 to 195 (median = 76). 
The follow-up periods for assessing outcome measures ranged from 3 to 12 
months. The range of follow-up periods for outcomes included in the 
mediation analysis was 6 weeks to   8 months, with only one study 
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including outcomes up to 8 months in the mediation analysis (Chilcot & 
Moss-Morris, 2013). A summary of the study characteristics is presented 
in Table 1. 
Quality assessment 
RCT quality assessment 
Studies ranged in quality from 4 of 12 (Hunt et al., 2009; Labus et al., 
2013) to 9 of 12 (Chilcot & Moss-Morris, 2013; Garland et al., 2012). The 
majority of studies were found to be of moderate quality fulfilling 7 of 12 
or above (Appendix S3). 
Mediation quality assessment 
Three studies met 7 of 8 or 6 of 7 of the QA items (Chilcot & Moss-Morris, 
2013; Ljo´tsson et al., 2013; Wolitzky-Taylor et al., 2012). The majority of 
the rest were of moderate quality fulfilling 4–5 of 8 of the criteria (Hunt et 
al., 2009; Lackner et al.,  2007;  Appendix S4). 
Population characteristics 
The mean age of participants in each study ranged from 33 to 48. A greater 
proportion of participants were women (72.5% or greater) as is generally 
found in IBS populations (Dalrymple & Bullock, 2008). One study chose 
to recruit only female participants (Garland et al., 2012), with the reasons 
for this not explained. Classification into types of IBS differed across 
studies. Only one study used the ROME I (Jones et al., 2011) or III 
criteria (Ljo´tsson et al., 2013). The majority of recruited participants 
conformed to ROME II criteria (Chilcot & Moss-Morris, 2013; Garland et 
al., 2012; Labus et al., 2013; Lackner et al., 2007; Wolitzky-Taylor et al., 
2012). One study relied on GP diagnosis of IBS (Reme et al., 2011) and 
another on self-reported IBS (Hunt et al., 2009). 
The measures of illness severity included the Irritable Bowel Syndrome 
Severity Scoring System (IBS-SSS; Francis, Morris, & Whorwell, 1997), 
the Gastrointestinal Symptom Rating Scale modified for IBS (GSRS – 
IBS; Wiklund et al., 2009), the Bowel Symptom Severity Scale (BSSS; 
Boyce, Gilchrist, Talley, & Rose, 2000), a composite BSSS measure 
(Wolitzky-Taylor et al., 2012), a global GI rating using a 20-point rating 
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scale (Labus et al., 2013), and a physician-rated severity score ranging 
from symptoms absent to very severe symptoms (Lackner et al., 2007). 
Samples consisted of participants suffering with moderate-to-severe 
symptoms. One study did not use classifications of mild-to-severe 
symptom severity, but instead provided means out of a total possible 
score of 40 for frequency, distress, and interference of symptoms (Jones 
et al., 2011). 
Therapy models & interventions 
Nine of the studies assessed mediation in the context of cognitive 
behaviourally based interventions. Protocols varied across studies as 
reflected in Table 2. One study conducted mindfulness-based stress 
reduction tailored to IBS symptoms (Garland et al., 2012). The method of 
intervention delivery, duration of sessions, and period of interventions are 
summarized in Table 1. 
Hypothesized pathways 
The hypothesized pathways of change are illustrated in Figure 3. It is 
important for mediation analysis to be conducted according to a 
hypothesized model rather than as   an exploratory exercise (Johansson & 
Høglend, 2007). Accordingly, it would be expected that studies would 
assess models of mediation to match the stated hypothesized pathways. 
One paper presented two contrasting hypothesized pathways (represented 
by a and c in Figure 3; Lackner et al., 2007). However, the final model 
that was evaluated includes additional paths incorporating QoL. This 
appears to be exploratory modelling aiming to achieve the second aim of 
the paper, which was stated as ‘to examine the interrelationships amongst 
symptom improvement, QoL and distress’. Another paper did not state a 
directional hypothesis regarding which variables were likely to mediate 
treatment effect but rather hypothesized that numerous variables may do 















































RCT 75 100% female 
Mean age 42 





MBSR 8 weekly 2-hr group sessions 
and1 half day retreat. MBSR 
programme with adaptation for 
IBS in terms of focal points of 
meditation and homework 
including psycho-education on 
IBS 
Certified health 
coach with 10 years’ 
experience in 
teaching MBSR in 
clinical settings 
NR Baseline* 









RCT 149 82% female Mean 
age 33 





CBT 6 weekly 50-min sessions face to 
face. CBT based on Lang’s three- 
systems model and adapted to IBS 
in terms of cognitions and 
behaviours focused upon 270 mg 
Mebeverine taken 3 times daily in 
addition 
Four general practice 





First follow-up at 




Labus et al 
(2013) 
RCT 69 72.5% female 
Mean age 46 
ROME II 
WL Control CBT 5 weekly 2-hr group sessions. 
Intervention consisted of (1) 
education on neurobiology of 
stress and IBS in the context of the 
three-systems CBT model; (2) 
psychological focus of role of 
cognitions and behaviours; (3) 
relaxation training; and (4) 
homework including symptom 
diaries and relaxation training 
Lead by a 
gastroenterologist 
(45% of sessions) 












RCT 64 73% female  
Mean age 39  
ROME I modified 
or ROME II 
Receiving TAU 
TAU receiving 
an IBS fact 
sheet on how 
IBS diagnosed 
CBT One 1-hr face-to-face session with 
a Health psychologist and a 
comprehensive CBT-based self-
management manual divided into 
seven chapters to be completed 
over 7 to 8-week period in addition 
to IBS fact sheet 
Self-management 
intervention with 



















































Jones et al. 
(2011) 
RCT 105 81% female 





CBT 8 weekly 1-hr face-to-face CBT 
sessions. Intervention consisted 
of a manual-based programme 
incorporating realistic symptom 
appraisal, enhanced coping 
strategies, cognitive 
restructuring, and 
problem-solving. PTs also received 
TAU and relaxation training 













RCT 54 81.5% female 




WL Control CBT 5 weekly Web delivered modules 
with homework assignments 
submitted by email. Individualized 
feedback given within 48 hr. 
Modules included the following: 
(1) psycho-education on biological 
link between stress and GI 
symptoms and relaxation training; 
(2) cognitive stress management; 
(3) catastrophic thinking; (4) 



















RCT 147 82% female 






CBT 10 weekly 90-min group CBT 
sessions. 
Intervention consisted of a manual-
based programme incorporating 
contextual/ situational factors 
associated with flare-ups, 
unhelpful cognitions, enhancing 








treatments to painful 
medical disorders. 
90.8% completed 

















































RCT 195 79% female 






CBT 10-week Internet-delivered CBT. 
Intervention consisted of exposure 
and 
Mindfulness exercises, including 
(1) exposure to symptoms by 
engaging in behaviours believed to 
trigger symptoms; (2) reduction in 
safety behaviours; (3) exposure to 
behaviours normally avoided when 
experiencing symptoms; (4) 
altering of toileting habits; and (5) 
a range of mindfulness exercises to 
practice daily. Participants also 





NR Weekly from 







RCT 76 74% female 







CBT 10 weekly 50-min sessions. CBT- 
introceptive exposure intervention 
based on CBT for panic disorder 
and adapted for the IBS 
population. Intervention 
consisted of (1) psycho-education 
of brain–gut physiological 
relationship; (2) attentional control 
skills; (3) cognitive reframing of 
specific illness cognitions; (4) 
interoceptive exposure to IBS- 
relevant visceral sensations; and 
(5) exposure to behaviours 
normally avoided when 
experiencing symptoms 











Table 2: Treatment models and intervention protocols used.  
Study Treatment Model 
Explicitly Referenced 
Intervention Protocol Components 
Garland et 
al  (2008) 
Mindfulness Based 
Stress Reduction 
tailored to IBS 
symptoms (Gaylord et 
al., 2009) 
 
(1) Sitting, walking, yoga and body scan 
mediations. (2) Mindfulness tailored towards 
IBS by emphasizing relevance of mindfulness in 
coping with IBS-related symptoms and 
perceptions. (3) Psychoeducation component 
was included regarding the physiological 
relationship between stress and symptoms (4) 
Promotion of awareness of sensory versus 
emotional processing of interoceptive signals, 
with view to counteract catastrophizing.  
Reme et al 
(2011) 
CBT Three systems 




(1) Assessment of main symptom, precipitating 
factors, maintaining cognitions & behaviours, 
discussion of treatment rationale (2) Monitoring 
symptoms, behaviours & cognitions and 
interrelations (3) Long term & short term 
behavioural goal setting with relation to 
symptoms- graded exposure (4) Behavioural 
experiments to test beliefs about consequences 
of IBS  (5) Psychoeducation about stress and 
bowel symptoms (6) Problem solving and 
symptom & stress management techniques (7) 
Managing flare ups 
Labus et al 
(2012) 
Biopsychosocial 
model of IBS 
(1) Psychoeducation about stress, IBS self 
management regarding diet and medication (2) 
Psychoeducation regarding role of symptom 
appraisal, beliefs and attitudes and links between 
cognitions, mood, stress, behavioural responses 
and symptoms (3) Alternative responses (4) 
Relaxation exercises (5) Monitoring symptoms, 





CBT (Moss-Morris et 
al., 2010) 
Treatment rationale explained (2) Monitoring 
symptoms, behaviours & cognitions and 
interrelations (3) General consideration of 
unhelpful cognitions, perfectionism and patterns 
of boom/bust (4) Long term & short term 
behavioural goal setting with relation to 
symptoms- graduated exposure (5) 
Psychoeducation about stress and bowel 
symptoms, sleep hygiene (6) Problem solving 
and symptom & stress management techniques 
including relaxation techniques (7) Managing 
flare ups 
Jones et al 
(2011) 
CBT/Biopsychosocial 
model (Jones et al., 
2011) 
 
(1) Realistic symptom appraisal (2) Enhanced 





Table 2 (continued) 
Study Treatment Model 
Explicitly Referenced 
Intervention Protocol Components 
Hunt et al 
(2009) 
CBT with inclusion of 
module targeting IBS 
specific 
catastrophizing (Hunt 
et al., 2009) 
 
(1) Psychoeducation about stress and bowel 
symptoms  (2) Relaxation training (3) 
Monitoring cognitions & emotions (4) IBS 
specific catastrophizing, thought records & 
identification of interrelationship between IBS-
specific cognitions, behaviours, emotions and 
symptoms  (5) Graduated exposure (6) 
Behavioural experiments to test beliefs about 
social consequences of IBS  
Lackner et 
al (2007) 
CBT (Blanchard et al., 
2007) 
(1) Psychoeducation about stress and bowel 
symptoms (2) Monitoring symptoms, behaviours 
& cognitions and interrelations (3) Problem 
solving and symptom & stress management 
techniques (4) Relaxation training (5) cognitive 
restructuring for modifying faulty threat 






Therapy (Ljótsson et 
al., 2011) 
 
(1) Mindfulness exercises to promote awareness 
of interrelationship between GI symptoms, 
cognitions, emptions, behaviours/behavioural 
impulses (2) Exposure exercises & behavioural 
experiments 
Wolitzky 
et al (2012) 
Adapted protocol of 
CBT for panic disorder 
(DeCola, 2001, Craske 
and Barlow, 2006)   
(1) Cognitive restructuring of IBS specific 
beliefs (2) Exposure exercises & behavioural 
experiments (3) Attentional control skills to 
reduce symptom focussing 
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Figure 3: Hypothesized mediated pathways; The diagrams illustrate the hypothesized 
mediation pathways across papers included in review. The letters indicate which 
hypothesized pathways were identified in which papers. A. (Jones et al., 2011; Lackner et al., 
2007) B. (Lackner et al., 2007) C. (Chilcot & Moss-Morris, 2013; Reme et al., 2011) D. (Hunt et 
al., 2009; Labus et al., 2013; Ljo´tsson et al., 2013; Wolitzky-Taylor et al., 2012) E. (Garland et 
al., 2012). a = Reme et al. (2011) included gastrointestinal specific behaviours and Chilcot & 





Results of analyses are grouped by the specific mediator variables entered 
into the models. 
Mediators of treatment effect on symptom severity outcome 
Perceived stress  
One study assessed perceived stress as a mediator of treatment effect (Labus et 
al., 2013). This was not a significant mediator.  
Cognitions & metacognitions 
Four studies investigated whether both cognitions and general 
anxiety/psychological distress mediated the treatment effect (Chilcot & 
Moss-Morris, 2013; Garland et al., 2012; Hunt et al., 2009; Labus et al., 
2013). Of these, three found that cognitions rather than anxiety mediated 
the treatment effect (Chilcot & Moss-Morris, 2013; Garland et al., 2012; 
Hunt et al., 2009), whilst one did not (Labus et al., 2013). Of these 
studies, one study assessed all mediators simultaneously (Garland et al., 
2012) and three conducted mediation analyses for each mediator 
separately (Chilcot & Moss-Morris, 2013; Hunt   et al., 2009; Labus et 
al., 2013). 
In addition, one study assessed cognitions as a mediator of treatment 
effect without a measure of anxiety/psychological distress. This found 
that cognitions significantly mediated symptom severity along with 
behaviours (discussed below; Reme et al., 2011). The types of cognitions 
that mediated treatment effects included negative illness- specific beliefs 
(Chilcot & Moss-Morris, 2013; Reme et al., 2011), pain-specific catastro- 
phizing (Garland et al., 2012), and general catastrophizing (Hunt et al., 
2009; Table 3). The illness-specific beliefs measure used by Chilcot and 
Moss-Morris (Chilcot & Moss- Morris, 2013) was the Brief Illness 
Perception Questionnaire tailored to IBS. This measured beliefs about the 
chronicity, seriousness, and controllability of IBS symptoms The 
Cognitive Scale for Functional Bowel Disorders (CSFBD), used by Reme et 
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al. (2011), measured the degree of unhelpful beliefs about IBS, with 
specific items about interpretations of bowel symptoms and reactions to 
them. Metacognitions were also found to be significant mediators of 
treatment effect (Garland et al., 2012). These included non-reactivity and 
reinterpretation of pain. 
General anxiety or psychological distress  
Of the three studies that investigated the mediating role of anxiety, one found a 
significant mediated effect in participants who had low baseline QoL (Labus et 
al., 2013) and one did not demonstrate a significant indirect effect of anxiety 
(Jones et al., 2011). The third did not report confidence intervals, effect sizes, or 
significance levels of the path containing distress as a mediator (Lackner et al., 
2007; Table 3). The extent to which the model fit the data was also not reported 
in this study. 
Jones et al. (2011) tested whether both anxiety and depression had a 
mediating role in a path model that included a feedback loop from anxiety 
and depression to symptom severity, and a direct path from treatment to 
symptom severity. The model was not found to fit the data adequately, and 
individual confidence intervals, effect sizes, or significance levels were 
not reported for individual indirect effects for either variable. Labus et al. 
(2013) also investigated the mediating role of depression but found no 
significant mediation. 
Gastrointestinal-specific anxiety 
Two studies assessed the GSA utilizing the Visceral Sensitivity Index 
(VSI; Labus et al., 2004) individually as a mediator of treatment effects 
(Ljo´tsson et  al., 2013; Wolitzky- Taylor et al., 2012) both finding 
significant mediation. One found that reduction in GSA mediated 
treatment effect for the intervention group, but this did not differentiate 
from the two comparative control groups (Wolitzky-Taylor et al., 2012). 
In the three other studies in which GSA was included as a mediator along 
with other variables, one found it to be a significant mediator along with 
other cognitive and metacognitive measures (Garland et al., 2012). One 
study used an alternative measure to the VSI and did not find significant 
mediation of GSA (Hunt et al., 2009). It did however conclude that there 
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was marginal mediation with indirect effects yielding a significance of P = 
.09. The third study did not find GSA to be a significant mediator (Labus et 
al., 2013). 
Behaviours 
Behavioural responses were assessed as mediators in two CBT-IS studies, one 
assessing CBT delivered face to face (Chilcot & Moss-Morris, 2013; Reme 
et al., 2011) and one evaluating a self-management CBT intervention with 
some minimal face to face and telephone therapist contact (Chilcot & Moss-
Morris, 2013). The former measured behaviours specific to IBS, such as 
checking stools for abnormalities and avoidance of social events due to 
bowel symptoms (Reme, Darnley, Kennedy, & Chalder, 2010). The latter 
measured all-or-nothing and resting/avoidance behaviours related generally 
to illness but not specifically IBS. These were not found to mediate treatment 
effect, whereas behaviours specific to IBS did significantly mediate. IBS-
specific behaviour was found to be a significant mediator in a path following 
this sequence: treatment→behaviours→cognitions→symptom severity. This 
model was found to fit the data better than a change in cognitions preceding a 
change in behaviour. It must, however, be noted that the analysis lacked 
temporal precedence limiting the inferences about order of causality of these 
mediators. The authors stated that mediation was conducted utilizing two 
time points instead of three, as there was no further change at the third time 
point. 
QoL 
One study found this to significantly mediate treatment effect for participants 
with low baseline QoL, but not for those with medium-to-high baseline QoL 
(Labus et al., 2013). 
Mediators of treatment effect on QoL outcome 
Five of the studies (Chilcot & Moss-Morris, 2013; Garland et al., 2012; Hunt et 
al., 2009; Lackner et al., 2007; Reme et al., 2011) assessed mediation of 
treatment effects on QoL outcomes, including impaired functioning as 
measured by the Work and Social Adjustment Scale (Mundt, Marks, Shear, & 
Greist, 2002). Change in IBS-specific cognitions appeared to mediate change in 
outcome, with three of four studies assessing cognitions as a mediator of 
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treatment on QoL, finding significant mediation (Chilcot & Moss-Morris, 
2013; Garland et al., 2012; Reme et al., 2011; Table 3). One study found no 
mediation through anxiety or general and IBS-specific catastrophizing 
cognitions (Hunt et al., 2009), and another found that reduction in symptom 
severity mediated improvement in QoL (Lackner et al., 2007). The latter 
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Summary of results 
The review assessed which psychological variables significantly mediated 
treatment effects on the outcome of symptom severity and/QoL. Eight studies 
assessed mediation in the context of CBT interventions. The results indicate that 
both GI-specific cognitive change and GSA are key mechanisms by which 
psychological treatments have effect on both symptom severity and QoL. Four 
of five studies assessing cognitions as a mediator found them to mediate the 
effects of treatment on symptom severity. Three of five studies assessing GSA as 
a mediator found significant mediation, and one found a trend towards 
significant mediation. Of the three studies that assessed general 
anxiety/psychological distress, only one found it to significantly mediate 
treatment effect (Labus et al., 2013). This study found evidence of moderated 
mediation, in that anxiety was only found to significantly mediate treatment in 
participants who had low baseline QoL. The stratification of analysis by QoL 
does unfortunately reduce the power to detect significant mediators and makes 
results hard to interpret. 
Only two studies assessed behavioural responses as a mediator (Chilcot & Moss-
Morris, 2013; Reme et al., 2011); one measuring IBS-specific behaviours found 
it to be a significant mediator (Reme et al., 2011) and the other, measuring more 
general all-or- nothing (boom or bust) and avoidance behaviour, did not (Chilcot 
& Moss-Morris, 2013). Similarly, the trend for mediation of treatment effects on 
QoL found that changes in cognitions resulted in improved QoL (Chilcot & 
Moss-Morris, 2013; Reme et al., 2011). Two studies assessed the mediating 
effect of psychological distress and cognitive factors on QoL. Of these, one 
found no mediation (Hunt et al., 2009) and the other found that a decrease in 
GSA and pain catastrophizing resulted in an enhanced QoL (Garland et al., 
2012). Lackner et al. (2007) found a series of significant paths demonstrating that 
CBT had direct effects on symptom severity and that this influenced QoL 
(Table 3). However, the fit of this path model to the data was not reported, 
and therefore, the results should be interpreted with caution. 
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Quality of studies 
Most studies were classified as moderate-to-high quality in the RCT QA. The 
two criteria that were most commonly not met were whether the outcome 
assessor was blinded and whether compliance was described and acceptable. 
Often it was unclear as to whether the outcome assessor was blind or not, or 
what the process for collecting outcomes was. In terms of the compliance of 
participants to the interventions, this was often not described and where it was, it 
was low. In one study, around 40% of participants were considered not to have 
completed a full course of therapy (Kennedy et al., 2005; Reme et al., 2011). 
Quality as assessed specifically for the mediation analyses was also generally 
moderate across the studies. All studies included a control group in the analysis, 
and all studies were designed to influence mediating variables as determined by 
the inclusion criteria. Around half of the studies failed to account for temporal 
ordering of mediator change prior to outcome change in the analysis using 
variables measured at the same time point (Garland et al., 2012; Hunt et al., 
2009; Jones et al., 2011; Lackner et al., 2007; Reme et al., 2011). This means that 
the extent to which causal interpretations can be made is limited. Four studies of 
seven that used path analysis or SEM did not make clear whether they used more 
than one assessment of model fit (Chilcot & Moss-Morris, 2013; Jones et al., 
2011; Labus et al., 2013; Lackner et al., 2007). Not reporting a range of model 
fit indices reduces transparency as to whether the model fits the data taking into 
account different factors such as sample size and model complexity. 
Five of the nine studies did not present confidence intervals for the indirect 
paths (Garland et al., 2012; Hunt et al., 2009; Jones et al., 2011; Lackner et al., 
2007; Wolitzky- Taylor et al., 2012). Neglecting to report confidence 
intervals in any study employing statistical methods renders it uninterpretable; 
in these cases, it prevents us from gaining insight into the likely values of the 
mediated effect. Furthermore, a subset of these studies conducted path analysis 
but did not report path coefficients for the indirect effect (Jones et al., 2011; 
Lackner et al., 2007). Consequently, interpretations of the size or extent of the 
mediated effect cannot be made without doing further calculations. 
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Issues with analysis comparisons  
A predominant limitation of the use of the Baron and Kenny framework utilizing a 
series of regressions is that it has low statistical power as compared to SEM or 
path analysis (Hayes, 2009; MacKinnon, 2008; MacKinnon et al., 2002; 
Windgassen et al., 2016). It also does not allow for investigation of more 
complex mediation modelling investigating whether one mediator precedes 
another or works simultaneously. Different approaches to mediation analysis 
make study comparison challenging, as some analyses provide more 
comprehensive assessment of mediation than others. 
Another issue complicating the comparison of mediation studies is the inclusion 
or non-inclusion of covariates. Some analyses control for covariates such as 
baseline measures of the outcome, mediator variable, or both. Inclusion of 
covariates is recommended in order to reduce bias in mediation effect estimates 
and leads to a greater understanding of the influence of potential confounding 
variables (MacKinnon & Pirlott, 2015; MacKinnon et al., 2007; VanderWeele, 
2015). Less than half of the papers included in the review included covariates in 
the analysis. It is generally straightforward to adjust for baseline measures of 
mediators and outcome, which may be amongst the most important 





Figure 4: Mediation model of IBS. The figure depicts a hypothesized model of mediation based 
on the results of the review. 
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The role of theory 
The design of intervention RCTs should be informed by theory, which should 
include the important mediating variables that are hypothesized to change with 
treatment and in turn have an effect on outcome/s. It is interesting to note that 
four of nine papers assessed the mediating role of anxiety/psychological distress, 
without an inclusion of a cognitive measure. This is despite the fact that the 
majority of studies referenced a cognitive behavioural model as a basis for 
informing intervention design. 
Gastrointestinal-specific anxiety versus general anxiety 
All studies except one (Hunt et al., 2009) measuring GSA utilized the VSI 
(Labus et al., 2004). The VSI incorporates items that pertain to feelings of anxiety 
specifically relating to IBS symptoms, as well as IBS-specific cognitions and 
behaviours. The other measure of GSA was not a validated measure. The authors 
used items from a general anxiety scale that had been tailored to apply to specific 
IBS-related symptoms (Hazlett-Stevens, Craske, Mayer, Chang, & Naliboff, 
2003). There may be an argument for the development of a scale that specifically 
measures GSA, without the inclusion of cognitive and behavioural items. Such a 
measure may allow the elucidation of the relationship between illness-specific 
cognitions, behaviours, and GSA. 
The review suggests that psychological treatments achieve improved 
outcomes, predominantly by reducing GSA, rather than general anxiety. 
Analysis conducted by Garland et al. (2012) compared a series of path models 
to assess how well they fit the data. The model including a general measure of 
psychological distress was found not to fit the data as well as the final model, 
which included GSA amongst other variables described earlier. It must, 
however, be acknowledged that there is a high comorbidity of anxiety in IBS 
populations (Fond et al., 2014). Consequently, it is likely that psychological 
approaches targeting general anxiety may also achieve a reduction in symptom 
severity. The distinction between general and GSA is important particularly 




An assimilated model of mediation  
A model of mediation for psychological treatment effect is proposed based on the 
findings of the review (Figure 4). The review finds that both illness-specific 
cognitions and GSA are predominant mediators of treatment effect. There is also 
preliminary evidence that illness- specific behaviours have a mediating effect. 
The paper assessing the role of illness-specific behaviours found that change in 
behaviours preceded change in illness-specific cognitions (Reme et al., 2011). 
This may indicate that interventions, targeting IBS- specific behaviour change, 
are effective because this subsequently results in cognitive change. It must, 
however, be acknowledged that the study lacked temporal precedence (Reme et 
al., 2011). This limits the extent to which the sequence of causality can be 
inferred. 
The review opens questions regarding the relationship between illness-specific 
cognitions, behaviours, and GSA. It seems likely that there is a bidirectional 
relationship between symptoms of GSA, cognitions, and behaviour. We propose 
that the relationship between these three variables impact on symptom severity 
via the autonomic nervous system and HPA axis. These are systems involved in 
the physiological stress response and key components of the BGA (Figure 4; 
Kennedy, Cryan, Quigley, Dinan, & Clarke, 2014; Kennedy et al., 2012). This 
makes intuitive sense as the GSA is likely to be predictive of and predicted by 
autonomic arousal (Mayer & Tillisch, 2011). 
This review does not support the hypothesis that psychological treatments are 
effective in reducing symptom severity by targeting comorbid anxiety. The 
implications for psychological treatments delivered for IBS would be that target 
for change should be illness-specific factors (GSA, cognitions, behaviours) 
rather than general levels of anxiety. 
Less commonly measured mediators 
Interestingly, two studies investigated the potential mediating role of QoL on 
treatment outcome (Labus et al., 2013; Lackner et al., 2007). One assessed 
whether the impact of treatment on QoL produced a reduction in symptom 
severity, and the other assessed whether QoL had a mediating role in a path 
leading from treatment → symptom severity→ QoL→ distress, including a 
feedback loop to QoL. The hypothesized mediating role between the studies 
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was therefore rather different. In neither study was a rationale for the 
investigation of QoL as a mediator presented, although both studies found 
significant mediation. Intuitively, QoL is generally regarded as an outcome 
measure rather than a mediator measure. 
Variables that were not shown to mediate the effect of treatment on symptom 
severity were depression (Jones et al., 2011) and perceived stress (Ljo´tsson et 
al., 2013). Such results provide a greater understanding of how to focus 
treatment, suggesting that depression and stress do not necessarily need to be 
targeted in order to achieve improve outcomes. Further studies assessing these 
variables as mediators would be required before definitively drawing this 
conclusion. 
Limitations 
The review is limited by the small number of meditational studies that have 
been conducted to date. Perhaps also due to the empirically based nature of CBT, 
the majority of the psychological interventions included in review were CBT or 
designed in accordance with a CBT model. The review was therefore not able to 
explore mechanisms that may be responsible for change in different 
therapeutic approaches. Furthermore, potential similarities between different 
treatment approaches cannot be considered. 
Another limitation of the literature reviewed was that the degree of mediation 
effect could not be uniformly compared across studies. Some papers did not 
report effect sizes for the mediator variables or paths at all, whilst others 
presented effect sizes for mediating paths rather than individual variables. The 
review examines objectively whether mediation was found by considering 
the significance, confidence intervals, and effect sizes available of the 
indirect effects and path models tested. It does not examine the nuances of 
individual analyses contained in the discussion of included papers. 
Recommendations for future mediation studies 
The review highlights the importance of theoretically informed design of 
mediation studies. Future studies conducting mediation in the context of a 
psychological intervention should carefully consider what the targets of 
change are as informed by the prescribed model of treatment. Measurements 
of these targets for change in the form of validated and reliable questionnaires 
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should be included in mediation models. This would allow more complete 
mediation analysis that can accurately assess how well such models fit the data. 
In the context of mediation studies within psychological treatments for IBS, 
this would mean that researchers include measurements of anxiety/distress, 
cognitions, and behaviours. 
Based on the results of this review, it would appear important for researchers to 
further elucidate the relationship between cognitive change and change in 
anxiety, or more specifically, GI anxiety. It may be useful to understand whether 
change in one is dependent on change in the other, or whether change is co-
occurring. In addition, few researchers have investigated the potential mediating 
role of illness-related behaviours. Future studies assessing mediation in this area 
should include a behavioural measure to further understand whether this is an 
important mechanism for change. 
Conclusion 
There is a clear indication that cognitive change is important for reducing 
symptom severity as well as enhancing QoL in IBS. From the minimal 
investigation into the mechanistic role of behaviour, it seems that the 
reduction in certain toileting and avoidance behaviour may also be important 
for improving these outcomes in IBS. Different studies utilized different 
measures of distress/anxiety with equivocal findings regarding their 
mechanistic role in psychosocial interventions on outcome. This was further 
complicated by the use of the VSI, which appears to be a compound 
measure. 
Future mediation studies and models need to include all mediating variables 
implicated by the theoretical model of treatment. The limited number of studies 
to date suggests that it is premature to draw conclusions about the need for the 
modification of treatment practices. However, the review does provide 
substantial support for the targeting of unhelpful cognitions as a mechanistic 
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Supplementary Appendix S1.  
Search Stategy across Ovid, PsycInfo, Embase, MEDLINE, PsycArticles and Global 
Health.  
Search terms included [cbt] OR [“cognitive behav$ therap$”] OR [“cognitive therap$”] 
OR [“behav$ therap$”] OR [“psycholog$ therap$”] OR [psychotherap$] OR [“psycho$ 
intervention”] OR [“relaxation training”] OR [“mindful$ based cognitive therapy”] OR 
[mbct] OR [mbsr] OR [“mindful$ based stress reduction”] OR [“mindful$ based 
intervention”] OR [“acceptance and commitment therap$”] OR [act] OR [“dynamic 
psychotherap$”] OR [“psychodynamic therap$”] OR [“multicomponent therapy”] OR 
[“multi-component therapy”] OR [“multicomponent psychotherapy”] OR [“stress 
manag$”] OR [counsel$] OR [psycho$educat$] OR [“motivational interview$”] OR 
[“group therap$”] OR [“self$help”] OR [self$manag$] OR [hypno$] AND [“irritable 
bowel syndrome”] OR [IBS] AND [mediat$] OR [mechanis$]. 
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Supplementary Material Appendix S2 
PICOS inclusion & exclusion criteria  
Category Inclusion Criteria Exclusion Criteria 
Populations • Irritable Bowel Syndrome participants 
• Any other patient population 
including Inflammatory Bowel 
Disease 
Interventions • Any psychological or psycho-
educational intervention  
• No intervention  
• Pharmacological intervention  
Comparators • Any control group including wait-list 
controls and placebo intervention 
controls 
• No control/comparative group 
Outcomes • Primary or secondary outcomes 
relating to symptom severity and or 
Quality of Life (QoL)/impact on life 
• Any other outcomes 
Study Design • Prospective mediation analysis 
 
• No mediation analysis  
• Cross sectional mediation 
analysis 
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1 1 1 1 1 0 0 0 1 1 1 1 9 
Garland et al 
2008 
1 1 1 1 1 1 0 0 1 0 1 1 9 
Hunt et al 
2009 
0 0 0 1 1 1 0 0 0 0 0 1 4 
Jones et al 
2011 
1 1 0 1 1 1 1 0 1 0 0 0 7 
Labus et al 
2012  
1 0 1 1 1 0 0 0 1 0 0 0 5 
Lackner et al 
2007 
0 0 1 1 1 1 1 0 1 0 1 1 8 
Ljotsson et al 
2013  
1 0 1 1 1 1 0 0 0 0 1 1 7 
Reme et al 
2011 
1 0 1 1 1 1 0 0 1 0 0 1 7 
Wolitzky et al 
2012  
1 0 0 1 1 0 0 0 1 0 0 1 4 
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Morris 2013 1 1 1 1 1 1 0 1 7 8 
Garland et al 2008 
1 1 1 1 0 0 1 0 5 8 
Hunt et al 2009 
1 1 1 1 0 0 x 0 4 7 
Jones et al 2011 1 1 1 1 0 0 0 0 5 8 
Labus et al 2012 1 1 1 0 1 1 0 1 6 8 
Lackner et al 2007 1 1 1 0 0 1 0 0 4 8 
Ljotsson et al 2013 1 1 1 1 1 1 1 1 8 8 
Reme et al 2011 
1 1 1 1 0 0 1 1 6 8 
Wolitzky et al 




There are relatively few studies assessing mediation of treatment effect in the context of 
psychological interventions for IBS (n=9). Different methods of mediation analysis were 
used across studies. These methods included a series of regressions utilising the causal 
steps approach (Baron & Kenny, 1986), path analysis/ structural equation modelling and 
latent growth curve analysis. A quality assessment criteria for mediation analysis was 
developed to help contextualise interpretation of results. This assessment criteria can be 
used as a guideline for informing the mediation analysis to be conducted in study two 
(chapter five).  
Generally mediator variables entered into analysis were consistent with those postulated 
in the cognitive behavioural models of IBS. These included illness-related and general 
cognitions, anxiety and behaviours.  The results of the review indicate that illness-
related cognitions mediate treatment effect, with some evidence to suggest that 
gastrointestinal specific anxiety (GSA) and illness-related behaviours also mediate 
treatment effect. The review suggested that changing general anxiety may not be an 
important target for change in psychological treatments, as only one of three studies 
found it to be a significant mediator. This study only found significant mediation of 
general anxiety, when baseline QoL was low. In contrast, three of five studies assessing 
GSA found it to be a significant mediator, and therefore the results may suggest that this 
is an important target for change in psychological interventions for IBS.  
Further studies are required with sufficient sample sizes to assess whether all potential 
mediators as identified by the cognitive behavioural models of IBS are indeed 
significant mediators of change in outcomes. This would involve the assessment of 
parallel mediation models, which include general and/or GI specific anxiety, GI related 





5. A Mediation Analysis of Cognitive Behavioural 
Treatment Effect in Irritable Bowel Syndrome  
5.1 Chapter Overview  
The systematic review in the previous chapter identified common mediator variables 
entered into analyses assessing the treatment mechanisms of CBT in IBS. These 
included GI related cognitions and general anxiety, with only a few studies assessing the 
role of behaviours as potential mediators of treatment effect. The mediation analysis 
conducted in study two consequently aimed to assess whether mediators identified in the 
CB models of IBS did significantly mediate treatment effect. Specifically, the analysis 
aimed to assess the mediating roles of GI related avoidance behaviours, GI related safety 
behaviours, GI related cognitions, and general anxiety on the outcomes of symptom 
severity and work and social adjustment.  
An additional aim of study two was to identify which mediating variables changed first 
in sequential mediator models.  It was hypothesized that cognitive and behavioural 
change would precede change in anxiety, as these were the targets for change in the 
treatment protocol informed by the three systems model. Furthermore, in the previous 
mediation study based on the same data, cognitive and behavioural change was found to 
precede changes in anxiety (Reme, Stahl et al, 2011). In this study, sequential mediation 
models found that change in behaviours preceded change in cognitions, and that this 
sequence led to change in the outcomes of anxiety, symptom severity and work and 
social adjustment.  
In the systematic review in study one, some common limitations to analyses were found. 
These included: (1) lack of temporal precedence of mediating and outcome variables 
(i.e. these variables were not taken from sequential time points to uphold inferences 
regarding causality) (2) analysis not being informed by a theoretical model in terms of 
the design of the mediation analysis (3) analysis not controlling for the potential 
confounding effects of baseline mediator and outcome variables (4) lack of 
quantification of indirect effects (i.e. not presenting the path coefficient or confidence 
intervals of the indirect effect) (5) non-reporting of assessment fit criteria of path 
models. The analysis conducted in study two therefore aimed to address all of these 
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Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder 
characterised by abdominal pain and altered bowel movements.  Cognitive behavioural 
therapy (CBT) has been shown to be effective in reducing symptom severity in IBS and 
enhancing quality of life/ functioning. The present study sought to identify how CBT 
achieves change in these outcomes.  
Method: Structural equation modelling was used to conduct a series of simple and 
sequential mediation models. Avoidance behaviour, safety behaviour, gastrointestinal 
cognitions and general anxiety were included in simple mediation models to assess 
whether they mediated treatment effect. Sequential models compared the fit of 
mediational sequences to identify whether cognitive and behavioural change preceded a 
reduction in anxiety. 
Results: Simple mediation models showed that gastrointestinal (GI) safety behaviours, 
GI related cognitions and general anxiety mediated treatment effect on the outcomes of 
symptom severity and work and social adjustment. Avoidance behaviour was not found 
to be a significant mediator for either outcome. Sequential mediation models indicated 
that unhelpful GI related cognitions reduced before anxiety did, and this sequential path 
(R→ GI related cognitions→ anxiety→ outcome) was significant for both outcomes. A 
reduction in GI safety behaviours were also found to precede a reduction in anxiety. 
This sequence (R→ GI safety behaviours→ anxiety→outcome) was also significant for 
both outcomes.  
Conclusion: Results suggest that CBT for IBS works by reducing unhelpful GI 
cognitions and behaviours, which subsequently reduce anxiety. Consequently, 




Irritable bowel syndrome is a functional gastrointestinal disorder characterised by 
abdominal pain and associated changes in bowel habits (Drossman, 2016). The 
prevalence of IBS is estimated to be between 10 and 22% in the UK (Kennedy & Jones, 
2000; Wilson, Roberts, Roalfe, Bridge, & Singh, 2004). There are no physiological 
diagnostic markers for IBS and it has long been established as a ‘biopsychosocial 
illness’ (Drossman, 1998; Halpert & Drossman, 2005). As such physiological factors 
such as genetics or infection interact with psychological and social factors such as 
unhelpful gastrointestinal (GI) related cognitions, anxiety and life stress to result in 
bowel symptoms and abdominal pain.  
The comorbidity of anxiety and depression in IBS is well established (Fond et al., 2014) 
with a high prevalence of both found in this patient population (Van Oudenhove, Levy 
et al. 2016). Anxiety and depression have a negative impact on symptom severity and 
quality of life (QoL) in IBS (Van Oudenhove, Levy, et al., 2016). These affective factors 
are also associated with negative cognitive patterns such as catastrophising (Knowles et 
al., 2017; Sherwin, Leary, & Henderson, 2017) and unhelpful illness-related behaviours 
such as avoidance (Knowles et al., 2017; Wilpart et al., 2017) or over reliance on 
healthcare services (Whitehead, Palsson, & Jones, 2002). Unhelpful GI related 
cognitions and behaviours also independently negatively impact on symptoms and QoL 
in IBS (Van Oudenhove, Törnblom, Störsrud, Tack, & Simrén, 2016; Knowles et al., 
2017; Sherwin et al., 2017). Some research would also indicate that these illness-related 
cognitions and behaviours have a causal role in anxiety and depression (Reme et al., 
2011; Knowles et al., 2017; Sherwin et al., 2017; Wilpart et al., 2017). 
To date CBT has received the most empirical support for reducing symptom severity 
and enhancing quality of life in IBS (Ford, Talley, Schoenfeld, Quigley, & Moayyedi, 
2009; Ford et al., 2014). Generally CBT involves the targeting of unhelpful cognitions 
and changing of behavioural responses to symptoms (Windgassen et al., 2017). There 
                                                     
1AIC, Akaike’s information criterion; BIC, Bayesian information criterion; CBT, cognitive 
behavioural therapy; CFI, comparative fit index; GI, gastrointestinal; IBS, irritable bowel 
syndrome; QoL, quality of life; RCT, randomised controlled trial; RMSEA, root mean square 
error of approximation ; SEM, structural equation modelling; TLI; tucker-lewis index; WSA, 
work and social adjustment; 𝜒2 GOF, Chi Square goodness of fit 
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are however variations in the cognitive behavioural models applied in IBS (Windgassen 
et al., 2017). Some focus on the role of GI related cognitions (“it is extremely 
embarrassing to keep going to the toilet”) and GI related behaviours (e.g. avoiding 
situations, checking stools) in the maintenance of symptoms (Kennedy et al., 2005; 
Chilcot & Moss-Morris, 2013) as based on Lang’s three system’s model (Lang, 
Melamed, & Hart, 1970) (appendix A). Others, such as the four-factor CBT model of 
IBS, focus on reducing GI specific anxiety (Labus et al., 2013) or general anxiety 
(Blanchard et al., 2007). The different treatments may therefore exert their effects by 
targeting different mechanisms.  
Mediation analysis is a statistical method of identifying the mechanisms of treatment 
effect. It determines whether change in an outcome is brought about by change in an 
intermediary variable (a mediating variable) (Mackinnon, Fairchild, & Fritz, 2007; 
MacKinnon, 2008; Windgassen, Goldsmith, Moss-Morris, & Chalder, 2015). Mediation 
analysis is important for both advancing theoretical understanding of psychological 
processes and for refining clinical practice (Mackinnon et al., 2007; Windgassen et al., 
2015). Identifying whether hypothesised mechanisms are affected by a treatment 
approach can provide valuable information about potential avenues for treatment 
modification. 
Previous mediation studies investigating the efficacy of CBT for IBS have assessed a 
variety of mechanisms (Windgassen, Moss-Morris et al. 2017). Some have shown 
significant mediating effects of general anxiety (Labus et al., 2013) whilst others have 
indicated that change in unhelpful illness-related cognitions are the predominant 
mechanism of treatment effect (Hunt, Moshier, & Milonova, 2009; Garland et al., 2012; 
Chilcot & Moss-Morris, 2013). Only 2 of 7 studies conducting mediation in CBT for 
IBS studies included a measure of behaviours in the analysis (Reme et al., 2011; Chilcot 
& Moss-Morris, 2013). These included all-or-nothing behaviours, which were not 
shown to meditate treatment effect (Chilcot and Moss-Morris, 2013) and GI related 
behaviours such as avoiding certain foods or spending excessive time straining on the 
toilet (Reme, Stahl et al. 2011), which did significantly mediate treatment effect.  
The mediation analysis by Reme et al (2011) was conducted in the context of a 
randomised controlled trial (RCT) comparing the efficacy of an antispasmodic with and 
without the addition of nurse delivered-CBT in IBS. The CBT delivered was based on 
the three system’s model (Lang et al., 1970), and therefore focussed on changing GI 
related cognitions and GI behaviours. Sequential mediation models were designed to 
assess whether cognitive change preceded behavioural change or vice versa for three 
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outcomes: symptom severity, work and social adjustment (WSA) and anxiety. For all 
three outcomes the best fitting models involved behavioural change preceding cognitive 
change. The best fitting model was that for the outcome of anxiety, suggesting that GI 
related cognitions and GI behaviours in IBS have a causative role in the anxiety 
experienced in IBS (Reme, Stahl et al, 2011).  
The present paper explored the same data as Reme and colleagues (2011) but with some 
key differences in the approach to address some of the limits of the previous study. 
Firstly the previous study assessed GI-related behaviours as a unitary measure and not in 
the composite subscales of avoidance (avoiding certain activities or foods in anticipation 
or reaction to symptoms) and GI safety behaviours (such as straining to pass a stool or 
wearing protective undergarments). The previous study also assessed mediation using 
mediator and outcome measures from the same time points (change between baseline 
and 1.5 month follow up).  Finally, mediation models were tested including only GI 
related cognitions and GI behaviours as mediators and not anxiety. Therefore the present 
study sought to fill these gaps with two aims (1) to assess whether GI related avoidant 
and safety behaviours, GI related cognitions and general anxiety, mediated the effect of 
CBT on outcomes. It was hypothesized that all four variables would significantly 
mediate the effect of CBT on both symptom severity and WSA based on the theoretical 
CBT treatment model and findings from previous studies (Windgassen et al., 2017) (2) 
to identify which mediating variables changed first in sequential mediator models. We 
hypothesized that cognitive and behavioural change would precede change in anxiety, as 
these were the targets for change in the treatment protocol informed by the three systems 
model (Lang et al., 1970). Furthermore, in the previous study, cognitive and behavioural 
(assessed as a unitary measure) change was found to cause reduction in anxiety (Reme, 
Stahl et al. 2011). Mediation models in the present paper were designed to maintain 
temporal precedence to aid inferences about causality. Therefore models used mediators 
and outcomes measured at sequential time points. They also assessed GI avoidance and 
GI safety behaviours as separate mediators of treatment effect, as these are arguably 
different processes (Beesdo‐Baum et al., 2012; Helbig-Lang et al., 2014; Goetz, Davine, 
Siwiec, & Lee, 2016). 
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Figure 1: Mediation models tested. Anx, anxiety; Cog, GI related cognitions; Beh A,GI  
avoidance behaviour; Beh C, GI control behaviour; M1, first mediator in sequence; M2, second 





The present study is a secondary mediation analysis of a RCT comparing the effect of 
CBT plus Mebeverine with Mebeverine alone on symptom severity and WSA outcomes 
(Kennedy et al., 2005). Results indicated that the addition of CBT improved treatment 
response up to six months after treatment.     
Participants and procedure 
Individuals aged between 16 and 50, diagnosed with IBS and meeting the Rome I 
criteria were recruited from London general practices. A total of 149 participants were 
randomised to either receive mebeverine alone or to receive CBT in addition to 
mebeverine (Kennedy et al., 2005). Data of one participant were completely missing, 
leaving 148 participants for inclusion in the mediation analysis.  
Measures were taken at 7 time points, 2 of which were taken 2 (visit 1) and 4 weeks 
(visit 2) prior to randomisation. The baseline measure was taken just prior to 
randomisation (visit 3) and the first follow up was taken 1.5 months post randomisation 
at discharge (visit 4). The second follow up was at 3 months post randomisation (visit 5) 
and the final follow up at 12 months (visit 7).  
CBT treatment  
A CBT treatment based on Lang’s three systems model (Lang et al., 1970) was 
developed for IBS (appendix A). The treatment included psycho-education, cognitive 
restructuring and behavioural techniques such as thought diaries and graded exposure, 
for example gradually reintroducing avoided foods (appendix B).  
Measures 
The measures used are listed below, with further detail contained in appendix C. All 
measures have been shown to be valid and reliable.  
Primary Outcomes 
The Symptom Severity Scale (SSS) measures symptom severity specific to IBS, and has 
been found to be sensitive to change over time (Francis, Morris, & Whorwell, 1997). 
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The Work and Social Adjustment Scale (Mundt, Marks, Shear, & Greist, 2002) is a 
measure of work and social adjustment (WSA)/functioning.  
Mediators 
The Cognitive Scale for Functional Bowel Disorders (CSFBD) (Toner et al., 1998) is a 
measure of GI related cognitions. An example questionnaire item is “my bowel 
symptoms make me feel out of control”.  
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) is a 
general measure of depression and anxiety. Just the anxiety subscale was used to assess 
general anxiety with items such as “I feel tense or wound up”.  
The IBS Behavioural Responses Questionnaire (IBS-BRQ) (Reme, Darnley, Kennedy, & 
Chalder, 2010) was used to measure GI avoidance behaviour (“I avoid going out in case 
I have problems with my IBS”) and GI safety behaviour (“I spend more time on the 
toilet than I would ideally like”). Both types of behaviour are asserted to maintain 
anxiety in the anxiety and health anxiety literature (Helbig-Lang et al., 2014). However 
the nature of each behaviour is different. One seeks to exert control over the experience 
of illness in some sort of way (safety behaviours) and the other relies on withdrawing 
from certain activities to prevent anticipated troublesome symptoms or experiences 
(avoidance behaviours).  
Statistical Analysis  
General 
The data were standardised by subtracting the mean of the given scale from each 
individual’s score and dividing by the standard deviation for each given time point. 
Standardising data reduces potential problems of multicollinearity and allows 
comparison of indirect effects (Lance, 1988; Frazier, Tix, & Barron, 2004). It has been 
recommended that mediation variables are assessed for significant change prior to 
mediation analysis (Lubans, Foster, & Biddle, 2008). For anxiety and GI related 
cognitions, assessment of main effects and interactions were conducted in the previous 
mediation paper (Kennedy et al., 2005; Kennedy et al., 2006) and presented again in this 
paper for contextual clarity. Repeated measures ANOVAs were conducted to assess the 
main effects of group and time and the interaction (time x group) on the avoidance and 
safety behavioural subscales of the BRQ, over the three time points included in the 
mediation analysis (visit 3, 4 and 5). This analysis allowed assessment of whether 
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change in mediator variables occurred over time, between the treatment and control 
groups. Significant interactions indicate that there was a change over time, which 
differed between groups  
Mediation models 
The mediation models were designed to assess whether the mediators identified in the 
three systems cognitive behavioural model of IBS (Kennedy et al., 2005), GI-related 
cognitions and GI behaviours, as well as anxiety, significantly mediated the treatment 
effect on outcome. Previously Reme et al (2011) found that behavioural change 
preceded cognitive change, and that this mediational sequence explained change in 
anxiety. However, the authors used change scores by taking baseline scores from scores 
at 1.5 month follow up (visit 4) for all mediator measures and outcomes. This limits the 
causal plausibility of the effects as mediators and outcome were therefore measured 
using the same time points. In addition, these authors did not assess the potentially 
different roles of GI related avoidance and safety behaviours. Our models therefore 
sought to assess whether both types of GI related behavioural responses were mediators 
of treatment effect. We also sought to identify whether cognitive and behavioural 
change preceded changes in anxiety for the outcomes of symptom severity and WSA.  
Mediation models were fitted in the structural equation modelling (SEM) framework 
using Mplus version 7. SEM is advocated as an approach that allows simultaneous 
modelling of several variables, enabling the investigation of more complex mediation 
models (Mackinnon et al., 2007; MacKinnon, 2008; Hayes, 2009) than would be 
possible by conducting a series of regressions utilising Baron & Kenny’s framework 
(Baron & Kenny, 1986). Path tracing rules (Kline, 2015) akin to what is specified in the 
mediation literature were used to calculate indirect effects (MacKinnon 2008). 
All mediation models controlled for baseline measures of the mediator and outcome to 
account for the potential confounding of the non-randomised mediator-outcome 
relationship, which is widely agreed to be important (MacKinnon, 2008; Emsley, Dunn, 
& White, 2010; Goldsmith, Chalder, White, Sharpe, & Pickles, 2016). Baseline 
measures of the mediator and outcome are likely to be amongst the most important 
confounders (Dunn, Emsley, Liu, & Landau, 2013; Pickles et al., 2015) and may also 
provide adjustment for other related confounders not included in the model. For most 
variables, baseline was assessed at visit 3 (pre-randomisation), apart from GI avoidance 
and safety behaviours where these data were not collected at this time point. In these 
cases, data from visit 1 was used. 
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Simple mediation models with single mediators were run first to assess whether the 
variables identified in the CBT model of IBS significantly mediated treatment effect on 
outcome (figure 1). Models were run for each potential mediating variable: anxiety, GI 
related cognitions, GI avoidant and GI safety behaviours. These were run separately for 
each outcome also.  
Sequential mediation models were then run to further elucidate the relationship between 
cognitive and behavioural processes and anxiety. Specifically, we sought to understand 
whether it was necessary for cognitive and behavioural change to occur first in order to 
produce a subsequent reduction in anxiety, ultimately leading to improved outcomes. To 
assess this we wanted to compare models that had cognitive or behavioural change 
preceding change in anxiety to models where change in anxiety preceded cognitive or 
behavioural change.   
To allow for causal interpretations of mediational analyses, it is important to ensure that 
variables are measured in a plausible temporal sequence (Maxwell & Cole, 2007; 
MacKinnon, 2008; Maxwell, Cole, & Mitchell, 2011; Goldsmith et al., 2016). In other 
words, to infer that treatment causes change in a mediator and that this change causes 
subsequent change in an outcome, the mediator should be measured at an earlier time 
point than the outcome. To this end, the simple mediation models with a single mediator 
and outcome used mediators assessed at visit 4 (figure 1). In sequential mediator 
models, the first mediator in the sequence was measured at visit 4 and the second 
mediator at visit 5. For both simple and sequential mediator models, visit 7 outcome 
measures were used.  
Three types of model fit criteria were used to select the best fitting mediation model. 
Two absolute model fit indices were used to assess how well models fitted the data 
(Hooper, Coughlan, & Mullen, 2008). The Chi Square Goodness of Fit (𝜒2 GOF) 
statistic compares the model hypothesized against the saturated model indicating 
whether they are significantly different. As such a model with good fit should not 
produce a significant 𝜒2 statistic. The root mean square error of approximation 
(RMSEA) is another model fit index that is recommended for small sample sizes (Kline, 
2015) . An acceptable fit has been defined as ≤0.08 (Browne & Cudeck, 1993) with a 
value of ≥1.0 indicating poor fit. Good fit to the data is indicated by a value of ≤0.05 
(MacCallum, Browne, & Sugawara, 1996) . The two incremental indices used were the 
comparative fit index (CFI) and the Tucker-Lewis Index (TLI). Adequate fit of the CFI 
is indicated by values of ≥0.90 (Marsh, Balla, & Hau, 1996), however more stringent 
guidelines suggest models should have a value of ≥0.95 for both CFI and TLI (Hu & 
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Bentler, 1999). Research suggests the CFI performs well with small sample sizes 
(Tabachnick, Fidell, & Osterlind, 2001). The two information criteria used to compare 
models were the Akaike’s Information Criterion (AIC) and the Bayesian Information 
Criterion (BIC). The AIC allows comparisons between models to choose which of the 
models considered fits the data best. Differences of >2 between models indicate that the 
model with the lower AIC value better explains the data (Burnham & Anderson, 2003). 
The BIC is closely related to the AIC and also penalizes models for the number of 
parameters included, with lower values indicating a better fit (Burnham & Anderson, 
2004). 
Final models were selected based on whether they had acceptable or good fit across the 
majority of the three types of fit indices (absolute, incremental and information) as has 
previously been recommended (Williams & Holahan, 1994; Marsh & Hau, 1996; 
Schumacker & Lomax, 2004; Preacher & Merkle, 2012; Preacher, Zhang, Kim, & Mels, 
2013), giving priority to the RMSEA, CFI and TLI. This method was designed to tackle 
the sometimes conflicting criteria and the issues with model selection uncertainty 
(Preacher & Merkle, 2012). Further details of the analysis are contained in appendix D. 
Results 
Change in primary outcomes during the course of the trial 
There was a significant difference between the groups post treatment (visit 4) on IBS-
SSS and WSAS in the CBT + Mebeverine group, compared to Mebeverine alone. The 
difference between groups, however, was no longer significant by the 6-month follow 
up (visit 6). The trajectories for both outcomes are illustrated in panel A and B in 
appendix E. Further detailed results have been reported elsewhere (Kennedy et al., 2005; 
Kennedy et al., 2006). Conducting mediation even when there is no treatment effect is 
important as it can clarify why this has happened, for example, if the treatment has not 
targeting the mediator as expected, or if there is suppression (MacKinnon, Krull, & 
Lockwood, 2000; Mackinnon et al., 2007), which is when the direct and indirect effect 
are in opposite directions and cancel each other out (MacKinnon et al., 2000). 
Changes in mediating variables: Anxiety, behaviours and cognition 
The line graphs in figure 2 depict change in mediator variables over the 3 time points 
included in the mediation analysis. The changes in anxiety and cognition were 
previously reported in detail (Kennedy, Jones et al. 2005; Kennedy, Chalder et al. 2006) 
with a summary of the results presented here for ease. There was a significant main 
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effect of group but not time on both anxiety and GI related cognitions, indicating that on 
average over the different follow-up time points anxiety and GI related cognitions were 
significantly lower in the CBT group than in the control group (figure 2, panels A and 
B).  
Analysis of the behavioural subscales in the present paper found that there was a 
significant main effect of group on GI safety behaviours F(1,97) =12.81, p=.001 with 
lower levels of GI safety behaviours at follow-up on average in the CBT group. The 
main effect of time was significant, F(1.62,156.76) =4.47, p=.019, which is likely due to 
the relatively large decrease between baseline and post-treatment ratings of GI safety 
behaviours in the CBT group. For avoidance behaviours there was no significant main 
effect of time F(1.60,154.93) =2.49, p=.098 or group F(1,97) =1.16, p=.285 suggesting 
that there no difference between the groups on average over the three time points. This 
may be in part due to the difference between the two groups at baseline, with their 
profile plots crossing between baseline and post treatment (figure 2, panel C). There 
were significant group*time interaction effects for all four potential mediator variables 




Figure 2: Change over time in mediator variables anxiety (panel A), GI related cognitions (panel 
B), avoidance (panel C) and control behaviours (panel D) between groups. 95% confidence 
intervals plotted for each time point.  
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Simple mediation models 
The four variables of interest as mediators, GI related cognitions, avoidance behaviour, 
safety behaviour and anxiety were initially studied using simple mediation models.  
Simple mediation models, each in turn including anxiety, GI related cognitions and GI 
safety behaviours, fitted the data well (table 1). Anxiety significantly mediated the effect 
of treatment on symptom severity (-0.26, -0.46 to -0.11, p =0.004) and WSA (-0.35, -
0.56 to -0.16, p=0.001). GI related cognitions were a significant mediator of CBT 
treatment on symptom severity (-0.24, -0.43 to -0.09, p=0.005) and WSA (table 2). 
Safety behaviour was also a significant mediator for symptom severity (-0.33, -0.57 to -
0.11, p=0.005) and WSA (-0.35, -0.60 to -0.14, p=0.004). Avoidance behaviour did not 
mediate the effect of treatment on either outcome (table 1). Figure 3 shows the 
standardized indirect effects with the 95% confidence intervals across the four mediators 
tested. The mediated effects were negative as we expected, because they are products of 
the negative effect of the treatment on the mediator and the positive effect of the 
mediator on the outcome.  CBT compared to control gave a negative parameter estimate 
for the effect of the treatment on the mediator, i.e. the mediator values were lower 
(better) on average in the CBT group compared to the control group.  The effect of the 
mediator on the outcome gave a positive effect estimate because for every standard 
deviation increase in the mediator (worsening), there was an increase (worsening) in the 
outcome.  The significant indirect effects were similar sizes.  
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Figure 3: Standardized indirect effects for each mediator variable in simple mediation models 




Sequential Mediation Models 
Full and partial mediation models  
Comparisons of sequences modelled as full or partial mediation models for the outcome 
of symptom severity showed that full mediation models fit the best for all mediation 
sequences (appendix G) apart from the sequence R→ anxiety→ GI safety behaviours→ 
symptom severity (model 8a, table 1), where there was little difference in the fit of the 
models. Comparisons of full and partial mediation models on the WSA found that all 
sequences fit better as full mediation models (models 5b to 8b, table 1). While most of 
the differences seen in AIC and BIC between full and partial models were greater than 
two units, they were generally small (appendix G).   
GI related cognitions and Anxiety 
In line with our hypothesis, the sequence R→ GI related cognitions→ anxiety→ 
symptom severity (appendix F, panel A) showed the best fit to the data with a good fit 
according to the 𝜒2 GOF and the CFI model fit criteria (table 1, model 5a). The lower 
AIC and BIC of 61 and 57 units respectively indicated that change in GI related 
cognitions preceding change in anxiety was more plausible than change in anxiety 
preceding change in GI related cognitions. The indirect effect was significant (-0.22, -
0.40 to -0.90, p=0.005) and indicated that reduction in unhelpful GI related cognitions, 
resulted in a reduction of anxiety and this lead to the subsequent reduction in symptom 
severity (table 2). The same sequence was found to have the best fit for the outcome of 
WSA as well (appendix F, panel B), with lower AIC and BIC criteria (table 1, model 
5b). The indirect effect here was also significant (-.26, -.44 to -.11, p=0.003). For both 
outcomes, the path R→ GI related cognitions→ anxiety→ outcome had the largest 
standardised indirect effect compared across all sequential mediation models (figure 4).  
Behaviours and Anxiety 
As avoidance behaviour was not a significant mediator in the basic mediation models, 
this was not taken forward into a sequential model, and only GI safety behaviours were 
studied. Concurrent with our hypothesis, the sequence R→ GI safety behaviours→ 
anxiety→ symptom severity fit the data best (appendix F, panel B). This had a good fit 
according to the CFI and 𝜒2 GOF and an acceptable fit according to the RMSEA and 
TLI (table 1, model 7a). However, the AIC and BIC relatively weak support for the 
model where anxiety preceded GI safety behaviours, conflicting somewhat with the 
results of the other fit indices (table 1, model 8a). On balance we proceeded with the GI 
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safety behaviours→ anxiety model, where the indirect effect was significant (-0.11, -.24 
to -.01, p=.049) with improvement (decrease) in GI safety behaviours and anxiety 
causing an improvement (decrease) in symptom severity (table 2).  
This sequence (R→ GI safety behaviours→ anxiety→ outcome) was also shown to fit 
the data best for WSA (appendix F, panel D). The CFI indicated good fit and the 
RMSEA indicated acceptable fit, however the TLI, 𝜒2 GOF did not indicate good model 
fit (table 1, model 7b). As for symptom severity, the AIC and BIC provided more 
support for the reverse sequence (R→ anxiety →  GI safety behaviours) mediation 
model. Having given priority to RMSEA and CFI values, we therefore took forward the 
mediation model with superior RMSEA and CFI values (R→ GI safety behaviours→ 
anxiety→ outcome). We found that the indirect effect was significant (-0.12, -.23 to -.03, 
p=.025) indicating that as mediating variables decreased, WSA also decreased (table 2). 
Figure 4: standardised effect sizes of the indirect effects testing in sequential mediation models 
with 95% confidence intervals. Panel A: outcome of symptom severity. Panel B: outcome of 
work and social adjustment. R, randomisation, C, GI related cognitions, A, anxiety, SB, GI 
Safety Behaviours, SS, symptom severity, WSA, work and social adjustment 
Discussion 
Our paper aimed to establish whether illness-related cognitions, avoidance and safety 
behaviours and anxiety were significant mediators of treatment effect on the outcomes 
of symptom severity and WSA. Change in GI related cognitions, GI related safety 
behaviours and general anxiety were found to mediate the effect of CBT on both 
outcomes. However, avoidance behaviour was not a significant mediator. The secondary 
aim of the paper was to elucidate whether there was a particular sequence of change in 
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cognitive and behavioural processes and changes in anxiety. The results indicated that 
CBT reduced unhelpful GI related cognitions and that this reduced anxiety. This 
sequence was found to best explain the treatment effect on both outcomes. Reductions in 
GI related safety behaviours were also found to precede reductions in anxiety for both 
outcomes, indicating that change in GI related cognitions and behaviours are necessary 
to reduce both anxiety and consequently symptom severity and impaired WSA.  
Targeting mediators informed by the CBT model 
The CBT in this trial was based on a three systems model (Lang, Melamed et al. 1970), 
targeting change at unhelpful GI related illness cognitions and behaviours. The model 
suggests that GI related cognitions, behaviours and physical sensations (IBS symptoms 
as well as physical symptoms of anxiety) are interrelated and that making a change in 
one response brings about a change in others.  The results of our basic mediation 
analyses provided some support for the model as GI related cognitions and GI safety 
behaviours along with anxiety were found to significantly mediate the treatment effect. 
The finding that avoidance behaviour was not a significant mediator was surprising. The 
paths from avoidance behaviour to outcome in both of the simple mediation models 
were not significant, suggesting that change in avoidance behaviour was not related to 
outcome. In contrast, significant R→ avoidance behaviour paths at visit 4 indicated that 
CBT at least initially reduced avoidance behaviours (table 2). The findings may 
therefore suggest that changing avoidance behaviours does not result in reductions in 
symptom severity or enhanced functioning. Nevertheless the results demonstrate the 
importance of GI safety behaviours in the maintenance of symptoms and disruption to 
work and social functioning in IBS. Safety behaviours such as excessive straining on the 
toilet or the use of medications to prevent symptoms have been shown to further disrupt 
bowel functioning and motility (Drossman et al., 1988; Tack, Fried, Houghton, Spicak, 
& Fisher, 2006).  Furthermore, individuals with IBS have reported that engaging in 
behaviours such as taking preventative medication and wearing protective underwear 
has a substantial impact on their daily lives (Rønnevig, Vandvik, & Bergbom, 2009; 
Farndale & Roberts, 2011). As such the results give support to the necessity of changing 




Gastrointestinal related cognitions, GI safety behaviours and anxiety 
Our hypothesis was that GI related cognitions and GI safety behaviours would change 
prior to a reduction in anxiety. Both GI related cognitions and GI behaviours were 
targeted through the provision of psycho-education (about the interplay between the 
brain and the gut), cognitive restructuring (thought diaries, recognising and challenging 
automatic negative thoughts) and goal setting (to change GI avoidance and safety 
behaviours). Whilst change in anxiety may also be a key process by which treatment 
causes change in the outcome, and a desired effect of causing cognitive and behavioural 
change, it was not the target of treatment. The results of the sequential mediation models 
generally supported our hypothesis. We found that reductions in GI related cognitions 
such as “I cannot function normally when I get bowel symptoms”, led to decreased 
anxiety, with a consequent reduction in the severity of their symptoms. This fits with the 
wider literature, which suggests increased levels of anxiety are directly associated with 
worse symptom severity (Simrén et al., 2001; Hazlett-Stevens, Craske, Mayer, Chang, & 
Naliboff, 2003; Tack et al., 2006; Labus, Mayer, Chang, Bolus, & Naliboff, 2007). This 
sequence of change (R→ GI related cognitions→ anxiety→ outcome) also makes 
intuitive sense in explaining the treatment effect on WSA. The less individuals 
experience anxiety (as a result of reduced unhelpful GI related cognitions), the more 
likely they are to participate fully in their daily lives across work and social situations 
(Wells, 1999). 
We also found support for the hypothesis that change in GI safety behaviours would 
precede change in anxiety for both outcomes (R→  GI safety behaviours→  anxiety→ 
outcome). This provides further corroboration for the three system’s model. Although 
this theoretical model presents the relationship between the variables as bidirectional, 
the CBT therapy applied in this trial targeted GI safety behaviours (along with other 
behaviours and GI related cognitions) as a means of reducing anxiety, bowel symptoms 
and enhancing functioning. Our results fit with previous research in the context of 
anxiety disorders and health anxiety, which has suggested that targeting the use of safety 
behaviours is important for the reduction of anxiety (Beesdo‐Baum et al., 2012; Helbig-
Lang et al., 2014; Goetz et al., 2016) and improving illness trajectories (Olatunji, Etzel, 
Tomarken, Ciesielski, & Deacon, 2011).  
Limitations 
Our analysis was conducted in the context of a waning treatment effect at visit 7 (12 
month follow up) to preserve temporal sequencing of variables (Kennedy, Chalder et al. 
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2006). Future mediational studies with similar follow up periods are needed to ascertain 
whether the results are replicated when the treatment effect is still observed. 
Nevertheless, assessing mediation in the context of no treatment effect is now widely 
considered valid and important (Shrout & Bolger, 2002; Emsley et al., 2010; Goldsmith 
et al., 2016). It allows us to gather information about where in the theoretical mediation 
pathway our treatment fails. This can help us to refine and improve treatments.  
The final models with best fit were the full mediation models, which may in part be due 
to the lack of a sustained treatment effect i.e. there were no direct effects of treatment on 
outcome, yet there were significant indirect effects. It is, however, unlikely that our 
models included all possible mediators. We assessed two-mediator sequences, however 
other CBT theoretical models, such as the four-factor model suggests at least 3 
mediators (GI related cognitions, behaviours and anxiety). Future analysis would ideally 
include all hypothesised mediators in a model. Our study was also limited by a relatively 
small sample size, which may increase the probability of type II error (Fritz & 
MacKinnon, 2007).  
A final limitation of the present study is the lack of a GI specific measure of anxiety 
such as the visceral sensitivity index (Labus et al., 2004). Our previous systematic 
review suggested that this may be an important mediator of treatment effect in IBS 
(Windgassen, Moss-Morris et al. 2017). 
Strengths 
The present study used robust methodology to study the mediation effects of CBT in 
IBS. Unlike other studies reviewed (Windgassen, Moss‐Morris et al. 2017), the 
inclusion of mediator variables were theoretically informed and assessed at adequate 
intervals to allow temporal precedence, increasing the plausibility of interpreting effects 
as causal. Effects of baseline mediators and outcomes on the mediated effect and 
outcome were controlled for, to reduce the potential for residual confounding of the non-
randomised mediator → outcome relationships in the models. In addition, the mediation 
analysis was conducted using data from a RCT, which further reduces the potential for 
confounding factors where the treatment is randomised.  
Conclusion  
Our results suggest that first changing GI related cognitions and GI safety behaviours, 
leading to a decrease in general anxiety is necessary for cognitive behavioural therapy to 
reduce symptom severity and the impaired work and social functioning. Avoidance 
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behaviours were not found to mediate the effect of CBT on either outcome. Our 
hypothesis that reduction in anxiety followed cognitive and behavioural change for all 
models was supported.  
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Table 1: Mediation analysis of symptom severity & work and social adjustment scores with Randomisation (R), Anxiety (A), 
GI related cognitions (C), GI Safety Behaviours (SB), Symptom Severity (SS) and Work and Social Adjustment (WSA) 
 Model (+ baseline) RMSEA [90% CI] CFI TLI AIC BIC 𝜒2  GOF Indirect 




Symptom Severity  
1a R→A-→SS 0 [0, 0.15] 1.0 1.02 1616.5 1670.5 𝜒2(2)=1.36, 
p=0.508 
.002 
2a R→C-→SS 0 [0, 0.06] 1.0 1.05 1538.8 1592.8 𝜒2(2)=0.18, 
p=0.915 
.005 
3a R→AB→ SS 0.041 [0, 0.17] 0.996 0.984 1594.8 1648.7 𝜒2 (2)=2.49, 
p=0.287 
.19 
4a R→SB→ SS 0 [0, 0.15] 
 






5a R→C→A-→SS* 0.070 [0, 0.14] 0.981 0.952 2111.6 2198.5 𝝌2(6)=10.38, 
p=0.109 
.006 












Rows in bold indicate best fitting model in comparison of two mediation sequences; * denotes full mediation model; RMSEA, root mean 
square error of approximation; CFI, comparative fit index, TLI, Tucker-Lewis Index; AIC, Akaike’s Information Criterion; BCC, Brown-





Table 1 (continued) 
 Model (+ baseline) RMSEA [90% CI] CFI TLI AIC BIC 𝜒2  GOF Indirect 
effect p  




1b R→A→WSA 0.041 [0, 0.14] 0.997 0.988 1543.5 1597.4 𝜒2(2)=2.49, 
p=0.287 
.001 
2b R→C→WSA 0.034 [0, 0.17] 0.998 0.993 1393.3 1447.2 𝜒2(2)=2.34, 
p=0.311 
.001 
3b R→AB→WSA 0 [0, 0.10] 1.0 1.04 1542.2 1596.1 𝜒2(2)=0.46, 
p=0.793 
.09 






5b R→C→A→WSA* 0.151 [0.10, 0.21] 0.929 0.822 1974.8 2061.8 𝝌2(5)=26.20, 
p<0.001 
.002 
6b R→A→C→WSA * 0.160 [0.10, 0.22] 0.911 0.777 2018.6 2105.5 𝜒2(6)=28.63, 
p<0.001 
.003 
7b R→SB→A→WSA * 0.096 [0.03, 0.16] 0.966 0.914 2146.3 2233.2 𝝌2(6)=14.18, 
p=0.028 
.025 





Table 2: Direct, Indirect & Total Effects in all models 
Symptom Severity Work and social adjustment 
 b (95% CI) p  b (95% CI) p 
R →anxiety →SS R →anxiety →WSA 
Group → Anxiety -.60 (-.90,-.30) <0.001 Group → Anxiety -.61 (-.91, -.31) <0.001 
Anxiety → SS .44 (.25, .62) <0.001 Anxiety → WSA .57 (.41,.73) <0.001 
Group → SS -.04 (-.33, .67) 0.79 Group → WSA -.19 (-.44, .11) .18 
Group→ Anxiety → SS -.13 (-.46, -.11) .002 Group→ Anxiety → WSA -.35 (-.56, -16) .001 
R →cognitions →SS R →cognitions →WSA 
Group → Cognitions -.53 (-.79, -.26) <0.001 Group → Cognitions -.55 (-.80,-.29) <0.001 
Cognitions → SS .45 (.23,.66) <0.001 Cognitions → WSA .65 (.49, .80) <0.001 
Group → SS -.08 (-.37, .23) .62 Group → WSA -.16 (-.42, .12) .24 
Group→ Cognitions→SS -.24 (-.43, -.09) .005 Group→ Cognitions → WSA -.36 (-.57, -17) .001 
R →avoidance behaviours →SS R →avoidance behaviours →WSA 
Group → Avoidance behaviour -.49 (-.73, -.23) <0.001 Group → Avoidance behaviour -.50 (-.76, -.26) <0.001 
Avoidance behaviour→SS .22 (-.05, .51) .13 Avoidance behaviour → WSA .25 (.02, .47) .03 
Group→SS .02 (-.36, .41) .92 Group → WSA -.23 (-.54, 08) .14 
Group→ Avoidance behaviour →SS -.11 (-.29, .02) .19 Group→ Avoidance behaviour → WSA -.12 (-.30, -..01) .09 
R →safety behaviours →SS R →safety behaviours →WSA 
Group → Safety behaviour -.96 (-1.24,-.69) <0.001 Group → Safety behaviour -.99 (-1.26, -.71) <0.001 
Safety behaviour → SS .34 (.13, .54) .001 Safety behaviour → WSA .35 (.15, .56) .001 
Group →→ SS .23 (-.14, .58) .22 Group → WSA -.03 (-.35, .32) .86 
Group→→ Safety behaviour → SS -.33 (-.57, -.11) .005 Group→ Safety behaviour → WSA -.35 (-.60, -.14) .004 
R →cognitions →anxiety→ SS R →cognitions →anxiety →WSA 
Group → Cognitions -.51 (-.77, -.25) <0.001 Group → Cognitions -.53 (-.79, -.27) <0.001 
Cognitions →Anxiety .71 (.57, .85) <0.001 Cognitions  →Anxiety .74 (.58, .88) <0.001 
Anxiety→ SS .59 (.41, .79) <0.001 Anxiety→ WSA .65 (.50, .80) <0.001 





Table 2 (continued) 
Symptom Severity Work and social adjustment 
 b (95% CI) p  b (95% CI) p 
R→safety behaviours →anxiety→ SS R→safety behaviours →anxiety→ →WSA 
Group→Safety behaviour -.96 (-1.24, -.68) <0.001 Group→Safety behaviour  -.99 (-1.27, -.70) <0.001 
Safety behaviour→Anxiety  .34 (.21, .46) <0.001 Safety behaviour→Anxiety  .33 (.20, .45) <0.001 
Anxiety→SS .34 (.05, .61) .015 Anxiety→WSA .35 (.13, .58) 0.002 
Group→Safety Behaviour→Anxiety→ SS -.11 (-.24, -.01) .049 Group →Safety Behaviour Anxiety→WSA -.12 (-.23, -.03) .025 
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Figure of Three Systems Model in IBS 
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Psycho-education provided information about the physiology of the bowel and the brain-
gut connection. Cognitive restructuring was aimed at making individuals aware of 
unhelpful GI-related thoughts, recognising how these affected their behaviours, and GI 
symptoms.  Patients were encouraged to challenge them. Behavioural techniques 
involved goal setting to increase helpful behaviours such as eating regular meals, whilst 
reducing unhelpful behaviours. These could be avoidance behaviours such as avoiding 
situations that may be impacted by bowel symptoms, or safety behaviours such as taking 
precautionary measures like trying to force the bowels to empty before leaving the 
house. Techniques to manage stress and prevent relapse were also included. The 
treatment aimed to improve participants’ ability to participate in life despite their IBS 






The Symptom Severity Scale (SSS) sensitive to change over time (Francis, Morris, & 
Whorwell, 1997) measures symptom severity specific to IBS. The maximum score is 
500, with scores <75 indicating normal bowel function. Scores between 75-174 indicate 
mild IBS, 175-299 moderate IBS and scores between 300-500 indicate severe IBS. The 
scale has been shown to have good reliability and validity (Francis et al., 1997).  
The Work and Social Adjustment Scale (WSAS) is a measure of work and social 
functioning. It contains 5 items each rated 0 - 8, with a total potential score of 40. The 
items assess individuals’ ability to engage in day-to-day tasks at work, at home, socially, 
with family and in relationships. It was found to be a reliable and valid measure of 
impaired functioning (Mundt, Marks, Shear, & Greist, 2002). 
Mediators 
The Cognitive Scale for Functional Bowel Disorders (CSFBD) contains items that assess 
thoughts specific to the experience of functional bowel disorders such as “my bowel 
symptoms make me feel out of safety”. The scale consists of 25 items, with a possible 
total score of 25 to 175 with higher scores indicating more illness-related cognitions. 
The measure has been demonstrated to have good reliability and validity (Toner et al., 
1998).  
The Hospital Anxiety and Depression Scale (HADS) contains two subscales measuring 
anxiety and depression. The present study only used the anxiety subscale of the HADS, 
which is made up of 7 items scored from 0 to 3, with a total possible score of 21. Scores 
of 8 and above are said to indicate anxiety (Bjelland, Dahl, Haug, & Neckelmann, 2002) 
with good sensitivity (0.9). The measure assesses general anxiety rather than anxiety 
specific to IBS, with items such as “I feel tense or wound up”.  
The IBS Behavioural Responses Questionnaire (IBS-BRQ) consists of two subscales. 
The first measures avoidance behaviour such as “I avoid going out in case I have 
problems with my IBS” (15 items). The second subscale assesses safety behaviours (11 
items), which are referred to as ‘safety behaviours’ in the scale. An example safety 
behaviour item is “I spend more time on the toilet than I would ideally like”. Each item 
is scored on a scale of 1-7, and the two subscales are scored by summing the total of the 
items. Higher scores indicate higher levels of unhelpful behaviours. The scale has been 





Methodology regarding selection of partial versus full mediation models 
 
Partial versus full mediation  
In mediation the total effect of an independent variable (e.g. treatment) on an outcome 
can be partitioned into the direct effect (path R to O, figure 1) and the indirect effect 
(paths from R to O via M, figure 1). The indirect effect quantifies the extent to which the 
treatment effect on the outcome is transmitted via the mediator (mediated effect). The 
direct effect quantifies the remaining direct effect of treatment on the outcome.  We use 
the term full mediation model to describe a model explicitly assuming the direct effect is 
essentially equal to zero, allowing for no direct pathway between treatment and 
outcome, and so postulate that the full effect of the outcome is transmitted via the 
mediating variable (full mediation model, figure 1).  Models we describe as partial 
mediation models allow for both direct and indirect pathways (models 1-4 and the 
partial mediation model, figure 1). In this latter type of model, we can assess whether 
mediation is partial or full; if there is full mediation, the mediated effect will be 
statistically significant, with a non-significant direct effect.  If the mediated and direct 
effects are statistically significant, this indicates partial mediation. 
 
The first four models assessed mediation via a single mediator (figure 1). In figure 1, 
full and partial sequential mediation models are illustrated. Each sequence (e.g. R →GI 
related cognitions →anxiety→outcome) was tested in the context of a partial mediation 
model and a full mediation model, and the best fitting model was assessed using the AIC 
and BIC criteria. This followed the process of the previous mediation paper (Reme, 
Stahl et al, 2011; Kennedy, Jones et al. 2005) and was used to determine whether the 
inclusion of a direct path from randomisation to outcome enhanced or detracted from the 
fit of the models to the data. Once a full or partial mediation model was selected, each 
sequence was compared using the model fit indices described above. The mediated 
effect of all models assessed calculated confidence intervals using bootstrap resampling 
with 1000 repetitions and 95% confidence interval (Chalder, Goldsmith, White, Sharpe, 
& Pickles, 2015; Efron & Tibshirani, 1994; Shrout & Bolger, 2002; Williams & 
MacKinnon, 2008).  
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Appendix E:  
A 
B 




Best fitting models as indicated by standardised indirect effect size for symptom severity and work and 
social adjustment (WSA). Single headed arrows indicate hypothesized relationships between variables 
with standardized regression coefficients next to each path with 95% confidence intervals in brackets. 
Not shown in the diagrams for simplicity are the paths indicating the baseline outcome and mediator 




Appendix G: Comparison of model fit indices for full versus partial mediation models of sequences  
 Full/Partial 
Model 
RMSEA [90% CI] CFI TLI AIC BIC 𝜒2  GOF Indirect effect 
p 
Symptom Severity  
R→C→A→SS Full 0.070 [0, 0.14] 0.981 0.952 2111.6 2198.5 𝝌2(6)=10.38, p=0.109 .006 
Partial 0.083 [0, 0.16] 0.977 0.932 2113.3 2203.2 𝜒2(5)=10.15, p=0.071 .006 
R→A→C→SS Full 0.102 [0, 0.17] 0.949 0.872 2174.0 2260.9 𝜒2(6)= 15.20, p=0.019 .010 
Partial  0.117 [0.05, 0.19] 0.944 0.831 2176.0 2266.0 𝜒2(5)=15.16, p=0.010 010 
R→SB→A→SS Full 0.08 [0, 0.15] 0.976 0.939 2218.9 2305.8 𝝌2(6)= 11.17, p=0.083 .046 
Partial 0.09 [0, 0.16] 0.975 0.924 2220.1 2310.0 𝜒2(5)=10.42, p=0.064 .046 
R→A→SB→SS Full 0.121 [0.06, 0.18] 0.943 0.898 2202.0 2289.0 𝜒2(6)= 18.91, p=0.004 .014 
Partial 0.119 [0.05, 0.19] 0.954 0.862 2200.6 2290.5 𝜒2(6)= 15.14, p=0.009 .014 
Work and Social Adjustment 
R→C→A→WSA Full 0.151 [0.10, 0.21] 0.929 0.822 1974.8 2061.8 𝝌2(6)=26.20, p<0.001 .002 
Partial 0.166 [0.11, 0.23] 0.928 0.785 1976.0 2065.9 𝜒2(5)=25.33, p<0.001 .002 
R→A→C→WSA Full 0.160 [0.10, 0.22] 0.911 0.777 2018.6 2105.5 𝜒2(6)=28.63, p<0.001 .003 
Partial  0.177 [0.12, 0.24] 0.908 0.724 2020.2 2110.2 𝜒2(5)=28.29, p<0.001 .003 
R→SB→A→WSA Full 0.096 [0.03, 0.16] 0.966 0.914 2146.3 2233.2 𝝌2(6)=14.18, p=0.028 .025 
Partial  0.105 [0.04, 0.18] 0.966 0.898 2147.2 2237.2 𝜒2(5)=13.10, p=0.023 .025 
R→A→SB→WSA Full 0.115 [0.06, 0.18] 0.954 0.884 2125.8 2212.7 𝜒2(6)=17.66, p=0.007 .017 
Partial  0.131 [0.07, 0.20] 0.950 0.849 2127.8 2217.7 𝜒2(6)=17.66, p=0.003 .017 
Rows in bold indicate best fitting model; RMSEA, root mean square error of approximation; CFI, comparative fit index, TLI, Tucker-Lewis Index; AIC, 
Akaike’s Information Criterion; BCC, Brown-Cudeck criteria; 𝜒2  GOF, Chi square goodness of fit. R. randomisation; A, general anxiety; C, GI related 
cognitions; SB, GI safety behaviours; WSA, work and social adjustment; SS, symptom severity   
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Baseline measures of data set 1 
Baseline measures taken at visit 1 (n=235) 
   Total sample (n=235) 
Variable   Mean Standard 
deviation 
Symptom severity   298.2 94.7 
Work and social adjustment   14.3 8.1 
GI related cognitions   108.4 30.6 
GI related safety behaviours   44.7 10.7 
GI related avoidance behaviours   44.5 17.5 
Anxiety   11.0 4.6 
Depression   7.2 3.8 
Baseline Measures taken at visit 3 (n=180) 
 CBT + mebeverine (n=89) Mebeverine alone (n=91) Total sample (n=180) 




Mean  Standard 
deviation 
Symptom severity 253.5 109.9 272 116.9 262.9 113.6 
Work and social adjustment 13.4 8.9 14.5 9.0 14.0 8.9 
GI related cognitions 107.2 26.1 109.1 29.8 108.2 28.0 
GI related safety behaviours* 44.8 11.3 45.5 10.1 45.2 10.7 
GI related avoidance 
behaviours* 
45.3 16.6 45.8 18.0 45.6 17.3 
Anxiety 9.6 4.3 10.3 4.9 9.9 4.6 
Depression 6.4 3.1 6.7 3.4 6.6 3.3 




The results of this study support the findings from the systematic review in study one 
(chapter four), that change in GI related cognitions significantly mediate the treatment 
effect on the outcomes of symptom severity and work and social adjustment (WSA). 
The results of the systematic review suggested that reducing general anxiety may not be 
as important for producing change in outcome as changing cognitions. However the 
results of study two indicated that general anxiety was a significant mediator of 
treatment effect on both symptom severity and WSA. The systematic review indicated 
that GSA may be a more important mediator, however because data set 1 was already 
collected, GSA was not able to be included in the mediation analysis as this had not 
been measured at the time of data collection. The results of study two, however, may 
still support the findings of study one with regards to general anxiety being of less, or 
rather, secondary importance to changing GI related cognitions. This is because the 
results of the sequential mediation analysis indicated that CBT changed GI related 
cognitions prior to general anxiety reducing. This sequence then produced change in 
symptom severity and WSA. Together these studies may therefore establish that of 
primary importance in CBT for IBS is to achieve a change in GI related cognitions, 
which will subsequently result in the reduction of anxiety, symptom severity and 
increase work and social functioning.  
Study one identified that there were few studies assessing the potential mediating role of 
behaviours in CBT for IBS, despite the fact that these are a key process implicated in the 
CB models of IBS. Study two contributed to the understanding of how particular 
behaviours may have differential roles in CBT for IBS. Unlike in the one previous study 
assessing GI related behaviours as mediators in IBS (Reme et al, 2011), study two 
divided these behaviours into avoidance and safety behaviours in line with the IBS 
behavioural responses questionnaire subscales (Reme et al, 2010). The simple mediation 
models demonstrated that safety behaviours were significant mediators of treatment 
effect on both outcomes however avoidance behaviours were not. This finding could be 
due to the sample not being particularly avoidant at baseline (page 169). It may also be 
due to measurement bias, should the IBS-BRQ not sufficiently measure the avoidance 
tendencies of individuals with IBS or should the measure not be sensitive to change.  
In the sequential mediation models of study two, change in safety behaviours were 
found to occur prior to reduction in anxiety, as with the sequences including GI related 
cognitions and anxiety. The results of study two along with the findings of study one 
would therefore suggest targeting change in GI related cognitions and behaviours is 
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particularly important for achieving change in outcomes, including anxiety. Future 
studies should seek to assess the mediating role of GSA in addition to GI related 
cognitions and behaviours. Ideally mediation models would include a measure of all 
three variables (or more if behaviours were to be subdivided). This would allow 
comparison of the quantification of the indirect effects of all mediators, in order to 
identify whether particular variables have stronger mediating effect than others. Such 
analysis would ideally be conducted in a large sample with sufficient power and a 






6. The Importance of Examining Subgroups in Irritable 
Bowel Syndrome 
6.1 Chapter Overview  
The previous two studies have investigated psychological treatment mechanisms in IBS 
to address objective one of the thesis. The subsequent two studies were designed to 
address objective two: to identify cognitive and behavioural factors associated with IBS 
bowel pattern subtypes. In IBS subgroups are currently classified according to 
predominant bowel subtypes only. There are increasing calls to increase the 
dimensionality of subgroups in IBS, so that they are characterised by additional factors 
such as psychological comorbidity (Whitehead et al, 2002) and somatic comorbidity 
(Reidl et al, 2008) in addition to bowel pattern subtype. There are a number of 
arguments for increasing the multidimensionality of subgroups in IBS, which are 
presented in this chapter. It presents “cluster analysis” as a means of statistically 
identifying subgroups that are multi-factorially characterised. This chapter provides a 
context for the importance of the analysis conducted in studies three and four (chapters 
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In clinical populations substantial heterogeneity exists in patient characteristics, illness severity 
and treatment responses. Better understanding of such heterogeneity may lead to more effective 
and efficient treatment by personalising care to better suit patient profiles. In this editorial we 
argue that the statistical method of cluster analysis is a means by which such heterogeneity can 
be understood, potentially leading to improved care in mental health services. The method is as 




The Importance of Cluster Analysis for Enhancing Clinical Practice: An Example 
from Irritable Bowel Syndrome  
Introduction  
In clinical populations substantial heterogeneity exists in patient characteristics, illness severity 
and treatment responses. Better understanding of such heterogeneity may lead to more effective 
and efficient treatment by personalising care to better suit patient profiles. In this editorial we 
argue that the statistical method of cluster analysis is a means by which such heterogeneity can 
be understood, potentially leading to improved care in mental health services. The method is as 
yet relatively under-utilised and as such the barriers to its use and implementation are also 
considered.  
Cluster analysis is a statistical method that identifies subgroups as defined by multiple 
characteristics. For example in depression there is heterogeneity in terms of age of onset (e.g. 
early versus late onset), exposure to life stress (Van den Berg et al., 2001) and severity of 
depression (e.g. mild, moderate or major depressive disorder) (Merikangas et al., 1994). Cluster 
analysis could help to identify subgroups within this patient population defined by the 
characteristics of age, stress exposure and depression severity all together. Use of such analysis 
could have several benefits including the development of diagnostic criteria, explanations of 
heterogeneous outcomes and tailoring of treatments (Taylor et al., 2001; Song & Jason, 2005). 
We use the word ‘subgroup’ to refer to subsets of individuals within a given population that can 
be described using several characteristics. The use of this term should not be confused with what 
is traditionally called ‘subgroup analysis’ in the clinical trials literature. Subgroup analysis in 
that literature refers to quantification of treatment responses in subsets of individuals identifiable 
by a single characteristic (e.g. a demographic or psychological variable). This may involve 
analysis within the subgroup of interest, or via simple regression models including interaction 
terms (moderation analysis) (Assmann et al., 2000). Instead, this paper provides a brief 
overview of cluster analysis, how it can be used to identify subgroups, the usefulness of such 
analysis and its potential application to clinical practice. We use some recent results in irritable 





Diagnostic utility  
 Mental and physical health diagnostic criteria are often criticised because they are considered to 
be too restrictive, too broad or to actually exclude important factors within a given condition 
(Bentall & Pilgrim, 1999; Wakefield, 2010). In irritable bowel syndrome (IBS) there are four 
subgroups defined by a single parameter - the predominant bowel pattern. Individuals can either 
be constipation predominant (IBS-C), diarrhoea predominant (IBS-D), alternating (IBS-A) or 
unclassified (IBS-U). However, assigning individuals to subgroups based on one parameter may 
limit the diagnostic utility and clinical relevance. Increasing the multidimensionality of the 
clinical profile of IBS subgroups could aid healthcare professionals in making positive 
diagnoses of IBS as opposed to diagnosis by exclusion. Improving clarity and validity of 
diagnostic criteria would also have the benefit of reducing the cost associated with diagnosis by 
exclusion, which often involves additional consultations and unnecessary diagnostic procedures. 
It also has a negative effect on the prognosis and illness trajectories of IBS patients as it leaves 
them with feelings of uncertainty regarding their condition and can lessen trust in healthcare 
professionals (Spiegel et al., 2010). 
Multidimensionality of IBS clinical profiles has been examined using mixture modelling cluster 
analysis, which included measures of bowel symptom type (IBS-C, IBS-D, IBS-A), symptom 
severity, the occurrence of extra-intestinal symptoms, anxiety and depression (Polster et al., 
2017). Six subgroups were found, identified by bowel pattern subtype and further subdivided by 
high or low ratings of comorbidities (somatic and psychological). Whilst supporting the 
distinctions between bowel patterns, the results indicate that assessments of additional somatic 
and psychological comorbidities are also important factors in distinguishing IBS subtypes. 
Furthermore, when the groups were compared on symptom severity and anxiety and depression, 
high comorbidity groups were found to have significantly higher levels of symptom severity, 
anxiety and depression than low comorbidity subgroups. Level of comorbidity therefore appears 
to be an important factor in distinguishing levels of symptom severity and psychological distress 
in IBS. Increasing the multidimensionality of subgroups in IBS could provide a means of 
understanding heterogeneity in outcomes that subgrouping by bowel pattern alone cannot.   
How can cluster analyses improve treatment approaches? 
The more comprehensive characterisation of subgroups provided by cluster analysis can help 
target treatments more specifically. For example in IBS, cognitive behavioural therapy (CBT) is 
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the primary recommended treatment approach (Spence & Moss-Morris, 2007; Drossman, 2016). 
CBT aims to change unhelpful cognitions and behaviours contributing to the maintenance of 
symptoms. When assessing subgroups in IBS, including a measure of such tendencies to engage 
in unhelpful cognitive and behavioural patterns along with other empirically directed 
characteristic measures (such as anxiety and bowel pattern subtype) can inform how the 
different subgroups may be best targeted by CBT. For example two hypothetical subgroups 
identified by cluster analysis may be (1) individuals with IBS-D and IBS-A with higher levels of 
gastrointestinal avoidance behaviour and high levels of general anxiety compared with (2) 
individuals with IBS-C who have high levels of safety behaviours and gastrointestinal (but not 
general) anxiety. The characterisations of these groups by the different measures included in the 
cluster analysis would therefore provide a basis for tailoring treatment for the subgroups. For 
instance group 1 may benefit from behavioural experiments designed to demonstrate the 
likelihood of having an accident in public and stress management training to reduce general 
anxiety. In contrast, group 2 may benefit from cognitive restructuring regarding fears about not 
passing stools and behavioural exposure techniques to reduce anxiety specific to the experience 
of gastrointestinal sensations. The efficacy of such tailoring could be tested in an experimental 
design comparing the conditions and a control group with use of moderation analysis.  In the 
context of randomised controlled trials, moderation analysis including clusters (subgroups) 
would identify whether there is an interaction between cluster membership (e.g. subgroup) and 
treatment group. In this example, moderation would determine whether membership of group 1 
or 2 would affect treatment response in the different conditions.  
Methodological Approaches to the Identification of Subgroups   
There are numerous approaches available to researchers intending to identify subgroups that 
exist under the umbrella term of ‘cluster analysis’ (Nathan & Langenbucher, 2003). One of the 
most popular methods is finite mixture modelling, such as latent class analysis (LCA) (Stahl & 
Sallis, 2012). LCA operates on the assumption that a given dataset includes a mixture of scores 
from different underlying latent classes (subgroups) (Stahl & Sallis, 2012). The approach 
deduces information about the underlying distributions of the subgroups by identifying similar 
patterns of values and assessing the probability that certain cases are members of the identified 
subgroups (Fraley & Raftery, 1998). The LCA algorithm derives a range of subgroups from the 
data, and uses a goodness of fit statistic such as the Bayesian Information Criteria (BIC) 
(Nylund et al., 2007) to identify the optimal number of subgroups that adequately explains the 
distribution of the data. For example, an LCA may identify one model with 5 subgroups (also 
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termed clusters or classes) and one with 4 subgroups. It will use the BIC goodness of fit statistic 
to identify which model best fits the observed data.  
This method of identifying the optimal number of subgroups is a key advantage of LCA 
compared to other methods of cluster analysis such as distance based cluster analysis that use 
more arbitrary criterion. Other advantages of LCA include its ability to combine both continuous 
and categorical measures to define subgroups and allow for the inclusion of covariates and 
modelling of directional relationships. This means LCA can control for potential effects of other 
background variables and when used in prospective data, can be used to assess directional 
relationships (e.g. whether cluster membership predicts outcome) (Hagenaars & McCutcheon, 
2002; Stahl & Sallis, 2012). 
Barriers to Implementation  
Although cluster methods provide a powerful tool for understanding subgroups and differences 
in treatment response they also require careful consideration prior to implementation.  Good 
statistical power is necessary for robust results (Lanza & Rhoades, 2013). Sample size depends 
on the number of clusters being identified and the number of items/variables entered into the 
analysis (Dziak et al., 2014). There is no consensus on an adequate sample size, but previous 
research suggests samples above 200 are necessary to achieve sufficient power (Tekle et al., 
2016), with some suggesting a minimum sample of 500 (Finch & Bronk, 2011). A strong 
empirical and/or theoretically informed basis for such analysis is vital to inform which measures 
are included in analysis and the extent to which clusters identified make theoretical/clinical 
sense (Breckenridge, 1989). Replication is also essential as the models derived from the analysis 
use the existing data distribution so further samples are needed to test the robustness of the 
models (Milligan, 1996). It is therefore recommended that two datasets are used or a large 
enough dataset that allows splitting the data in two samples. One sample is then used as the 
‘training’ dataset and the other is used as a validation sample (Everitt et al., 2001). Only once 
the identification of subgroups within a given population has been replicated (cross-validated) in 
multiple samples would there be a strong enough basis for updating existing diagnostic criteria 
and informing practice.  
Conclusion 
Cluster analysis is important for understanding the heterogeneity of clinical disorders, 
particularly those that challenge customary distinctions between physical and psychological 
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aetiology. Cluster analysis methods can improve diagnostic criteria to provide more 
comprehensive and clinically meaningful profiles within a condition. In IBS this involves 
consideration of psychological aspects such as anxiety and in the future a wider approach 
including cognitive and behavioural factors. Cluster analysis also has the potential to improve 
our understanding of differential treatment responses in different patient subgroups and to 
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7. ANOVAs Assessing Psychological, Work and Social 
Functioning and Symptom Severity Differences Between 
IBS Subtypes (Study Three) 
7.1 Chapter Overview  
The previous chapter presented the importance of examining subgroups in IBS. It 
proposed the use of cluster analysis techniques such as latent class analysis to increase 
the multidimensionality of subgroups in IBS. An important first step before conducting 
such analysis is to identify theoretically and empirically informed variables that should 
be included in such analysis. The analyses conducted in study three (this chapter) and 
four (chapter eight) can serve as this first step. The analyses were designed to meet 
objective two: to identify cognitive and behavioural factors associated with IBS bowel 
pattern subtypes. Specifically the aim of study three was to assess whether there were 
differences in cognitive and behavioural factors in addition to levels of anxiety, 
depression, symptom severity, abdominal pain and work and social adjustment across 
IBS subtypes. Assessing whether there are psychological and physiological differences 
between the existing subtypes in IBS can indicate which variables may be important to 
include in future cluster analysis. It can also help to identify whether the distinctions in 
bowel pattern predominance are clinically meaningful in the context of psychological 
interventions for IBS.  
One-way ANOVAs were conducted using baseline data (n=235) of individuals 
diagnosed with IBS and meeting the Rome I criteria (data set 1). Bowel pattern subtype 
was classified according to the use of the illness perception questionnaire adapted for 
IBS, which asked participants to rate the frequency of symptoms of diarrhoea and 
constipation. The results are presented and discussed with consideration of their clinical 
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Behavioural differences between Irritable Bowel 




Irritable Bowel Syndrome (IBS) is a heterogeneous functional 
gastrointestinal condition consisting of four subtypes characterised by 
predominant bowel pattern. Cognitive behavioural therapy is an evidenced 
based approach formulated to reduce symptom severity and impact on 
functioning in IBS. 
Aims  
Our paper aimed to assess the associations between bowel pattern subtypes 
and a range of psychological factors as well as impact measures. 
Method 
Three bowel pattern subtypes, diarrhoea predominant (IBS-D), 
constipation predominant (IBS-C) and alternating bowel pattern (IBS-A) 
were assessed for associations with psychological variables using one-way 
ANOVAS. The fourth unclassified bowel pattern subtype (IBS-U) was not 
compared due to a disproportionately small sample. Variables assessed 
included functional gastrointestinal specific cognitions, avoidance 
behaviour, control behaviour, anxiety and depression and abdominal pain.   
Results 
Individuals with IBS-A had the highest ratings of abdominal pain severity, 
which were significantly higher than individuals with IBS-D. Those with 
IBS-A and IBS-D engaged more in unhelpful behaviours than those with 
IBS-C. IBS-A had higher levels of avoidant behaviour than IBS-C, and had 
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higher levels of control behaviour than IBS-C and IBS-D. Those with IBS-
D showed a non-significant trend towards higher ratings of unhelpful 
gastrointestinal related cognitions. Unhelpful illness-related behaviour is 
more prominent in those with IBS-A and IBS-D.  
Conclusions 
Treatments targeting behavioural techniques in IBS may be particularly 
helpful to these specific IBS subtypes. The paper identifies specific 








Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, with a 
biopsychosocial aetiology (Drossman, 2016; Lackner, Mesmer, Morley, Dowzer, & 
Hamilton, 2004). The ROME IV is the most recent diagnostic criteria for IBS, 
stipulating that a diagnosis of IBS is contingent on the presence of abdominal pain, 
which must be associated with changes in bowel movements or stool consistency 
(Drossman, 2016). Symptoms must be experienced for a minimum of once a week 
consistently for at least six months. There is substantial heterogeneity within IBS, as 
symptom severity can vary substantially from individual to individual, as can 
predominant symptom type (Guilera, Balboa, & Mearin, 2005).  
The iterations of the ROME criteria have led to different approaches in the 
categorisation of IBS bowel pattern subtypes. Initially individuals were classified only 
as being either diarrhoea predominant (IBS-D) or constipation predominant (IBS-C). 
ROME III (Drossman, 2006) introduced two additional subtypes: (1) Alternating bowel 
pattern (IBS-A) which includes individuals who frequently experience both constipation 
and diarrhoea, and (2) Unclassified bowel pattern (IBS-U) where individuals do not 
regularly experience either type of bowel symptom.   
The ROME III criteria specify that classification of bowel pattern subtypes is 
dependent on the proportion of total stools that are loose/watery or hard/lumpy. The 
specified scale for assessing this is included in the ROME III criteria (see table 1). A 
limitation of this scale is that individuals with IBS can experience extensive periods of 
time without symptomatic stools. Consequently, individuals with IBS could be 
misclassified. Therefore, a significant change made in the ROME IV criteria is the 
specification that IBS subtypes should be based on symptomatic stools rather than all 
stools. Furthermore, the updated criteria consider bowel pattern subtypes to exist on a 
continuum, rather than as distinct disorders (Drossman, 2016). This acknowledges that 
bowel pattern subtypes may be transitory rather than stable (Penny et al., 2008) and that 
symptomatic treatment may consequently vary across consultations.  
In addition to the ROME criteria, there are alternative IBS diagnostic tools such 
as the Manning Criteria (Talley et al., 1990). Research investigating IBS subtypes have 
inconsistently classified subtypes using differing criteria, or have developed additional 
tools to identify bowel pattern subtypes such as symptom diaries (Dang, Ardila‐Hani, 
188 
 
Amichai, Chua, & Pimentel, 2012; Ersryd, Posserud, Abrahamsson, & Simrén, 2007; 
Saito et al., 2000; Whitehead and Drossman, 2010). Different approaches to 
classification of bowel pattern subtypes may be partly responsible for inconsistent 
findings in research investigating associations between bowel pattern subtypes and 
psychological and physical factors. Outcomes assessed for associations with subtypes 
include: (a) symptom severity (Fond et al., 2014), (b) QoL (Dang, et al., 2012; Eriksson, 
Andren, Eriksson, & Kurlberg, 2008; Jamali et al., 2012; Monnikes, 2011; Simren, 
Abrahamsson, Svedlund, & Bjornsson, 2001), (c) personality factors (Farnam, Somi, 
Sarami, Farhang, & Yasrebinia, 2007), (d) demographic factors (Lovell and Ford, 
2012a), (e) cognitive factors (Guthrie et al., 2003; Stengel et al., 2010; Sugaya and 
Nomura, 2008), and (f) anxiety or depression (Eriksson, et al., 2008; Farnam, et al., 
2007; Fond, et al., 2014; Sugaya and Nomura, 2008).  
In relation to QoL some studies found no difference in QoL between bowel 
pattern subtypes (Fond, et al., 2014; Guthrie, et al., 2003; Jamali, et al., 2012). In one 
study worse QoL was found in IBS-A and D compared to IBS-C (Dang, et al., 2012), 
whereas another study found worse QoL in patients with IBS-C compared to IBS-D 
(Eriksson, et al., 2008). Similar contradictory findings have emerged when examining 
the relationship between psychological distress and bowel pattern subtypes. Some 
indicated that higher levels of anxiety were found in IBS-D compared to IBS-C (Prior, 
Maxton, & Whorwell, 1990; Sugaya and Nomura, 2008) while others found higher 
levels of anxiety in IBS-C (Farnam, et al., 2007; Prior, et al., 1990). When examining 
differences in illness-related cognitions (such as thoughts about symptoms and 
catastrophising) across bowel subtypes no significant differences were found (Guthrie, 
et al., 2003; Stengel, et al., 2010; Sugaya and Nomura, 2008). It is important however, to 
note that studies investigating cognitive differences used different measures of illness-
related cognitions and had a variety of methodological problems. These include small 
sample sizes (Stengel, et al., 2010), unstandardised classification of bowel subtype using 
symptom diaries (Guthrie, et al., 2003) and failure to include third and/or fourth bowel 
subtype groups in comparison (Sugaya and Nomura, 2008).  
These contradictory findings are indicative of a need for better understanding of 
psychological factors potentially associated with the different IBS subtypes. Formulating 
a clearer picture of such factors could enhance the design and development of 
psychological treatment approaches for IBS. Treatments such as Cognitive Behavioural 
Therapy (CBT) have established efficacy in improving quality of life (QoL) and 
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symptom severity in IBS (Ford, Talley, Schoenfeld, Quigley, & Moayyedi, 2009; 
Lackner, et al., 2004). In a mediation study of CBT in IBS, it was found that 
gastrointestinal specific cognitions and behaviours were mediators of change in both of 
the outcomes of work and social adjustment and symptom severity (Reme et al., 2011). 
These results demonstrate the importance of cognitive and behavioural factors in IBS. 
Therefore, increasing understanding in how these factors relate specifically to bowel 
subtypes could lead to therapeutic techniques being tailored to the particular bowel 
symptoms experienced by individuals. This would be particularly useful when tailoring 
interventions and when designing online and remote IBS interventions.  
Some researchers have questioned the clinical value of sub-classification in IBS 
based on predominant bowel patterns (Guthrie, et al., 2003; Heitkemper et al., 2011). 
Indeed a previous study investigating the psychological differences across IBS subtypes, 
subdivided the bowel pattern subtypes further according to whether individuals 
classified under each bowel pattern, also experienced either high or low abdominal pain 
(Heitkemper, et al., 2011). They then investigated whether the interaction between 
bowel pattern subtype and abdominal pain classification was associated with a range of 
physical and psychological outcomes. These outcomes included QoL, symptom severity, 
IBS-specific cognitions and anxiety, which were found to significantly differ between 
abdominal pain categories (high or low) but not bowel pattern subtypes. One significant 
interaction was found whereby those with IBS-A and IBS-D who also had high 
abdominal pain, were more likely to have higher symptom severity ratings. This 
research suggests that abdominal pain, an important factor for the diagnostic criteria of 
IBS, may also be important in the subtyping of IBS.  
The aim of this study was to further investigate the characterisation of bowel 
pattern subtypes in several ways.  We replicated previous studies in testing the 
associations of subtypes with physical and psychological outcomes but with the addition 
of unhelpful IBS-specific behaviours as a potential distinguishing factor. These are 
identified as important factors in maintaining symptoms in IBS according the cognitive 
behavioural models of IBS (Kennedy et al., 2005) and have been found to influence 
cognitive change in the context of cognitive behavioural treatment (Reme, et al., 2011). 
Specifically, we sought to understand whether unhelpful gastrointestinal specific 
cognitions and behaviours were differentially associated with bowel pattern subtypes in 
IBS. We hypothesised that due to the nature of the symptoms and the additional burden 
they create, IBS-A and IBS-D subtypes would be associated with more extreme 
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symptoms, disability and cognitive behavioural responses as compared to IBS-C.  This 
is because both subtypes experience diarrhoea, which is likely to be more unpredictable 
and cause more acute inconvenience and uncertainty than the symptom of constipation. 
As such individuals may have more concerns about public embarrassment than those 
with IBS-C. IBS-A has also been of particular empirical interest due to its heterogeneity 
and has previously been found to be associated with increased physical and 
psychological symptoms (Fond, et al., 2014; Jamali, et al., 2012; Singh et al., 2014). In 
addition, building on previous research by Heitkemper et al (2011) we aimed to assess 
whether abdominal pain was associated with particular bowel pattern subtypes.  
Method 
The present study used the baseline data previously collected in a study 
assessing the efficacy of CBT in addition to antispasmodic treatment in IBS (Kennedy et 
al., 2005). Two hundred and thirty-five individuals aged 16-50 with moderate to severe 
IBS symptoms were initially recruited from general practices in South London. There 
were three data collection time points before individuals began treatment: upon referral 
to the nurse (visit 1), after 2 weeks of GP care (visit 2) and upon randomisation (visit 3). 
Data used for this secondary analysis were taken from visit 1, prior to randomisation. 
Ethical approval was received from St Thomas’ Hospital Research Ethics Committee, 
Guy’s Hospital Research Ethics Committee and Barnet, Enfield and Haringey LREC.  
Measures 
Table 1: ROME III classifications of IBS bowel subtypes 
 Stool Type 
Bowel Subtype Loose/Watery Hard/Lumpy 
IBS-D >25% <25% 
IBS-C <25% >25% 
IBS-A >25% >25% 




 Classification of IBS Bowel Pattern Subtypes  
Predominant bowel pattern was identified through recoding of the adapted 
“Illness Identity symptom” items of the Illness Perception Questionnaire (IPQ) (Moss-
Morris et al., 2002), which asked participants how often they experienced diarrhoea and 
constipation. Responses were rated as “never = 0”, “occasionally = 1”, “frequently = 2” 
or “all of the time = 3”.  
Constipation predominant IBS was defined as individuals who never 
experienced diarrhoea and scored ≥1 for constipation. Diarrhoea predominant was 
defined as individuals who never experienced constipation and scored ≥1 for diarrhoea. 
Individuals who scored ≥1 for constipation and diarrhoea were classified as having 
alternating bowel pattern. Those who scored 0 for both diarrhoea and constipation were 
excluded from analysis as there were too few to form a meaningful comparison group 
(n=8).   
Abdominal Pain  
Abdominal pain was assessed using an item from the Gastrointestinal Rating 
Scale (Revicki, Wood, Wiklund, & Crawley, 1997). This assessed the severity of 
abdominal pain on a Likert scale ranging from “no discomfort at all” = 0 to “severe 
discomfort” = 5.   
IBS Symptom Severity Scale (IBS-SSS) (Francis, Morris, & Whorwell, 1997).  
The IBS-SSS is a well-validated and reliable measure of symptom severity in 
IBS (Francis, et al., 1997), consisting of 12 items with a maximum possible score of 
500. Mild, moderate and severe cases of IBS are indicated by scores of 75 to 175, 175 to 
300 and >300 respectively. Clinically meaningful change has been identified as a score 
change of ≥50 (Passos et al., 2009). 
Work and Social Adjustment Scale (WSAS) (Mundt, Marks, Shear, & Greist, 2002)  
The WSAS is a five-item questionnaire measuring ability to participate in five 
areas of life: social leisure, work, private leisure, relationships and home management. 
Each item is scored on a scale of 0 – 8, with 0 being not at all impaired and 8 being 
severe impairment in the given aspect of life. The maximum score is 40. Scores of 10 
and above indicate significant functional impairment and scores of 20 and above 
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indicate severe impairment. It has been demonstrated to have good reliability with 
Cronbach’s α ranging from 0.70 to 0.94, and good validity (Mundt, et al., 2002). The 
WSAS is sometimes taken as a measure of QoL (Moss-Morris, McAlpine, Didsbury, & 
Spence, 2010). 
Hospital and Anxiety Scale: Anxiety and Depression (HADS) (Zigmond and Snaith, 
1983) 
 The HADs is a well-established measure of anxiety and depression. The scale 
consists of 14 items, 7 measuring anxiety and 7 measuring depression, all of which are 
scored from 0 – 3. A total composite score can be calculated ranging from 0 to 42 
(Norton, Cosco, Doyle, Done, & Sacker, 2013), as well as individual scores ranging 0 to 
21 for anxiety and depression subscales. For the subscale, scores of 0-7 are considered 
normal, 8-10 mild anxiety/depression, 11-14 moderate anxiety/depression and 15-21 
severe anxiety/depression.  It has been demonstrated to have good reliability and validity 
(Zigmond and Snaith, 1983). 
Cognitive Scale for Functional Bowel Disorders (CS-FBD) (Toner et al., 1998) 
 The CS-FBD is a measure designed to assess negative illness cognitions in IBS. 
It consists of 25 items, each rated on a Likert scale 1 to 7, with higher scores indicating 
more negative IBS-related thoughts. The total score ranges from 25 to 175. It has been 
demonstrated to have good reliability (α= .93) and validity (Toner, et al., 1998). 
The Irritable Bowel Syndrome Behavioural Responses Questionnaire (IBS- BRQ) 
(Reme, Darnley, Kennedy, & Chalder, 2010) 
The IBS-BRQ is a measure of unhelpful behaviours specific to IBS. It has two 
subscales, one measuring avoidant behaviours (15 items) and one measuring control 
behaviours (11 items). Example of an avoidant item would be “I avoid going out in case 
I have problems with my IBS” and an example of a control item would be “After opening 
my bowels, I check my stools”. Each item is rated on a Likert scale of 1 to 7 with higher 
scores indicating higher levels of unhelpful behaviours. The scale has been demonstrated 






Demographic variables, including gender, age, ethnicity, marital status, IBS 
duration and post infective IBS instances, were summarised across the subtype groups. 
The difference in age between the groups was assessed using a one-way ANOVA. 
Differences across subtype groups in the categorical variables of interest: ethnicity 
grouping, marital status, banding of IBS duration and whether IBS was post-infectious 
or not, were assessed using Chi Square tests of independence. 
One-way ANOVAs were used to examine associations between IBS bowel 
pattern subtypes and each of the dependent variables (cognitive and behavioural 
responses, anxiety, depression, pain, symptom severity and work and social adjustment). 
Although pain was assessed as one item on a Likert scale, it was treated as a continuous 
variable upon comparisons of the distributions for each subtype, which were assessed as 
normal.  ANOVA assumptions were investigated for all dependent variables. 
Homogeneity of variances across subtypes was assessed using Levene’s test statistic.  
Where there was homogeneity of variance across subtypes, the F-test statistic was used 
to assess the overall association between IBS subtype and the dependent variable, with 
Tukey’s Honest Significant Difference (HSD) used to evaluate individual comparisons 
between the subtypes.  Where the assumption of homogeneity of variance was violated, 
Welch’s test statistic and the Games-Howell post hoc test were used.  
Results 
The division of the bowel symptoms into three categories, IBS-C, IBS-D and 
IBS-A resulted in 67% of participants being categorised as IBS-A group (n=156), 18% 
as IBS-D (n= 43) and 12% IBS-C (n= 27). Unclassified (IBS-U) individuals made up 
3% (n=8) of the total sample. There were no significant differences in demographics 
between the groups other than IBS-C having significantly fewer individuals with post-
infective IBS (table 2). Although not significantly different, there was a higher 
proportion of those with IBS-A (38.5%) and IBS-D (37.2%) categorised as single than 
those with IBS-C (14.8%).  
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Table 2: Demographics across bowel subtype groups 
 IBS-C 
n = 27 
IBS-D 
n = 43 
IBS-A 
n = 156 
P value 
Age at time of referral  
Mean (SD) 
34.4 (7.9) 33.2(7.9) 33.6(8.9) .85 
Female gender n (%) 22 (81.5) 33 (76.7) 131(84.0) .54 
Ethnicity n (%)    .12 
White 20 (83.4) 34 (85) 120 (82.3)  
Asian 1 (4.2) 2 (5) 2 (1.4)  
Afro/Caribbean 1 (4.2) 2 (5) 18 (12.3)  
Mixed 2(8.3) 2 (5) 3 (2.1)  
Other 0(0) 0 (0) 3 (2.1)  
Marital Status n (%)    .08 
Single 4(14.8) 16(37.2) 60(38.5)  
Married/Cohabiting  14(51.9) 16(37.2) 70(44.9)  
Widowed/separated/divorced  9(33.3) 11(25.6) 26(16.7)  
IBS duration n (%)    .44 
3 months – 1 year 4(14.8) 9(20.9) 22(14.1)  
1-5 years 13(48.1) 14(32.6) 52(33.3)  
5 years + 10(37.0) 20(46.5) 82(52.6)  
IBS started with gastroenteritis 
n (%) 
26(96.3) 32(74.4) 133(85.3) .034* 
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IBS-A: Unhelpful IBS-specific behaviours & symptom severity 
Abdominal pain was significantly higher in those with IBS-A compared to those 
with IBS-D (MD=.8, p=.021, 95% CI .09, 1.4). Those with IBS-A also had the highest 
mean severity and those with IBS-D had the lowest mean symptom severity, although 
these differences were not significant (table 4).  
A significant difference between subtypes was detected for avoidance 
behaviours F (2,178) =7.2, p=.001 and control behaviours F (2,178) =9.0, p<.001. 
Specifically, IBS-A had significantly higher levels of avoidance behaviours than IBS-C 
(MD= 13.8, p=.004, 95% CI -23.9, -3.8) (figure 1, panel A). IBS-A also had higher 
levels of control behaviours than IBS-C (MD= 7.2, p=.017, 95% CI 1.1, 13.4) and IBS-
D (MD=7.2, p=.001, 95% CI 2.5, 11.9) as depicted in figure 1, panel B. 
IBS-D: Avoidance behaviour & unhelpful gastrointestinal-specific cognitions 
Those with IBS-D also had significantly higher levels of avoidance than the 
IBS-C group, (MD= 18.3, p=.001, 95% CI 6.7, 30.0) as shown in figure 1, panel A. 
There were no significant differences in the level of avoidance behaviours between IBS-
D and IBS-A, or in the level of control behaviours between IBS-D and IBS-C (figure 1, 
panel B).  
There was a larger mean difference in unhelpful cognitions between IBS-D and 
IBS-C, as compared to those between the other subtypes (table 4). However, the 
differences between the subtypes did not reach statistical significance F(2,192) =1.7, 
p=.18) (figure 1, panel C).  
Comparable outcomes across IBS subtypes 
Work and Social Adjustment scores did not significantly differ across the three 
IBS subtypes F (2,217) =.08, p=.93 (table 3 and 4). There were also no significant 
differences between subtypes for anxiety F(2,219) =.098, p=.91 or for depression 
F(2,221) =.045, p=.96. Group means were similar for each subtype for both outcomes 
also (table 4).  
[insert table 3, table 4 and figure 1] 
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Table 3: Means and standard deviations of outcomes across IBS subtypes 
 IBS-C 
n = 27 
IBS-D 
n = 43 
IBS-A 
n = 155 
Dependent Variable M  
(SD) 
95% CI M (SD) 95% CI M (SD) 95% CI 
Abdominal Pain 2.9  1.8 2.2, 3.6 2.8  1.8 2.2, 3.3 3.5    1.5 3.3, 3.8 
Symptom Severity 300 104  259, 341 277, 97 247, 307 309 88 295, 322 
Work & Social 
Adjustment 
14 7 11, 17 14 18 12, 17 14 8 13, 15 
Cognitions 10127 90, 113 115 25 107, 124 108 30 103, 114 
Avoidance Behaviours 3114 24, 38 49 17 43, 55 45 17 42, 48 
Control Behaviours 39 9 34, 44 39  9 36, 42 46 10 44, 48 
Anxiety 104 8, 12 11 4 9, 12 11 4 10, 11 
Depression 73 6, 8 7 5 5, 8 7 3 6, 7 
M, Mean; SD, standard deviation; CI, confidence interval  
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Table 4: Mean differences in psychological & severity measures between IBS subtypes 
 95% CIs 










4.6 .01 IBS-D – IBS-C -.1  -1.1 .8 
IBS-D – IBS-A -.7 .02 -1.4 -.1 
IBS-A – IBS-C .6  -.2 1.4 
Symptom 
Severity 
1.9 .14 IBS-D - IBS-C -23.2  -76.5 30.2 
IBS-D – IBS-A -31.7  -69.1 5.7 




0.08 .93 IBS-D - IBS-C 0.6  -4.2 5.3 
IBS-D – IBS-A 0.5  -2.8 3.8 
IBS-A – IBS-C 0.1  -4.0 4.1 
Cognitions 1.7 .12 IBS-D - IBS-C 14.1  -4.1 32.4 
IBS-D – IBS-A 7.0  -5.9 19.9 
IBS-A – IBS-C 7.1  -8.4 22.6 
Avoidance  7.1 .001* IBS-D - IBS-C 18.3 .001* 6.7 30.0 
IBS-D – IBS-A 4.5  -3.2 12.2 
IBS-A – IBS-C 13.8 .004* 3.8 23.9 
Control  9.0 >.001
* 
IBS-D - IBS-C 0.1  -7.1 7.2 
 IBS-D – IBS-A -7.2 .001* -11.9 -2.5 
 IBS-A – IBS-C 7.2 .017* 1.1 13.4 
Anxiety 0.1 .91 IBS-D - IBS-C 0.5  -2.2 3.1 
IBS-D – IBS-A .3  -1.6 2.2 
IBS-A – IBS-C 0.2  -2.0 2.4 
Depression 0.05 .96 IBS-D - IBS-C -.2  -2.4 2.0 
IBS-D – IBS-A -.0  -1.5 1.6 
IBS-A – IBS-C -.2  -2.1 1.6 
F, F statistic; P1, significance of one way ANOVA between groups; P2, significance of one way 
ANOVA post hoc comparisons; CIs, confidence intervals 
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Figure 1: A, Mean differences in avoidance behaviours with upper and lower 95% confidence limits across groups; B, mean differences in control behaviours with upper and 




The main aim of this paper was to investigate whether bowel symptom subtypes 
were associated with particular psychological characteristics or varied in the degree of 
symptom severity, abdominal pain or functioning. The psychological factor 
distinguishing the IBS subtypes was the degree of unhelpful IBS-specific behaviours. As 
predicted those with IBS-A engaged in unhelpful behaviours more than those with IBS-
C. They were also the group with the highest levels of abdominal pain. Our findings 
would suggest that across the IBS subtypes, individuals present with similar levels of 
symptom severity, work and social functioning and distress. These findings are 
comparable to the findings of previous studies (Drossman et al., 2009; Guthrie, et al., 
2003; Jamali, et al., 2012; R Moss-Morris, et al., 2010; Reme, et al., 2011; Rey, Garcia-
Alonso, Moreno-Ortega, Alvarez-Sanchez, & Diaz-Rubio, 2008).  
Cognitive & Behavioural Differences  
Our results suggest that those with IBS-A and IBS-D are prone to more avoidant 
behaviours relating to their symptoms than those with IBS-C. A qualitative study 
investigating psychological factors impacting on QoL in IBS found that uncertainty and 
unpredictability of symptoms were identified as key factors impacting upon cognitive 
and behavioural reactions to having IBS (Drossman, et al., 2009). Our findings are 
consistent with this and it makes intuitive sense that individuals with an unpredictable 
symptom such as diarrhoea might be more prone to control behaviours such as these. In 
comparison, the symptom of constipation may provide less uncertainty, which may 
negate excessive control and avoidant behaviours.  Individuals with IBS-A also had 
significantly higher levels of control behaviours than those with IBS-C and IBS-D.  
There was an apparent mean difference in unhelpful cognitions between IBS-D 
and IBS-C subtypes. This difference was not statistically significant which may be due 
to inadequate power, however it was appreciably larger than the other subtype contrasts. 
This could indicate a greater tendency towards unhelpful cognitions in those with IBS-D 
as compared to those with IBS-C. A previous study investigating cognitive differences 
between subtypes found that cognitive appraisals in the IBS-D group were more extreme 
compared to controls compared to the IBS-C group (Passos, et al., 2009). The cognitive 
appraisals were measured using a four-factor scale that assessed the extent that 
symptoms were perceived as threatening, controllable and affecting their lives and the 
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extent to which individuals were engaged in trying to address their symptoms. The scale 
therefore shares qualities with the CS-FBD but the items do differ and load onto four 
distinct factors, unlike the CS-FBD, which is a unitary scale. Results from these studies 
suggest that there may be an important distinction in the cognitive tendencies of those 
with IBS-D compared to those with IBS-C.  
Limitations  
There are some limitations of our study with respect to measurement. Perhaps 
the most fundamental limitation is the designation of IBS subtypes.  
Classifications of bowel subtypes could not be made in accordance with Rome 
III or Rome IV criteria as these was not used in the original trial (Kennedy, et al., 2005). 
Nevertheless, the IPQ items used to create classifications did closely resemble those of 
the Rome III and if anything, had more explicit wording with regards bowel pattern 
predominance. Another more salient limitation was that the measurements of bowel 
patterns were not limited to symptomatic bowel movements only. This was due to the 
original collection of data predating the Rome IV criteria. The results shown here should 
be replicated using a sample where the updated classification of bowel pattern subgroups 
has been applied.   
The method used to assess bowel pattern subtypes returned a proportionately 
low number of individuals with IBS-U compared to other studies (Lovell and Ford, 
2012b). This led to this group being excluded from analysis, precluding any insight into 
the aspects of symptoms, functioning and behaviours in these individuals. Furthermore, 
the overall sample was relatively small. This compromised the power of the study to 
detect relationships that may exist in the wider population. Future studies should be 
designed with larger sample sizes to more rigorously assess these relationships. A meta-
analysis reporting on affective differences across IBS subtypes similarly concluded that 
there is need for future studies with larger sample sizes and greater power in order to 
resolve inconsistent findings (Fond, et al., 2014). 
It should also be noted that the participants took part in a RCT (Kennedy, et al., 
2005) assessing the efficacy of CBT in addition to antispasmodic treatment in IBS. As 
such the results may only be representative of a limited subsection of those with IBS: 
those that were willing to be enrolled in a clinical trial. There is the possibility that 
results could also be confounded by self-selection bias (Ford, et al., 2009). The 
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eligibility criteria of this trial limited inclusion to those with a clinical diagnosis of IBS, 
meeting Rome I criteria. Participants were excluded if they were pregnant, had co-
occurring disease such as inflammatory bowel disease or coeliac or were treating 
abdominal pain successfully with acid-inhibiting drugs. As such, the present results may 
not be generalisable to other populations.  
Conclusions 
The present study is the first to our knowledge that has investigated the potential 
differences in IBS related behaviours between IBS subtypes. The results may have 
implications for psychological treatments for IBS. Two of the main targets for change in 
CBT are avoidance and control behaviour. Our results suggest that targeting avoidance 
behaviours may be particularly important for IBS-A and IBS-D subtypes. Techniques 
such as graded exposure to feared stimuli (e.g. leaving the house for increased 
increments in time when feeling symptoms) can be used to help reduce avoidance. 
Reductions in control behaviour in IBS-A individuals can be facilitated by goal setting. 
For example individuals may aim to reduce the number of times they check their stools, 
or aim to increase the amount of time they are out in public without checking for the 
nearest toilet. It may therefore be appropriate to tailor behavioural techniques such as 
according to the IBS subtype presenting. As such it is important for clinicians to 
ascertain the bowel pattern subtype in the context of psychological assessment and 
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7.3 Summary  
The study identified some key cognitive and behavioural differences between IBS bowel 
pattern subtypes. Those with IBS-A and IBS-D engaged more in unhelpful behaviours 
than those with IBS-C. IBS-A had higher levels of avoidant behaviour than IBS-C, and 
had higher levels of safety (control) behaviour than IBS-C and IBS-D. Those with IBS-
D showed a non-significant trend towards higher ratings of unhelpful gastrointestinal 
related cognitions. Although there were no differences in symptom severity between 
subtypes, those with IBS-A had significantly higher ratings of abdominal pain severity 
than the other two subtypes. The results suggest that unhelpful illness-related behaviour 
is more prominent in those with IBS-A and IBS-D than those with IBS-C. Psychological 
treatment approaches to IBS, such as CBT, may be modified to focus on the targeting of 
the particular GI related behaviours associated with these IBS subtypes. The CBT-IE 
model adapted for IBS (section 1.13.3) may be particularly suited to such subtypes as 
this focuses on the use of exposure techniques. Distinctions in cognitive and behavioural 
factors between subtypes may suggest that these are important variables to include in 
future analysis designed to increase the multidimensionality of subgroups in IBS.  
Nevertheless, the analysis was conducted in a sample of participants that met the Rome I 
criteria, which is now out-dated and replaced with the Rome IV criteria. Studies have 
shown that the Rome I criteria is less restrictive than the subsequent iterations (Chey et 
al., 2002; Drossman & Dumitrascu, 2006; Dang et al., 2012) and therefore the same 
analysis in a sample of participants meeting the Rome III/IV criteria may not 
demonstrate the same findings. The study was not powered a priori to detect differences 
between subtypes on all of the outcome variables assessed. As such power to detect 
differences varied across the dependent variables (appendix G). To validate the findings, 
it is necessary to replicate the analysis in a greater sample of IBS participants, ideally 
meeting the Rome III or Rome IV criteria as these share the most updated subtype 




8. ANOVAs Assessing Psychological, Work and Social 
Functioning and Symptom Severity Differences Between 
IBS Subtypes (Study Four) 
8.1 Chapter Overview  
The final study presented in this chapter shared the objective and aims of study three in 
the previous chapter. The objective was to identify cognitive and behavioural factors 
associated with IBS bowel pattern subtypes. The aim was to assess whether there were 
differences in cognitive and behavioural factors in addition to levels of anxiety, 
depression, symptom severity and work and social adjustment across IBS subtypes. 
Study four aimed to validate the findings from study three in a larger sample with bigger 
power to detect differences across the different dependent variables. It was hypothesised 
that cognitions and behaviours would differ between subtypes. Based on previous 
results, the three specific hypotheses were that (1) unhelpful cognitions would be greater 
in those with IBS-D than IBS-C, (2) unhelpful avoidance behaviours would be greater in 
those with IBS-D and IBS-A compared to IBS-C, and (3) safety (control) behaviours 
would not significantly differ across subtypes. 
Analysis replicating study three, was conducted on baseline data of 557 individuals with 
refractory IBS recruited into the assessing cognitive therapy in irritable bowel (ACTIB) 
randomised controlled trial (data set 2). Bowel pattern subtype was classified according 
to the ROME III criteria.  
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Cognitive and behavioural differences between irritable bowel syndrome subtypes 
Abstract 
Irritable bowel syndrome (IBS) is a functional gastrointestinal syndrome consisting of four 
bowel pattern subtypes: diarrhoea predominant, (IBS-D) constipation predominant (IBS-C), 
alternating (IBS-A) or unclassified (IBS-U). This paper aimed to identify whether there were 
significant associations between bowel pattern subtypes in irritable bowel syndrome and 
psychological factors or outcome variables. One-way ANOVAs were conducted to assess 
differences between IBS-related cognitions, behaviours, general anxiety, depression, symptom 
severity and work and social adjustment. Analysis was conducted on baseline data of 557 
individuals with refractory IBS recruited into the assessing cognitive therapy in irritable bowel 
(ACTIB) randomised controlled trial. Bowel pattern subtype was classified according to the 
ROME III criteria. Due to the small number of individuals with IBS-U (n=16), this group was 
excluded from analysis. The most predominant bowel pattern subtype was IBS-A (n=287). IBS-
D (n=178) was more predominant than IBS-C (n=76). Results indicated that individuals with 
IBS-D had significantly higher levels of unhelpful cognitions than those with IBS-C. Those with 
IBS-D and IBS-A engaged in more unhelpful IBS-related avoidance behaviours than those with 
IBS-C. In contrast both IBS-C and IBS-A engaged in more unhelpful safety behaviours than 
those with IBS-D. The results may be important for informing assessment and formulation in 




Irritable bowel syndrome (IBS) is a functional gastrointestinal syndrome characterised by 
abdominal pain and associated disruptions to bowel patterns. The aetiology of IBS is generally 
agreed to be of biopsychosocial origin as biological, psychological and social factors interact to 
cause and maintain IBS symptoms (Drossman, 1996, 2016). Diagnostic criteria have been 
developed over the years to diagnose IBS in the absence of any physiological markers.  The 
most current diagnostic criteria are the ROME IV criteria (Drossman, 2016). Four IBS subtypes 
are classified on the basis of the bowel pattern predominance: Constipation predominant (IBS-
C), diarrhoea predominant (IBS-D), alternating bowel pattern (IBS-A) or unclassified IBS (IBS-
U) for individuals who do not fall into the other bowel pattern categories. The IBS subtypes are 
thought to be reflective of differential pathophysiological mechanisms that may be targeted by 
pharmacotherapeutic approaches (Krogsgaard, Engsbro, & Bytzer, 2013).  As yet it is unclear as 
to whether differentiation in bowel pattern subtypes is important in understanding the 
psychological processes that may be maintaining symptoms (Fond et al., 2014).  
The predominant psychological treatment approach for IBS is cognitive behavioural therapy 
(CBT). The CBT model of IBS suggests that affective factors (e.g. anxiety/worry), unhelpful 
illness related cognitions and unhelpful behavioural responses perpetuate symptoms and impact 
quality of life (Hutton, 2005; Kennedy et al., 2005; Spence & Moss-Morris, 2007). An example 
of an unhelpful illness-related cognition is “it is embarrassing to keep going to the toilet”. 
Unhelpful behavioural responses to IBS symptoms may include avoidance behaviours such as 
avoiding certain foods or social occasions, or safety (also termed ‘control’) behaviours such as 
excessive straining on the toilet or carrying extra items when leaving the house in case of 
symptoms (Reme, Darnley, Kennedy, & Chalder, 2010). More recently a CBT model has been 
developed in IBS based on the CBT model used in panic disorder (Craske & Barlow, 2006). 
This aims to target change in gastrointestinal anxiety (also termed ‘visceral anxiety’) using 
exposure techniques, cognitive restructuring, attentional control exercises and psychoeducation 
                                                     
1 CBT, cognitive behavioural therapy; CS-FBD, cognitive scale for functional bowel disorders; BRQ, 
behavioural responses questionnaire; GI, gastrointestinal; IBS, Irritable bowel syndrome; IBS-A, 
alternating irritable bowel syndrome; IBS-C, constipation predominant irritable bowel syndrome; IBS-D, 
diarrhoea predominant irritable bowel syndrome; IBS-U, unclassified irritable bowel syndrome; WSAS, 




about the relationship between the brain and gut (Craske et al., 2011). Such models identify the 
importance of cognitions and behaviours in maintaining symptoms, but little research has been 
conducted into the differential role these may have across the IBS subtypes. Each subtype has a 
particular set of symptoms (Marquis et al., 2014; Fehnel et al., 2017) and these symptoms can 
have specific psychological effects and effects on outcome (Rønnevig, Vandvik, & Bergbom, 
2009). For example the experience of diarrhoea is associated with urgency and unpredictability 
(Drossman et al., 2009; Rønnevig et al., 2009; Drossman et al., 2011; Håkanson, 2014), which 
are two unique experiences that may differentiate the psychological responses of those with 
IBS-D from those with IBS-C.  
Understanding whether different subtypes have different affective, cognitive and/or behavioural 
responses may be important for informing therapeutic assessments and formulations. Increasing 
understanding in this way can therefore serve to individualise therapeutic strategy to optimise 
outcomes (Drake, Cimpean, & Torrey, 2009; Hamburg & Collins, 2010; Mönnikes, 2011). 
Furthermore, there are increasing calls to augment the multidimensionality of diagnostic clinical 
profiles in IBS (Whitehead, Palsson, & Jones, 2002; Riedl et al., 2008; Polster et al., 2017). As 
such research investigating whether there are different psychological patterns across bowel 
subtypes could be used to inform the development of future diagnostic measures.   
There have only been four studies to our knowledge that have assessed associations between 
cognitions and IBS subtypes and three did not find any significant differences between IBS 
subtypes (Sugaya & Nomura, 2008; Stengel et al., 2010; Thijssen et al., 2010; Windgassen, 
Moss-Morris, Goldsmith, & Chalder, submitted). The one study that found differences, was also 
one of only two studies assessing behavioural differences between IBS subtypes (Windgassen et 
al., submitted). This study assessed IBS-specific behavioural responses and found that those 
with IBS-D had higher levels of avoidance behaviour than IBS-C, as did those with IBS-A 
(Windgassen et al., submitted). Those with IBS-A also had higher levels of safety behaviour 
than IBS-C and IBS-D. The other study assessing behavioural differences across IBS subtypes 
assessed healthcare- seeking behaviour in IBS subtypes. It found that those with IBS-A had a 
higher tendency to seek healthcare compared to IBS-C and IBS-D (Katsinelos et al., 2009). 
There is more research investigating affective factors (anxiety/distress and depression) and 
personality types (Prior, Maxton, & Whorwell, 1990; Farnam, Somi, Sarami, Farhang, & 
Yasrebinia, 2007; Eriksson, Andren, Eriksson, & Kurlberg, 2008; Muscatello et al., 2010; Fond 
et al., 2014; Rey de Castro, Miller, Carruthers, & Whorwell, 2015; Kibune-Nagasako, Garcia-
Montes, Silva-Lorena, & Aparecida-Mesquita, 2016). However this has yielded contradictory 
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findings with regards to which subtype is more or less associated with psychological factors 
such as anxiety. 
The research regarding associations between outcome measures such as symptom severity and 
quality of life/work and social functioning and IBS subtypes is similarly limited and unclear. 
However, some studies have suggested that the IBS-A (also referred to as IBS-M for ‘mixed 
IBS’) subtype may be a particularly burdensome one (Tillisch et al., 2005; Singh et al., 2015; 
Kibune-Nagasako et al., 2016). Those with IBS-A have been found to have increased anxiety 
(Kibune-Nagasako et al., 2016) higher levels of symptom severity and somatisation compared to 
those with IBS-C and IBS-D (Tillisch et al., 2005). They have also been found to have worse 
quality of life and impairment of relationships than those with IBS-C (Singh et al., 2015).  
A lot of the previous studies assessing psychological differences across IBS subtypes have had 
small samples, some with as few as 44 participants (Stengel et al., 2010), limiting power to 
detect significant findings. Furthermore inconsistency in the findings across these studies is 
likely to be the result of the different criteria used to classify bowel subtypes. Many of the 
studies were conducted prior to the development of the Rome III criteria coming into use, which 
substantially altered the parameters for assigning bowel subtype classification when compared 
to Rome II (Ersryd, Posserud, Abrahamsson, & Simren, 2007). Although the Rome IV criteria 
are now in use, they remain similar to the Rome III in terms of classification of bowel pattern 
subtypes (Drossman, 2016). 
Hypotheses 
The study aimed to assess differences in psychological factors and outcomes across IBS 
subtypes, in a larger sample with greater power, utilising the clear and validated classification 
guidelines of the Rome III.  We intended to replicate the findings of our previous study, which 
informed the hypotheses of our present study.  
The specific scientific aims were to identify whether levels of unhelpful gastrointestinal (GI) 
related cognitions or behaviours, general anxiety or depression, work and social functioning and 
symptom severity differed across IBS bowel pattern subtypes. Based on previous results we 
hypothesised that (1) unhelpful cognitions would be greater in those with IBS-D than IBS-C (2), 
unhelpful avoidance behaviours would be greater in those with IBS-D and IBS-A compared to 
IBS-C (3) safety behaviours would not significantly differ across subtypes. Based on other 
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previous research we may also expect that individuals with IBS-A have worse outcome 
measures than the other bowel pattern subtypes.  
Method 
 The present study used baseline and screening data collected as part of the Assessing Cognitive 
Behavioural Therapy in Irritable Bowel (ACTIB) randomised controlled trial (RCT) assessing 
the efficacy of CBT in IBS (Everitt et al., 2015). The study compared the efficacy of a high 
intensity telephone delivered CBT intervention and a lower intensity web-based CBT 
intervention to a treatment as usual control group. Five hundred and fifty-eight individuals aged 
18 and above were recruited from primary and secondary care sites in South London and the 
South of England. To be included in the trial participants had to meet the Rome III criteria 
(Drossman, 2006b) for IBS and have a score of >75 on the IBS symptom severity scale (Francis, 
Morris, & Whorwell, 1997) at screening. Participants also had to have been previously offered 
first-line therapies, with continuing symptoms of 12 months or longer. Participants were 
excluded if they had a diagnosis of coeliac disease, inflammatory bowel disease, peptic ulcer 
disease or colorectal carcinoma. Unexplained rectal bleeding or weight loss also precluded entry 
from the trial (Everitt et al., 2015). The data for one participant was lost at screening leaving 
n=557 for analysis in the present paper.  
Measures  
Classification of IBS Bowel Pattern Subtypes  
The Rome III criteria (Drossman, 2006b) was used to assign bowel pattern subtypes (Rome IV 
is now in use, but had not been developed at the time the ACTIB study commenced). Individuals 
were classified as IBS-D if they had lose/watery stools ≥ 25% of the time and had hard/lumpy 
stools < 25% of the time. IBS-C was defined as those with lose stools <25% of the time and 
hard stools ≥25%. IBS-A was categorised as those with both hard and loose stools ≥25% of the 
time, while IBS-U experienced hard and loose stools <25%.  
IBS Symptom Severity Scale (IBS-SSS)  
The IBS-SSS (Francis et al., 1997) is a well validated measure of symptom severity in IBS, 
measuring the extent of the severity of abdominal and bowel symptoms in terms of frequency 
and degree of severity. The scale is made up of 5 items with a maximum score of 500. IBS 
severity is classified as mild for scores between 75 and 175, with scores between 76 and 300 
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indicating moderate severity.  A change in score of ≥50 is considered to be clinically meaningful 
(Francis et al., 1997). 
Work and Social Adjustment Scale (WSAS) 
The WSAS (Mundt, Marks, Shear, & Greist, 2002) measures the extent that participation in five 
areas of life has been affected by the disease in question, with higher scores indicating a higher 
impact. The five areas of life measured are social activities, private leisure activities, 
relationships, home and work. Each is measured by one item, scored on a scale of 0 to 8, with a 
total possible score of 40 across the five items. Scores of 10 and above indicate substantial 
functional impairment and scores of 20 and above indicate severe impairment (Mundt et al., 
2002). The scale has been demonstrated to be a valid and reliable measure of participation in 
life.  
Hospital and Anxiety Scale: Anxiety and Depression (HADS) 
The HADs is a measure of general anxiety and depression with a subscale for each construct 
(Zigmond & Snaith, 1983). Items such as “I feel tense or wound up” measure anxiety and items 
such as “I feel as if I am slowed down” measure depression. They are rated on a scale of 0 to 3. 
Zero indicates strongly disagree and 3 indicates strongly agree. Each subscale consists of 7 
items, with a total possible score of 21. Scores of 0-7 are considered normal, whilst scores of 8-
10 indicate mild anxiety/depression, 11-14 indicate moderate anxiety/depression, and 15 – 21 
severe anxiety/depression. The scale has been demonstrated to have good reliability and validity 
(Zigmond & Snaith, 1983). 
Cognitive Scale for Functional Bowel Disorders (CS-FBD) 
The CS-FBD (Toner et al., 1998) is a measure of gastrointestinal specific cognitions consisting 
of 31 items rated on a Likert scale from 1 to 7, with higher scores indicating a higher degree of 
unhelpful GI related cognitions. The total score ranges from 31 to 217 with good reliability (α= 
.93) and validity (Toner et al., 1998). An example of an item assessing GI specific cognitions is 
“I cannot function normally when I get bowel symptoms”. 
The Irritable Bowel Syndrome Behavioural Responses Questionnaire (IBS-BRQ) 
Behavioural responses to IBS are subdivided into two subscales measuring safety (control) and 
avoidance behaviours specific to IBS (Reme et al., 2010). An example of an item on the 
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avoidance behaviour subscale is “I avoid exercise when I have stomach pains”. An example 
safety behaviour item is “I strain when opening my bowels”. The avoidant subscale has 15 
items, and the safety subscale has 11 with items rated on a Likert scale of 1 to 7. Higher scores 
indicate higher levels of unhelpful GI specific behaviours. The scale has been shown to have 
good reliability and validity α=.86 (Reme et al., 2010).  
Analysis 
Demographic variables including age, gender, marital status and IBS duration were summarised 
across the different bowel subtype groups. Differences in continuous demographic variables 
(age and IBS duration) between IBS subtype groups were assessed using a one-way ANOVA. 
Differences in categorical demographic variables (gender, marital status and ethnicity) between 
subtypes were assessed using a Chi Square test of independence.  
One-way ANOVAs were used to assess associations between IBS bowel pattern subtypes and 
each of the psychological variables of interest (dependent variables). To ensure the data met the 
ANOVA assumptions, normal Q-Q plots were used to assess whether the data was normally 
distributed and boxplots were used to identify whether there were any outliers for each 
dependent variable. Homogeneity of variances across subtypes was tested using Levene’s test 
statistic. The F-test statistic was used to assess the overall association between IBS subtypes and 
the dependent variable using Tukey’s Honest Significant Difference (HSD) to evaluate 
individual comparisons between the subtypes.  
Results 
The division of the bowel pattern subtypes resulted in just 2.8% of the participant sample (n=16) 
being classified as IBS-U. As this was disproportionately low, IBS-U was excluded from the 
analysis to preserve sensitivity in finding meaningful differences between groups. Those with 
IBS-A were the most prevalent 51.4% (n=287), followed by those with IBS-D, which 
constituted 31.9% (n=178). Those with IBS-C made up 13.6% of the sample (n=76). Table 1 
summarises the demographic and illness characteristics across the three subtypes. The only 
significant difference between groups on these variables was the proportion of females, which 




Table 1: Demographics across bowel subtype groups 
 IBS-C 
n = 76 
IBS-D 
n = 178 
IBS-A 
n = 287 
F/χ2 P value 
Age at randomisation 
Mean (SD) 
 
45 (12) 43 (13) 42 (12) 1.6 .297 
Female gender  
n (%) 
 




   1.6 .454 
White 
 
69 (91) 165 (93) 256 (89)   




   7.3 .119 
Single 18 (24) 37 (21) 90 (31)   
Married/Cohabiting  51 (67) 122 (69) 176 (61)   
Widowed/separated/divorced  
 
7 (9) 19 (11) 21 (7)   
IBS duration mean 
n (SD) in years 
 
10 (8) 10 (9) 11 (10) 0.2 .801 
SD = standard deviation,  χ2 in italics 
Assumption violations and outliers in dependent variables of interest 
Some of the dependent variables were not normally distributed in the different IBS subtype 
groups. CS-FBD was mildly negatively skewed in the IBS-A group, while r the safety subscale 
of the BRQ had negative kurtosis in the IBS-C group. WSAS had negative kurtosis in all bowel 
subtype groups. None of the data was severely skewed. As one-way ANOVAs are quite robust 
to mild deviations from normality, particularly in large sample sizes, no transformations were 
made to the data. A number of outliers were identified for all dependent variables apart from 
symptom severity. These were checked to ensure they were not the result of data entry and 
measurement error. The most extreme outliers were removed and the analysis was rerun to 
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determine if inclusion of the outliers had substantially changed the results. They did not, so the 
outliers were included in the final analysis.  
Cognitive and behavioural differences between IBS-C and IBS-D 
A significant difference between subtypes was found for GI related cognitions F(2, 538), 3.50, p 
= .031. Tukey’s HSD post hoc comparisons identified that IBS-C and IBS-D significantly 
differed (MD = 11.8, p=.026, 95% CI 1.1, 22.5) with IBS-D having significantly higher levels of 
unhelpful GI related cognitions (figure 1). Figure 1 demonstrates that there was also a difference 
between IBS-C and IBS-A, which approached statistical significance, while there was no 
difference in GI cognitions between IBS-A and IBS-D subtypes.  
A significant difference between subtypes was also found for GI related avoidance behaviours 
F(2, 538), 10.25, p<.001, with IBS-D showing significantly higher levels of avoidance 
behaviours than IBS-C (MD = 11.0, p<.001, 95% CI 5.3, 16.7). Those with IBS-A also had 
significantly higher levels of avoidance behaviours than IBS-C (MD = 7.7, p=.002, 95% CI 2.3, 
13.1). Figure 2 illustrates that the group contrasts.  
Safety behaviours also significantly differed across groups F(2, 538), 10.55, p<.001. Post hoc 
tests indicated that IBS-C showed significantly higher levels of safety behaviours than those 
with IBS-D (MD = 4.6, p=.004, 95% CI 1.3, 8.0) as did those with IBS-A  (MD =4.3, p<.001, 
95% CI 2.0, 6.6) (figure 3).  
Comparable factors across IBS subtypes  
There were no significant differences between IBS subtypes for anxiety, work and social 





Figure 1: Mean differences in GI related cognitions with upper and lower 95% confidence limits across 
groups 
 
Figure 2: Mean differences in GI related avoidance behaviour with upper and lower 95% confidence 





Figure 3: Mean differences in GI related safety behaviour with upper and lower 95% confidence limits 
across groups 
Discussion  
IBS bowel pattern subtypes were generally comparable across demographic variables, with the 
exception of gender. There was a significantly higher proportion of females with IBS-A and 
IBS-C than those with IBS-D. Although IBS subtypes did not differ in terms of symptom 
severity, work and social adjustment and levels of anxiety and depression, there were cognitive 
and behavioural distinctions between groups. Those with IBS-A and IBS-D experienced a 
greater degree of unhelpful GI-related cognitions than those with IBS-C. Results also indicated a 
contrast in the type of behavioural responses that patients with IBS-C and IBS-D engage in. 
While those with IBS-D engage in more avoidant behaviour in response to symptoms, those 
with IBS-C instead utilise more safety behaviours. IBS-A was shown to have significantly 





Table 2: Mean differences in psychological outcomes between IBS subtypes 
 95% CIs 











IBS-C – IBS-D -6.1 .26 -15.2 3.0 
IBS-C – IBS-A -1.9 .86 -10.5 6.6 








IBS-C – IBS-D -0.8 .79 -3.5 2.0 
IBS-C – IBS-A 0.1 >.99 -2.5 2.7 
IBS-A – IBS-D -0.8 .56 -1.1 2.7 
Cognitions 3.5 .031 IBS-C – IBS-D -11.8 .026 -22.5 -1.1 
IBS-C – IBS-A -9.8 .060 -19.8 0.3 
IBS-A – IBS-D 
 
-2.0 .80 -5.4 9.5 
Avoidance 
Behaviours 
10.3 <.001 IBS-C – IBS-D -11.0 <.001 -16.7 -5.3 
IBS-C – IBS-A -7.7 .002 -13.1 -2.3 
IBS-A – IBS-D -3.3 .13 -0.7 -7.3 
Safety 
Behaviours 
10.4a <.001 IBS-C – IBS-D 4.6 .004 1.3 8.0 
IBS-C – IBS-A 0.3 .97 -2.8 3.5 
IBS-A – IBS-D 
 
4.3 <.001 2.0 6.6 
Anxiety .8 .43 IBS-C – IBS-D 0.7 .41 -0.6 2.1 
IBS-C – IBS-A 0.6 .50 -0.7 1.9 
IBS-A – IBS-D 
 
0.1 .95 -0.8 1.1 
Depression 1.3 .27 IBS-C – IBS-D 0.7 .33 -0.5 1.9 
IBS-C – IBS-A 0.7 .26 -0.4 1.9 
IBS-A – IBS-D -0.03 >.99 -0.9 0.8 
F, F statistic; a , Welch statistic; P1, significance of one way ANOVA between groups at 0.05 level; 
P2, significance of one way ANOVA post hoc comparisons at standard significance level 0.05; 
CIs, confidence intervals 
 
Similarities and distinctions between IBS-A and IBS-D 
The finding that individuals with both IBS-A and IBS-D have higher avoidance 
tendencies than IBS-C, may be understood in terms of the similarities in symptom 
profiles. Both experience diarrhoea, which is a particularly disruptive symptom that is 
often accompanied by a sense of urgency or lack of control. These individuals may 
choose to avoid situations or stimuli that decrease the likelihood of control. The CBT 
model of IBS highlights the bidirectional relationship between avoidance and unhelpful 
GI related cognitions (Hutton, 2005).  Unhelpful thoughts about the potential impact of 
symptoms such as ‘it is embarrassing to keep going to the bathroom’ are likely to 
increase avoidant tendencies. Simultaneously, avoidance increases the propensity to 
engage in unhelpful thinking patterns about bowel symptoms as individuals are deprived 
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of experiences that could counter unhelpful negative thinking regarding symptoms 
(Olatunji, Etzel, Tomarken, Ciesielski, & Deacon, 2011).  
Previous studies have demonstrated the association between unhelpful cognitions and 
behaviours in IBS (Rutter & Rutter, 2002; Reme et al., 2010; Reme et al., 2011). Our 
previous study also suggested that unhelpful cognitions and behaviours were generally 
associated (Windgassen et al., submitted).  Our finding that IBS-D had significantly 
higher levels of both avoidance behaviours and unhelpful cognitions is consistent with 
this. Whilst those with IBS-A had significantly higher levels of avoidance behaviour 
than participants with IBS-C, their levels of unhelpful cognitions were not significantly 
higher. The elevated level of unhelpful GI cognitions associated with IBS-D may be 
rooted in the differential experience of symptoms compared to the other two subgroups 
(Casiday, Hungin, Cornford, de Wit, & Blell, 2008; Rønnevig et al., 2009). Some 
studies have suggested that those with IBS-D have more visceral sensitivity (Prior et al., 
1990; Elsenbruch & Orr, 2001; Kanazawa et al., 2008), which may at least partially 
contribute to elevated levels of unhelpful cognitions.  
The finding may however be due to measurement bias. This may have arisen as some 
items of the CS-FBD relate more specifically to individuals with IBS-D than those with 
IBS-C. For example, items such as “I often worry that there may not be a bathroom 
when I need one” would not be relevant to individuals experiencing constipation. The 
possibility of measurement bias nevertheless highlights the importance of developing 
measures that account for the experience of each bowel subtype in IBS. This is 
increasingly recognised amongst researchers and collaborative working groups in IBS 
with regards to outcome measures (Fehnel et al., 2017). Our paper may suggest that this 
is important also for psychological and process measures developed for IBS.  
Behavioural differences  
The behavioural differences between IBS-D and IBS-C are reflective of the type of 
bowel symptoms experienced in each. It makes intuitive sense that those with IBS-D 
may be more avoidant in case of a toileting accident. However, those with IBS-C may 
seek to exert more control over their bowel by facilitating bowel movements using 
various safety behaviours (e.g. straining, stool checking, eating certain types of food to 
stimulate the bowels). These results partially replicate our previous findings 
(Windgassen et al, submitted) in that those with IBS-D were significantly more avoidant 
than IBS-C. However, novel to the present study was the finding that participants with 
IBS-C had significantly more safety behaviours than those with IBS-D.  
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Due to the stark contrast in behavioural associations between IBS-D and IBS-C we 
investigated whether the findings were due to measurement bias, supposing that the 
number of safety and avoidance subscale items could have been weighted towards the 
respective bowel pattern subtypes. For instance the item ‘I often go to the toilet and do 
not pass anything’ (item 7 of the BRQ) may only be applicable to those with 
constipation. However, inspection of the subscale items shows that there are an 
equivalent number of safety items relating to both types of symptom.  
A notable finding was that those with IBS-A appeared to have ‘the worst of both worlds’ 
in terms of having significantly higher levels of avoidance behaviour than those with 
IBS-C (along with IBS-D) and significantly higher levels of safety behaviour than those 
with IBS-D (along with IBS-C). Given the behavioural distinctions between IBS-D and 
IBS-C, it makes sense that individuals with alternating diarrhoea and constipation use 
both types of behaviour in an effort to cope with both types of symptoms.  
Differences in psychological but not outcome factors 
IBS-A has previously been characterised as being particularly burdensome (Tillisch et 
al., 2005; Singh et al., 2015; Kibune-Nagasako et al., 2016). Although our results 
partially support this in terms of this subtype having increased types of both maladaptive 
behaviours, they did not have worse outcomes with regards to symptom severity, work 
and social adjustment or anxiety and depression. Indeed, none of the IBS subtypes were 
found to differ in terms of these outcomes.   
This is in line with other previous findings (Simren, Abrahamsson, Svedlund, & 
Björnsson, 2001; Mönnikes, 2011; Jamali et al., 2012; Rey de Castro et al., 2015). As 
such we may conclude that in general subtypes are not associated with different levels of 
symptom severity, or psychological comorbidity. A previous study assessing subgroups 
in IBS using cluster analysis, instead found that whilst there are distinct bowel pattern 
subtypes in line with Rome III and IV criteria, these were further divided into those with 
high or low psychological and somatic comorbidity subgroups (e.g. IBS-A high 
comorbidity, IBS-A low comorbidity, etc.) (Polster et al., 2017). Therefore, it may be of 
more value to investigate the difference in outcomes between subgroups more 
comprehensively defined by a number of factors including psychological comorbidity. 
The authors of this study found that subgroups with higher rated comorbidities were 




In terms of informing psychological treatment approaches, the results suggest that 
individuals experiencing IBS-D may benefit from techniques focussing on addressing 
unhelpful cognitions, at least as identified in the CS-FBD. Those with IBS-D and IBS-A 
would appear to benefit from behavioural strategies targeting avoidance behaviours. In 
addition, techniques targeting a reduction in safety behaviours may be particularly 
transformative for individuals with IBS-C and IBS-A. Safety behaviours as measured by 
the BRQ include tendencies to eat specific foods to help open the bowels, checking for 
blood in stools and spending more time on the toilet than individuals would ideally like. 
The importance of changing cognitions and behaviours in IBS has previously been 
indicated in mediation studies (Windgassen et al., 2017). Future studies may seek to 
assess whether outcomes of psychological treatment for IBS may be differentially 
affected in this subtype using moderation analysis.  
Given the potential of measurement bias, the results also highlight the importance of 
considering the validation of psychological measures developed for IBS in application to 
the different IBS subtypes. Recent developments of IBS subtype specific outcome 
measures demonstrate the importance and utility of tailoring such measures (Fehnel et 
al., 2017).  
Finally, the present study supports the need for more comprehensively classified 
subgroups in the IBS field based on additional characteristics such as psychological 
factors (Whitehead et al., 2002; Polster et al., 2017). Increasing the dimensionality of 
subgroups can provide further understanding of heterogeneity in IBS.  
Limitations 
There were several limitations of our study relating to the statistical tests used. Ideally 
for one-way ANOVAs to adequately identify statistical differences between groups, the 
dependent variable should be normally distributed and yet for some of the outcome 
measures in our study, they were not. However, a non-parametric alternative to 
ANOVA, the Kruskal-wallis test, was also run which verified the results of the 
ANOVA.  
A difficulty with investigating the role of bowel pattern subtypes in IBS is that bowel 
subtypes have been demonstrated to fluctuate and change (Palsson, Baggish, Turner, & 
Whitehead, 2012). As such it is not clear whether the associations found in the present 
paper would also change in accordance to any fluctuations with bowel pattern changes 
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within subjects. Another difficulty in the assessment of bowel pattern subtypes is that 
different versions of the Rome criteria differentially classify the subtypes (Drossman, 
2006a). The present study used the Rome III criteria to categorise subtypes. However, 
the latest guidelines for classification is the Rome IV (Drossman, 2016). Rome IV states 
that subtypes are to be based on symptomatic stools only. This is likely to substantially 
shift the prevalence of each type of subtype.  
The sample of participants used in the present study has refractory IBS and were 
prepared to enter a CBT trial. This sample therefore may not be representative of the 
population of individuals with IBS 
Conclusion 
The present paper replicated our previous paper (Windgassen et al., submitted) 
demonstrating that although subtypes did not differ in terms of levels of symptom 
severity or distress, there were distinct cognitive and behavioural responses between 
groups.  The results may be important for informing assessment and formulation in 
psychological therapies for IBS. Cognitive and behavioural responses may also be 
important for inclusion in more multidimensional characterisation of diagnostic 
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Baseline measure of the total sample in data set 2 
Variables Mean  Standard 
Deviation 
Symptom severity 265.0 95.5 
Work and social adjustment 12.5 8.5 
GI related cognitions 150.2 33.5 
GI related avoidance 
behaviours 
51.3 18.1 
GI related safety behaviours 46.4 10.6 
Anxiety 10.7 4.2 




This study replicated the analysis of study three with a few key differences aimed to improve 
the quality and validity of the analysis. These differences included the use of a greater sample 
size of participants meeting the more recent Rome III criteria rather than Rome I criteria. This 
allowed the classification of bowel subtypes to follow the official stipulation of the Rome III 
and IV diagnostic criteria (Drossman, 2006; Drossmanm 2016). Both study three and four 
found that those with IBS-D and IBS-A had significantly higher levels of avoidance 
behaviour than those with IBS-C. There was however a distinction in the findings of study 
three and four regarding safety behaviours. In study three it was found that only those with 
IBS-A had higher levels of safety behaviours than the other two subtypes, whereas in study 
four both IBS-A and IBS-C had higher levels of safety behaviour than IBS-D. Another more 
consistent distinction between findings of study three and four was that the non-significant 
trend for a greater level of unhelpful GI related cognitions in IBS-D than IBS-C found in 
study three, became significant in study four.  
Study four therefore supports the conclusion of study three that there are distinct cognitive 
and behavioural patterns across the different IBS subtypes. The potential of measurement bias 
accounting, at least in part, for some of these results was raised as a possibility. Validation of 
measures across the different IBS subtypes is suggested to assess this further. In line with a 
more recent study, the results suggest that bowel pattern subtypes are important in 
distinguishing subgroups in IBS but psychological factors are also important in the 
characterisation of these subgroups (Polster et al., 2017). To further these findings, cluster 
analysis such as latent class analysis could be used to assess the existence of subgroups in IBS 





9.1 Chapter Overview 
The studies conducted in this thesis were designed to assess the importance of cognitive 
and behavioural factors in irritable bowel syndrome (IBS). Two of the studies examined 
the potential mediating roles of cognitive and behavioural factors in CBT for IBS 
(chapters four and five). Chapter four systematically reviewed the literature on factors 
that mediated the treatment effect in trials evaluating psychological interventions for 
IBS.  Chapter five assessed simple and sequential mediation models including process 
variables informed by the cognitive behavioural models of IBS. The results of these 
studies indicated that gastrointestinal (GI) cognitions appeared to be particularly 
important mediators of treatment effect on the outcomes of symptom severity and 
quality of life (QoL)/ work and social adjustment (WSA). There was some evidence for 
the mediating roles of gastrointestinal specific anxiety (GSA), general anxiety and GI 
related behaviours.  
The two subsequent studies, three and four, investigated whether cognitive and 
behavioural factors in addition to other psychological and outcome measures, were 
differentially associated with bowel pattern subtypes in IBS (chapters seven and eight). 
Results utilising data from two separately conducted RCTs were largely similar.  The 
different subtypes were associated with different cognitive and behavioural tendencies. 
A key difference was that in the larger RCT (Everitt et al., 2015), individuals with IBS-
C had higher levels of safety behaviours than those with IBS-D.  Neither of the studies 
found significant differences in physical and affective outcomes.  
The theoretical and clinical implications of all these results are discussed further. The 
results of the studies assessing mechanisms of treatment effect are considered in section 
9.2, and the results of studies assessing associations between subtypes and cognitive and 
behavioural factors are considered in section 9.3. A general discussion of the strengths 
and limitations of the studies and the implication for future research and clinical 
directions is also provided in section 9.4.  
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9.2 Assessing Mechanisms In IBS 
9.2.1 Revisiting the aims of study one and two 
The objective of study one and two was to assess whether cognitive and behavioural 
factors were mediators of treatment effect on the outcomes of symptom severity and 
work and social adjustment/QoL.  
9.2.1.1 Systematic review (study one) aims 
The aim of study one was to systematically identify psychological factors found to 
mediate the effect of psychological interventions for IBS on the outcomes of symptom 
severity and/or QoL. It was hypothesised that cognitions, behaviours and anxiety would 
be found to significantly mediate treatment effect, in line with cognitive behavioural 
(CB) models of IBS (Kennedy et al., 2005; Craske & Barlow, 2006; Moss-Morris, 
McAlpine, Didsbury, & Spence, 2010). 
9.2.1.2 Mediation analysis (study two) aims 
Study two had two specific aims:  (1) to assess whether GI related avoidant and safety 
behaviours, GI related cognitions and general anxiety, mediated the effect of CBT on 
symptom severity and WSA; (2) to identify which mediating variables changed first in 
sequential mediator models. It was hypothesised that all four variables would 
significantly mediate the effect of CBT on both outcomes based on the CB models of 
IBS and findings from previous studies (Windgassen et al., 2017). It was also 
hypothesised that cognitive and behavioural change would precede change in anxiety, as 
these were the targets for change in the treatment protocol informed specifically by the 
three systems model (1.13.1). Furthermore in the previous mediation study based on the 
same data, cognitive and behavioural change was found to precede changes in anxiety 
(Reme et al., 2011). 
9.2.2 Summary of systematic review (study one) 
In four out of five studies, cognitions were found to mediate the treatment effect in terms 
of symptom severity. Five studies also assessed GSA as a mediator, with three finding 
significant mediation and one finding a trend towards significance. Only one of three 
studies that assessed general anxiety as a mediator found significant mediation. This was 
a more complex analysis where the effect of moderators were assessed simultaneously.  
Anxiety was only found to significantly mediate treatment in participants with low 
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baseline quality of life (QoL) (Labus et al., 2013). Of the two studies assessing 
behavioural responses, the one that significantly mediated change, assessed IBS specific 
behavioural coping responses.  There was a similar trend in results for the mediation 
analysis with QoL as an outcome.  
9.2.3 Summary of mediation analysis (study two)  
Chapter five described the mediation analysis conducted using data from a previously 
reported RCT (Kennedy et al., 2005). The RCT compared CBT + mebeverine compared 
to mebeverine alone in GP diagnosed IBS patients meeting the Rome I criteria. The 
simple mediation models found that general anxiety, GI related cognitions and safety 
behaviours significantly mediated the treatment effect on the outcomes of symptom 
severity and WSA. Avoidance behaviour was not a significant mediator. Sequential 
models found that GI related cognitions and safety behaviours changed prior to a 
reduction in anxiety and that this meditational path accounted for improvement in 
symptom severity and WSA. These sequences were found to fit best for both outcomes 
according to the prioritised assessment of fit criteria.  
9.2.4 How results inform theory 
Theoretical models are devised to explain potential relationships between explanatory 
variables and outcomes such as symptoms, mood and/or disability. While the use of 
CBT has been found to be effective in improving such outcomes in IBS (Ford et al., 
2009; Ford et al., 2014), the mechanisms of efficacy are not as commonly assessed 
(Windgassen et al., 2016; Windgassen et al., 2017). As presented in chapter one (section 
1.13) there are a number of different CB models that have been adapted for IBS. All of 
the models assert that cognitions and behaviours interact to maintain symptom severity 
and impaired functioning/QoL. The four-factor model (1.13.2) and the CBT-IE model 
(1.13.3) respectively identify general anxiety and gastrointestinal specific anxiety (GSA) 
as also interacting with cognitions and behaviours to maintain symptoms.  The three 
system’s model (Lang, 1968) (1.13.1) in contrast, omits the role of anxiety as a key 
mediating factor. Instead it identifies GI related cognitions, behaviours and 
physiological responses as the processes that interact to maintain symptoms. The CBT 
provided in study two followed the three system’s approach (Kennedy et al, 2005) and 
this was the model primarily assessed in the present thesis.  
Although the studies in this thesis focussed on the three system’s model of IBS and 
more generally the CB models of IBS, there are a number of alternative health 
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psychology models that could be applied to understand the perpetuation of IBS 
symptoms and disability. The model that perhaps has the most parallels with the CB 
models of IBS is the ‘Common Sense Model’ (CSM) (Leventhal, Brissette, & 
Leventhal, 2003). This model posits that individuals utilise different sources of 
information that may be concrete (such as information provided by doctors) or abstract 
(such as internal beliefs) to inform mental (or cognitive) representations of their illness. 
There are six dimensions of illness representations: identity, cause, timeline, 
consequence, control and coherence. ‘Identity’ is the label given to illness, such as the 
medical diagnosis and symptoms patients believe to be associated with that label. 
‘Cause’ refers to the perceived cause of the illness, whether it is biological such as a 
bacterial infection or psychological, such as stress. Individuals may also believe there 
are multiple causes including biological, psychological and social factors. ‘Timeline’ 
representations are beliefs about the likely duration of an illness and whether it is acute, 
chronic and/or cyclical. ‘Consequences’ describes the individuals’ judgements on the 
impact that the illness will have on their life. ‘Control’ has been subdivided into 
‘treatment control’ and ‘personal control’ (Broadbent, Petrie, Main, & Weinman, 2006). 
Treatment control is the degree of control individuals believe that they have over their 
treatment, which may pertain to the degree of side effects they perceive to be associated 
with the treatment, the number of treatment options and the perceived efficacy. Personal 
control in contrast is the degree of control that the individual personally believes they 
can exercise over their illness. Finally, ‘coherence’ refers to the extent to which 
individuals understand their illness.  
In addition to cognitive representations, the model posits that the experience of illness 
also causes emotional representations such as fear, worry or sadness, and that together 
cognitive and emotional illness representations influence coping behaviours. The model 
advocates parallel processes whereby cognitive and emotional representations influence 
coping strategies via two different pathways (figure 9.1). Coping behaviour can be 
helpful or unhelpful, including but not limited to strategies such as avoidance or denial, 
expressing emotion, problem-focused coping and seeking social support (Hagger & 
Orbell, 2003). The final stage of the model is the appraisal of coping strategies as either 
effective or ineffective. These appraisals feed back to individuals’ illness experience and 
further representations of their illness. Appraisals therefore have the potential to change 
the use of coping strategies. The CSM has been used to explain a range of outcomes in 
long-term conditions including disease state, physical functioning and psychological 
distress (Hagger & Orbell, 2003), including IBS (Rutter & Rutter, 2002, 2007). 
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Figure 9.1: Common Sense Model of Illness adapted from ‘Improving uptake of cardiac 
rehabilitation: Using theoretical modelling to design an intervention’ by S.M Molesh, 2009, 
European Journal of Cardiovascular Nursing, 8 (2009), 161-168, pg 164.   
Both the CSM and the CB models of IBS identify similar process variables that impact 
on outcomes. The CB models of IBS identify GI related cognitions and GI related 
behavioural responses as key factors contributing to outcomes. Similarly, the CSM 
identifies illness representations, appraisals of coping strategies (i.e. cognitions) and 
coping strategies (i.e. behaviours) as key processes. The four-factor and CBT-IE models 
of IBS also share with the CSM the identification of affective factors as important 
processes impacting on outcomes. 
It may be argued that processes identified in the CSM are more general, while the 
processes in the CB models are more specific to the experience of IBS. For example an 
illness representation may pertain to general perceptions of the degree of control an 
individual has over their IBS symptoms. An example coping behaviour may be broadly 
described as tendencies to engage in emotion-focussed coping. In contrast unhelpful GI 
related thoughts and behaviours considered in the CB models of IBS have more 
specificity to the day-to-day experience of IBS. These include thoughts and behaviours 
such as ‘I am constantly frustrated by my bowel symptoms’ and ’I avoid exercise when I 
have stomach pains’. 
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The two models also contrast in the posited relationships between variables. While the 
CB models postulate that emotions, cognitions and behaviours interact with each other 
in a non-linear fashion, the CSM asserts a directional relationship between the factors. 
Namely, the CSM asserts that cognitions inform behaviours, which subsequently impact 
on appraisals of coping and illness outcomes (Rutter & Rutter, 2002). Furthermore in the 
CSM, emotional representations are purported to occur in parallel to cognitive illness 
representations, with no relationship identified between cognitions and emotions. 
Behaviours are therefore said to be affected by emotions and cognitions independently 
(figure 9.1). The partitioning of cognitions and emotions in this way is not intuitive, as 
experientially we can witness the interplay between emotions and cognitions on a daily 
basis. For instance, if an individual has the thought ’I do not have the resources to cope 
with this‘, it is likely to cause anxiety or feelings of worry or dread. Similarly, if 
individuals experience low mood this may have an impact on an individual’s cognitive 
perception of their ability to cope with a particular event. Indeed the interplay between 
cognitions and emotions in this way has been well demonstrated (Kark Smollan, 2006; 
Deary, Chalder, & Sharpe, 2007; Chida, Hamer, & Steptoe, 2008). Furthermore, 
proposed updates to the models by the authors include the integration of emotional and 
illness representations at the different ‘stages’ (representation, coping, appraisal) 
(Leventhal, Diefenbach, & Leventhal, 1992).  
Both the systematic review and mediation analysis identified the mediating role of 
illness related cognitions in IBS. Therefore the results provide some support for all of 
the adaptations of the CB models of IBS as well as the CSM. Although the constructs 
assessed in the IPQ-R adapted for IBS (Chilcot & Moss-Morris, 2013; Everitt et al., 
2015) are more generic than those assessed in the CS-FBD (Toner et al., 1998) there 
appears to be overlap between the constructs. For instance the item from the CS-FBD ’I 
cannot function normally when I get bowel symptoms’ is likely to overlap with the 
symptom control item in the CSM i.e.  ‘How much control do you feel you have over 
your IBS symptoms?’ Similarly, the item related to timeline in the IPQ-R ‘I often feel 
that this abdominal pain will never go away’ is reasonably specific. Broadly speaking, 
the results endorse the idea that changing the way individuals think about their illness 
has an effect on the outcomes of that illness. Thus both CB models and CSM have some 
validity.  
The systematic review was not able to assess the extent to which behaviours were 
important for causing change in outcome as only two of nine studies assessed the 
mediating role of behaviours. One study (Chilcot & Moss-Morris, 2013) used a measure 
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of ‘all-or-nothing’ behaviour (Skerrett & Moss-Morris, 2006), which includes items 
such as ‘I tend to overdo things and then rest up for a while’. This was not found to 
mediate treatment effect on symptom severity. In contrast the other study included in the 
review assessed GI related behavioural responses (Reme et al., 2011). This study found 
that safety and avoidance behaviours combined into a total score were significant 
mediators of treatment effect. However, in the more nuanced mediation study (see 
chapter five) GI safety behaviours rather than avoidance behaviours were found to 
mediate the treatment effect (discussed in 9.2.5). The results of both study one and two 
therefore partially support the CB models of IBS and the CSM as behaviours were 
shown to influence outcomes. However, the results lend more support to the CB models 
of IBS than the CSM, in that they indicate the importance of specifically GI related 
behaviours rather than more general unhelpful cognitions or coping behaviours.  
The assertion of the CSM, four-factor and CBT-IE models of IBS, that affective factors 
also influence outcomes was supported by both mediation studies. The systematic 
review identified GSA as a potentially important mediator. The mediation study carried 
out as part of this thesis identified general anxiety as a significant mediator of the 
treatment effect. Both studies lend support to the hypothesis in the biopsychosocial 
model of IBS that anxiety is one of the underlying process by which psychological 
factors have physiological effects (Mach, 2004; Fichna & Storr, 2012; Stasi, Rosselli, 
Bellini, Laffi, & Milani, 2012). However the results also show that changing GI 
cognitions and behaviours brings about change in anxiety  (discussed further 9.2.5.2). 
Therefore the three system’s model may have the benefit of identifying which factors 
are important to target for change (cognitions and behaviours). Meanwhile the four-
factor model and CBT-IE model have the benefit of making the distinction between 
anxiety and symptoms, which can increase clarity regarding how treatments work to 
change symptoms.  
9.2.5 How results inform clinical practice 
There are three main clinical implications from the findings of study one and two (1) the 
importance of targeting change in psychological factors specific to the experience of 
IBS; (2) the prioritisation of changing GI related cognitions and safety behaviours over 
the targeting of general anxiety and (3) the apparent importance of tackling safety 
behaviours. Each of these clinical implications are considered further below. An updated 
three system’s formulation is depicted in figure 9.2 based on the results. 
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9.2.5.1 The importance of targeting change in psychological factors specific to the 
experience of IBS 
Both studies specifically highlighted the importance of changing illness-related 
cognitions as opposed to general unhelpful cognitions. In study one most measures of 
cognitions were illness/GI specific such as the use of the cognitive scale for functional 
bowel disorders (CS-FBD) (Reme, Darnley, Kennedy, & Chalder, 2010). Study two also 
used the CS-FBD, which assessed unhelpful cognitions specifically related to GI 
symptoms such as abdominal pain and bowel movements. It included items such as ‘I 
often worry that there may not be a bathroom when I need it’ or ’I am constantly 
frustrated by my bowel symptoms’. The combined results therefore indicate the 
importance of changing negative thoughts specifically relating to the experience of IBS 
in order to improve outcomes. Similarly both studies suggest that changing behaviours 
specific to IBS are important for changing outcomes. Study one found that GI specific 
behaviours mediated treatment effect whereas non-IBS specific ‘all-or-nothing’ 
behaviours did not (Chilcot & Moss-Morris, 2013). Study two indicated that specifically 
GI related safety behaviours mediated treatment effect on outcomes. Finally, GI specific 
anxiety was shown to mediate treatment effect more often than general anxiety in the 
systematic review. Together these results highlight the importance of assessing 
psychological factors specifically relating to the experience of IBS.  
9.2.5.2 The prioritisation of changing GI related cognitions and safety behaviours over 
general anxiety  
The results of the sequential models suggest that GI related cognitions and GI safety 
behaviours changed in order to reduce general anxiety. This makes intuitive sense as a 
reduction in negative GI related thoughts such as ‘I cannot cope with these bowel 
symptoms’ is likely to alleviate anxiety that would have been associated with these 
thoughts. The impact of negative cognitions on predicting anxiety is established across 
healthy and illness populations (Brosschot, Gerin, & Thayer, 2006; Eysenck, 2014). 
Furthermore, the need to reduce safety behaviours in order to facilitate a reduction in 
anxiety is well documented in the literature on anxiety disorders and health anxiety 
(Beesdo‐Baum et al., 2012; Helbig-Lang et al., 2014; Goetz, Davine, Siwiec, & Lee, 
2016).  
These findings are important to consider when developing detailed treatment manuals 
specifically for improving symptoms and disability related to IBS. Models for 
understanding and treating IBS are different to those currently being used for anxiety 
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disorders. Clinicians in services such as Increasing Access to Psychological Therapies 
(IAPT) may be tasked with targeting general anxiety in individuals with IBS, assuming 
that reduction of general anxiety will cause IBS symptoms to subside. However, the 
results of the thesis suggest that targeting IBS specific cognitions and behaviours is 
important.  
9.2.5.3 The apparent lack of emphasise on changing avoidance behaviours 
The finding that avoidance behaviour did not significantly mediate treatment effect was 
a surprising one. Avoidance behaviour items included ‘I avoid going out in case I have 
problems with my IBS’ and ’I avoid certain work situations (e.g. meetings) because of 
my IBS’. While these behaviours did change during CBT, there was greater change in 
safety behaviours (chapter 5, table 2). One potential explanation for this finding is that 
participants were not particularly avoidant at baseline reducing the scope for change. 
This is supported by the fact that at baseline avoidance behaviours were moderate in the 
Kennedy trial (Kennedy et al., 2005), with a mean score (SD) of 44.5 (17.3) out of a 
potential total score of 105. The baseline avoidance (M=51, SD=18.1) was not much 
higher in the ACTIB study (data set 2), which recruited individuals with refractory IBS 
(IBS resistant to treatment and of long duration). As such avoiding daily activities may 
not be something that this patient population engage in particularly. Indeed, there 
appears to be a trend for the opposite in IBS, with individuals adopting a stoic ‘just get 
on with it’ attitude, taking great efforts not to allow the condition to take over their lives 
(Casiday, Hungin, Cornford, de Wit, & Blell, 2008; Håkanson, 2014). However, 
baseline levels of safety behaviours were also moderate (M=44.7, SD=10.7) and these 
were still found to be significant mediators. Furthermore, the direct effect of CBT on 
avoidance and safety behaviours was significant, indicating that therapy reduced both 
variables (chapter 5, table 2). The distinction was that the change in safety behaviours 
did result in change in outcomes, whereas change in avoidance behaviours did not.  
The fact that avoidance did not mediate the treatment effect does not preclude it from 
having a mediating effect in conjunction with other mediating variables. For example 
CBT may reduce avoidance behaviour, which in turn reduces anxiety and this sequence 
causes change in outcome. In this analysis, avoidance behaviour was not included in 
sequential mediation models for two reasons:  (1) the non-significance in simple 
mediation models and second; (2) to avoid data dredging (Breitborde, Srihari, Pollard, 
Addington, & Woods, 2010). Nevertheless it remains a possibility that avoidance 
behaviour could mediate treatment effects in future studies.  In the meantime the results 
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indicate that clinicians may be wise to prioritise change in safety behaviours over 
change in avoidant behaviours.  
Should future studies replicate the finding that the reduction of avoidance is not a key 
factor in reducing symptom severity or increasing work and social functioning in IBS, 
this would have implications for treatment model development (Kazdin, 2009; Holmes 
et al., 2018). The current three systems CBT approach for IBS may be modified by 
specifying that key unhelpful illness related control behaviours play a role in the 
maintenance of IBS symptoms rather than avoidance behaviours. This would have an 
impact on the use of treatment techniques, many of which are designed to reduce 
avoidance and the anxiety that is perpetuated by such avoidance. Instead therapeutic 
focus may be on the response prevention and cognitive restructuring as used in OCD 
(Olatunji, Davis, Powers, & Smits, 2013). Alternative potential mechanisms are 
considered in more detail in section 9.4.6. 
 
Figure 9.2: Adapted three systems formulation model based on study two results 
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9.3 Assessing Psychological Differences in IBS Subgroups 
9.3.1 Revisiting the aims of study three and four 
The overall objective of studies three and four was to identify cognitive and behavioural 
factors associated with IBS bowel pattern subtypes. Both studies aimed to assess 
whether there were differences in cognitive and behavioural factors in addition to levels 
of anxiety, depression, symptom severity and WSA, across IBS subtypes. 
9.3.1.1 Assessing psychological and outcome differences in subtypes (study three) aims 
It was hypothesised that due to the nature of symptoms and the additional burden created 
by the experience of diarrhoea, those with IBS-A and IBS-D would have more extreme 
symptoms, disability and cognitive, behavioural responses compared to those with IBS-
C. It was also hypothesised that IBS-A would have higher levels of abdominal pain than 
the other subtypes due to previous findings (Heitkemper et al., 2011).  
9.3.1.2 Assessing psychological and outcome differences in subtypes in ACTIB (study 
four) aims 
Study four aimed to validate the findings from study three in a larger sample with larger 
power to detect differences. It was hypothesised that cognitions and behaviours would 
differ between subtypes. Based on the results from study three, the three specific 
hypotheses were that (1) unhelpful cognitions would be greater in those with IBS-D than 
IBS-C (2) unhelpful avoidance behaviours would be greater in those with IBS-D and 
IBS-A compared to IBS-C (3) control behaviours would not significantly differ across 
subtypes. 
9.3.2 Summary and integration of study three and four results 
Both studies found that subtypes IBS-D and IBS-A had significantly higher levels of 
avoidance behaviour than IBS-C. The findings regarding association of safety 
behaviours and bowel pattern subtype differed slightly across the two studies. Both 
studies found that those with IBS-A had higher levels of safety behaviours than those 
with IBS-D. Only study four found that individuals with IBS-C had significantly higher 
levels of safety behaviours than those with IBS-D also. The non-significant trend for a 
greater level of unhelpful GI related cognitions in IBS-D than IBS-C found in study 
three, became significant in study four. Study three found a significantly higher 
proportion of those with IBS-A with abdominal pain, than those with IBS-C or IBS-D.  
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9.3.3 Discussing the results 
9.3.3.1 Increased avoidance in IBS-A and IBS-D 
A potential reason for increased avoidance in IBS-A and D compared to IBS-C was 
postulated in chapters seven and eight to be due to the nature of the bowel symptom of 
diarrhoea, experienced by both subtypes. This symptom has been shown to be of 
primary concern to both subtypes in a recent study aimed at developing a subtype 
specific symptom severity measure for IBS (Fehnel et al., 2017). Concept elicitation 
interviews were used to identify the relative importance of symptoms as varied by 
subtype. Those with IBS-D and IBS-A identified the same symptoms most important to 
treat. These were the bowel symptoms of urgency and loose, watery stools and the 
abdominal symptoms of abdominal pain and cramping. The urgency associated with 
diarrhoea in IBS has been described as unpredictable, causing uncertainty and the use of 
avoidant behaviour strategies (Drossman et al., 2009; Rønnevig, Vandvik, & Bergbom, 
2009; Drossman et al., 2011; Håkanson, 2014). 
9.3.3.2 Increased use of safety behaviours  
 Those with IBS-A engaged in increased safety behaviours in both studies.  Those with 
IBS-C also engaged in more safety behaviours in study four only, perhaps due to power. 
However, the post hoc power calculations (appendix G) indicated that the two studies 
had similar power to detect differences on this subscale (>0.9). It should be noted that 
there are issues with post hoc power calculations that can make them unreliable (Levine 
& Ensom, 2001). Nevertheless, the findings may also be due to the different participant 
samples; study four used individuals with refractory IBS, whereas this was not an 
inclusion requirement for study three. Individuals with refractory IBS-C will have had a 
longer duration of symptoms, which have not substantially improved after the use of 
first line medications. The lack of reprieve from symptoms over a long period may result 
in individuals becoming reliant on particular behaviours (such as stool checking or 
avoiding certain foods) to ease anxieties about the eventualities of not performing such 
behaviours (Thwaites & Freeston, 2005; Olatunji, Etzel, Tomarken, Ciesielski, & 
Deacon, 2011). The manifestation of safety behaviours in IBS generally, and specifically 
in IBS-C has been identified in the qualitative literature also (Casiday et al., 2008; 
Rønnevig et al., 2009; Håkanson, 2014). It remains unclear from the existing literature 
and from studies three and four, whether safety behaviours are generally heightened in 




Given the increased use of safety behaviours in IBS-C found in study four, and the 
increased use of avoidance behaviours in IBS-D found in both studies, the finding that 
those with IBS-A had higher levels of both types of unhelpful behaviour may be 
understood as a response to both diarrhoea and constipation symptoms. In IBS-A the 
fluctuations between bowel habits are rapid, with short symptom flare-ups and 
remissions (Tillisch et al., 2005). Traditional management approaches to IBS bowel 
symptoms involve the use of fibre supplements and laxatives to treat symptoms of 
constipation, and the use of antidiarrhoeal agents to treat diarrhoea symptoms. For 
individuals with IBS-A this approach may exacerbate symptoms, increasing frequency 
and severity of symptom fluctuations (Tillisch et al., 2005). Such issues regarding 
medication could explain the reliance on the use of avoidance and safety behaviours. 
Another factor that may account for the differences found in behaviours across the 
subtypes is measurement error. It is a possibility that more items on the avoidance 
subscale of the BRQ may be relevant to the experience of diarrhoea, while more items 
on the safety subscale may be relevant to the experience of constipation. This could 
account for all of the behavioural differences found across the subtypes. This highlights 
the need to validate the BRQ within each IBS bowel pattern subtype.  
9.3.3.3 More unhelpful GI related cognitions in IBS-D 
The increased power to detect effects in study four compared to study three is likely to 
account for why the non-significant trend towards higher levels of GI-related cognitions 
in IBS-D compared to IBS-C in study three became significant in study four (appendix 
G). Factors such as unpredictability and increased burden associated with diarrhoea 
could explain this finding.  
As with the BRQ, there is the possibility that measurement bias in the CS-FBD accounts 
for the findings. There may be more items in the scale that are relevant to those with 
IBS-D than they are to the other two subtypes. The validity of this scale for the different 
subtypes would need to be assessed before drawing further conclusions. 
9.3.4 Clinical and research implications 
9.3.4.1 Tailoring interventions  
The results of studies three and four suggest that individuals with different IBS subtypes 
may have different cognitive and behavioural experiences. These results could provide a 
basis for the tailoring of psychological treatments in IBS. An area where the tailoring of 
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psychological treatments is important, is in the development of online interventions 
(Lustria, Cortese, Noar, & Glueckauf, 2009) such as the one developed in the ACTIB 
study (2.3, appendices E & H). Online interventions include interactive features that can 
guide users down specific paths, based on their responses to particular questions (Noar, 
Benac, & Harris, 2007; Lustria et al., 2009). For example, questions identifying 
predominant bowel pattern may funnel participants to information and activities tailored 
towards their particular cognitive and behavioural experiences. Techniques for IBS A 
and D may focus on reducing avoidance behaviours, whereas those with IBS-C may 
receive guidance in limiting the use of safety behaviours. 
Membership of IBS subtypes fluctuates (Palsson, Baggish, Turner, & Whitehead, 2012). 
This could have implications for treatment development procedures. This is because 
should individuals receive a treatment course that has been tailored to their IBS subtype, 
subsequent change to the subtype may render the treatment no longer effective or 
appropriate. Treatments tailored to the IBS subtypes therefore need to be flexible to 
account for fluctuations in symptoms. Nevertheless, research generally suggests that 
from month to month subtypes remain stable (Engsbro, Simren, & Bytzer, 2012; Palsson 
et al., 2012). There are alternative methodologies that can assess the extent to which 
daily fluctuations of unique characteristics (such as bowel patterns) predict treatment 
response (Holmes et al., 2018). These methodologies include ‘ecological momentary 
assessment’, latent growth curve modelling and machine learning techniques (Holmes et 
al., 2018). Research utilising these methods could inform the extent to which bowel 
pattern subtype fluctuations impact on tailored treatment.  
Should it be determined that subtype fluctuations do affect treatment response, flexible 
formulation-based treatment could be used to facilitate continued treatment response 
(Toner, 2005; Persons, 2012). This is intuitively sensible as treatment is based on the 
specific experiences of patients who experience symptom fluctuations, which are 
experienced with regularity and significance over the course of treatment. Using 
principles from personalised treatment approaches, a clinician can apply the general IBS 
CBT protocol transdiagnostically (across bowel pattern subtypes) and utilise information 
regarding predominant bowel pattern subtype to tailor particular aspects of the 




9.3.4.2 Increasing the multidimensionality of subgroups in IBS 
Research in IBS increasingly suggests the importance of increasing the 
multidimensionality of subgroups in order to create more clinically meaningful symptom 
profiles (Whitehead, Palsson, & Jones, 2002; Riedl et al., 2008; Polster et al., 2017). 
These studies have all indicated that the characterisation of bowel pattern predominance 
remains important but only when considered in addition to other factors such as somatic 
and psychological comorbidity (Whitehead et al., 2002; Riedl et al., 2008; Polster et al., 
2017). Our study supports the suggestion that bowel pattern subtypes are important. The 
suggestion that cognitive and behavioural variables are also important factors for the 
characterisation of subgroups is novel. It concurs with the new characterisation of 
somatic symptom disorders in DSM-V (Association, 2013), where the importance of 
cognitive and behavioural responses have been highlighted. Subgroups identified using 
such variables may have the ability to further account for heterogeneity in IBS outcomes 
(e.g. symptom severity/QoL) and treatment outcomes.   
9.3.4.3 Investigation of measurement bias  
The results of studies three and four may indicate some measurement bias in relation to 
both the BRQ (Reme et al, 2010) and the CS-FBD (Toner et al, 1998) when applied 
across IBS subtypes (as discussed in 9.3.3.2 and 9.3.3.3). Therefore an important avenue 
for further investigation is the validity of these measures in different bowel pattern 
predominant samples.  
9.4 Overall Strengths & Limitations  
The specific strengths and limitations for each study are discussed in the respective 
chapters. Discussion here will focus on general issues arising across the studies and how 
the studies relate to each other.   
9.4.1 Mediation studies  
While narrow in the treatments included in the systematic review, the advantage was 
that the findings were more specific to CBT. This reduced potential ambiguities that 
could have arisen in the context of a mix of heterogeneous treatments. The disadvantage 
of only having mediation results from CBT studies was that inferences about mediators 
of other psychological approaches to IBS could not be made. As such the degree to 
which there are shared mechanisms across treatments remains unclear.  
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Although there were a limited amount of studies included in the review limiting the 
inferences that could be made regarding treatment mechanisms, the review provided an 
additional important contribution to the literature. It highlighted the disparity in the 
methods used for assessing mediation within the same field of research. The 
development of a clear set of quality assessment criteria (chapter 4, mediation quality 
assessment) aimed to remedy this by identifying standards future mediation research 
should adhere to. These criteria were used to guide the mediation analysis conducted in 
study two, substantially enhancing the methodological quality. Study two consequently 
ensured that (1) mediators and outcomes were temporally sequenced to allow causal 
inferences (2) analysis controlled for potential confounding effects of baseline mediator 
and outcome measures (3) multiple assessment of fit criteria were used for model fit (4) 
confidence intervals and path coefficients of indirect effects were reported (5) paths 
modelled were informed by theory, namely the three system’s model.  
There was however a limit to the extent to which study one could inform the design of 
study two as study two used data that had already been collected. Should there have 
been more flexibility in the design of study two, it would have been useful to include a 
measure of GSA in order to assess it as a mediator. This would also have allowed further 
analysis to explore the relationship between the constructs of GSA and general anxiety. 
Analysis such as principle component analysis could identify whether the two constructs 
overlap or are distinct (Abdi & Williams, 2010).  
Future mediation studies could utilise both specific and general measures of 
psychological constructs to assess their relative importance.  The illness perception 
questionnaire could be used as a general mediator.  
Finally, a strength of study two was that it appeared to have sufficient power (.80) to 
detect mediation in the simple mediation models based on the post hoc guidelines 
developed by Fritz & MacKinnon, (2007). This is because all effect sizes of α and β 
paths were >.26 - with the exception of avoidance behaviour which fell just below it - 
and there was a sample size of 148 (see 2.4.2.2 and chapter 5, table 2). However, it is 
unclear whether there was sufficient power to detect sequential mediation effects, as 
there is not currently sufficient information on how to calculate power for more complex 
mediation models (Thoemmes, MacKinnon, & Reiser, 2010).  
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9.4.2 Subtype studies  
A success of the two studies assessing subtype associations with various outcome 
variables was the partial replication of findings from study three in study four, 
suggestive of external validity (Francis, 2012; Makel, Plucker, & Hegarty, 2012). This is 
despite the fact that there were differences in the participant samples. Differences 
included the diagnostic criteria used to recruit participants and the exclusion of non-
refractory IBS in study four. Participants in study three had to meet the Rome I criteria 
whereas participants in study four had to meet the Rome III criteria. It has been 
suggested that the Rome criterion have become more restrictive (Chey et al., 2002; 
Drossman & Dumitrascu, 2006; Dang, Ardila‐Hani, Amichai, Chua, & Pimentel, 
2012) and therefore the two different studies may include slightly different subsections 
of the IBS population. This may also be likely due to the refractory nature of the IBS 
population in study four. Nevertheless both samples had similar baseline characteristics 
(chapters seven and eight). This may indicate that inclusion criteria differences did not 
contribute to difference in the two samples. 
Due to the use of different diagnostic criteria, the studies also employed different 
methods of assigning bowel pattern subtype classifications making comparison difficult. 
However the classification methods were chosen to ensure they were as similar as 
possible. The same number of parameters were used to inform classification, with 
similar rating scales (Likert scale of 4 in study three and 5 in study four). The 
predominant difference between the two methods was the wording. For example 
participants were asked to rate frequency of either ‘diarrhoea’ and ‘constipation’ or 
‘loose and watery stools’ and ‘hard and lumpy stools’.  
Both studies may have been underpowered to detect differences across all outcome 
measures other than behaviours based on post hoc power calculations (appendix G). 
This could account for the lack of differences found on all of the other measures 
assessed. Power achieved for detecting behavioural differences was excellent however 
(>.80), which provides a certain degree of confidence in the findings that these differed 
across subtypes. However, as raised previously in the discussion and the respective 
chapters, there was the potential of measurement bias in the cognitive and behavioural 
measures. This limits the extent to which interpretations about the findings can be made.  
Both studies were novel, providing important contributions to the field of research. 
Although the importance of cognitive and behavioural factors are discussed throughout 
the IBS literature (Creed & Guthrie, 1987; Drossman, Camilleri, Mayer, & Whitehead, 
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2002; Kennedy et al., 2012), very few studies have assessed cognitive differences 
between IBS subtypes. Those that have did not find significant differences between 
subtypes (Sugaya & Nomura, 2008; Stengel et al., 2010; Thijssen et al., 2010). The 
studies conducted in this thesis also appear to be the first studies to assess differences in 
GI related avoidance and safety behaviours across subtypes.  
There are issues with comparison of findings across studies using different samples that 
are not matched. In studies three and four the diagnostic criteria for IBS differed. 
Theoretically this could mean that the samples represent different patient groups. Studies 
have shown that there are differences in the sensitivity of the various IBS diagnostic 
criteria (Ersryd, Posserud, Abrahamsson, & Simren, 2007; Sperber, Shvartzman, Friger, 
& Fich, 2007; Park et al., 2010). As such, the comparison of similarities and differences 
in findings from the samples of the two studies may not be attributable to the 
independent variables of interest (i.e. subtypes). There are additional potential 
confounders arising from two non-matched datasets that reduce the validity of 
comparisons between them. These confounders include but are not limited to the 
following factors: differential diagnostic criteria, age ranges, level of baseline affect, 
comorbidity and symptom duration. 
9.4.3 Why assess mediators and subtype associations in one thesis?  
This thesis seeks to combine understanding of subtype associations and therapeutic 
processes. Although not necessarily natural bedfellows the former can help contribute to 
the planning of the latter. Moderated mediation has been conducted by previous 
researchers in IBS (Labus et al., 2013). Moderated mediation detects where a mediated 
effect (e.g. cognitions) is different at different values of the moderator (e.g. bowel 
pattern subtype) (Mackinnon, Fairchild, & Fritz, 2007; MacKinnon, 2011). In the 
previous study by Labus et al (2013), the rationale for stratifying mediation analysis by 
baseline levels of QoL was not theoretically or empirically informed. The combined 
findings from this thesis however could inform the basis of such analysis. As the 
mediation studies indicate the importance of cognitions, behaviours and anxiety, these 
could be included as mediators in analysis. The findings from the two other studies 
suggest that subtypes (i.e. IBS-A, D or C) could moderate the extent to which such 
mediator variables produce change in outcome. Therefore future studies with sufficient 
power could apply moderated mediation analysis in this way. 
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9.4.4 Issues with the Rome Criteria 
Although the Rome Criteria are widely adopted in IBS research, as previously discussed 
in the introduction (section 1.1, 1.8), it is used far less in the clinical diagnosis of IBS. 
This has implications for findings of research conducted in this thesis and more 
generally. Some studies have demonstrated poor validity of the Rome criteria in samples 
of patients with IBS as diagnosed by doctors  (Dang, Ardila‐Hani, Amichai, Chua, & 
Pimentel, 2012; Moayyedi et al., 2017; Mujagic et al., 2017; Chang et al., 2018). This 
may suggest that a proportion of patients diagnosed with IBS using methods alternative 
to that of the Rome criteria, may be precluded from IBS research. This may bias the 
results of such research, which may not be generalizable to all individuals with IBS in 
the general population.  
The use of diagnostic criteria that does not have standardised implementation in clinical 
practice is not exclusive to IBS. This is an issue in functional bladder syndromes such as 
interstitial cystitis and bladder pain syndrome also. Multiple criteria have been 
developed as in IBS, with a lack of consensus regarding which should be the primary 
method of diagnosis (van de Merwe et al., 2008; Hanno et al., 2011). As such there is 
poor adoption of such criteria in clinical practice and physicians generally rely on 
diagnosis by exclusion (Hanno et al., 2011). This results in similar uncertain prognoses 
and treatment trajectories for these patients (Hanno et al., 2011). Although it is good 
practice to rule out other potentially harmful disease diagnoses, the patient journey 
would be enhanced with clear protocols for diagnosis.  
9.4.5 The Effect of Comorbidities 
Studies show that both somatic and affective comorbidities have a substantial negative 
impact on the experience of IBS (Lackner et al., 2014; Vu et al., 2014). This may be due 
to the increased stress caused by such factors (Chang, 2011), physiological sensitisation 
(Van Oudenhove et al., 2016) or lower resilience to cope with the burden of multiple 
symptoms and negative experiences (Johnston et al., 2015; Jason, Carr, Washington, 
Hilliard, & Mingo, 2017). We did not have data from the studies in the present thesis to 
assess the potential affect of somatic comorbidities. With regards to the subtype studies, 
previous studies have demonstrated that the presence of somatic and affective 
comorbidities is a defining element of more multidimensional subgroups in IBS (Polster 




The subtype studies did however assess whether anxiety and depression were 
differentially associated with the IBS subtypes.  The findings as discussed previously, 
suggested that neither anxiety nor depression had a differential association between the 
subtypes. However, level of anxiety and depression were not controlled for in the 
ANOVAs. This means we cannot be certain that anxiety or depression accounted for the 
influence of subtypes on differences in avoidance and control behaviour or GI related 
cognitions. Although this is unlikely to have changed the results judging by the existing 
findings and the descriptive data at baseline, it is something that should perhaps be 
explored in future studies.  
In the mediation study, anxiety was controlled for in the sequential mediation models. 
This means that the potential effect of baseline anxiety was accounted for in the 
mediation models. The significant mediation pathways found therefore apply to 
individuals with low, moderate and high baseline anxiety. Depression, however, was not 
controlled for. The sample generally had low to moderate HADS depression scores 
suggesting that it’s probably unlikely that level of depression in our present sample 
would affect the findings. Nevertheless, it could be included as a covariate in future 
studies. A previous study demonstrated that low baseline QoL moderated mediation 
(Labus et al, 2013). Specifically, anxiety and cognitions were only found to mediate 
treatment effect of CBT on symptom severity, when baseline QoL was low. Although 
low baseline QoL is not a comorbidity, this demonstrates how baseline factors such as 
high comorbidity can affect mechanistic processes.  
9.4.6 Alternative approaches 
This thesis aimed to explore cognitive and behavioural factors in IBS. However, there 
are limitations to CBT generally and with specific application to IBS. A key 
consideration when interpreting results from CBT research is the extent to which 
patients remained adherent and within treatment. There is variation in adherence of 
between 20% and 50% in CBT (Bados, Balaguer, & Saldaña, 2007). This raises 
important questions regarding who makes use of CBT therapy. Such variability may 
suggest that CBT is only potentially effective for a self-selecting sample. There are also 
issues regarding the time-limited nature of CBT, particularly within stepped care 
services (Williams & Martinez, 2008). While for some patients a finite amount of 
specified sessions may be sufficient to induce change and positive outcomes, for others 
with more complex needs, it may be inadequate (Williams & Martinez, 2008). In IBS, 
there is a high prevalence of early life adverse events including sexual abuse (Bradford 
 
252 
et al, 2012). This can increase the complexity of the case, which may require more 
intensive treatment.  
It could be argued that CBT does not elucidate all of the potentially important targets for 
change (House & Loewenthal, 2008; Smith, 2017). There is an increasing focus on the 
mechanisms posited by therapeutic processes implicated in ACT (Smith, 2017). Key 
processes in ACT include cognitive defusion, acceptance and the use of value-based 
goals (Arch & Craske, 2008; Bravo Ferreira et al., 2011). Defusion refers to the process 
of gathering distance from thoughts or ‘decentring’ as practiced in mindfulness. 
Acceptance, rather than passive resignation is an intentional lowering of resistance to 
particular experiences. The focus on value-based goals allows clients to identify positive 
courses of action that are in line with these goals. Although these treatment targets may 
seem distinct from CBT, it could be argued that only the treatment procedures rather 
than the treatment targets are distinct (see section 9.4.8)(Arch & Craske, 2008). For 
example, both CBT and ACT target the reduction of avoidance and reduce the impact of 
unhelpful cognitions. The distinction lies in the employment of different treatment 
techniques to do so (Arch & Craske, 2008; Smith, 2017).  
 The studies in the present thesis focussed on the key processes and mechanisms 
identified in the cognitive behavioural model of IBS. This left other potential 
mechanistic processes identified by treatment models such as ACT unexplored. The 
systematic review in chapter 4 aimed to assess mechanisms of psychological treatment 
for IBS more broadly. However there were limited mediation studies conducted outside 
the context of CBT treatment. As such, it is difficult to make conclusions regarding 
other potential mechanisms of treatment effect, or key mechanisms that should be 
targeted in treatments going forward. More mechanistic studies are needed in the context 
of other treatment approaches in IBS. Ideally these should utilise robust methodologies 
as described in the guidelines developed in chapters three and four, to standardise 
assessment. These guidelines are in line with a recent Lancet Psychiatry commissioned 
report on psychological treatment development (Holmes et al, 2018)  
9.4.7 Terminology  
9.4.7.1 Terms to depict intervention ‘intensity’ 
In the ACTIB study, there were two treatment conditions. The main difference between 
conditions were the format of the intervention (web or paper manual) and the number 
and duration of sessions with a therapist over the phone (section 2.3.1). Both treatments 
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may therefore be categorised as ‘low intensity’ in the traditional sense of the word 
(Haaga, 2000; Bennett-Levy et al., 2010) as they consisted of a limited number of 
sessions, remotely accessed. However, a key distinguishing factor of the interventions 
provided in ACTIB, was that all of the therapists delivering treatment were highly 
experienced with a minimum of eight years treating long-term conditions with CBT. 
Rather than conceptualising treatments as high versus low intensity, it may be more 
appropriate to consider them in terms of ‘guided self-help’ or ‘guided self-management’. 
Such terms more accurately depict the treatments provided in the ACTIB trial.  
9.4.7.2 ‘Safety behaviour’ 
The term ‘safety behaviour’ was used in this thesis to refer to a particular type of 
behavioural response to IBS symptoms. The rationale for considering this subset of 
behavioural response as separate to avoidance behaviours, was that the BRQ had two 
subscales distinguishing between them (Reme at el, 2010). In the scale developed by 
Reme et al (2010) however, ‘safety behaviours’ were referred to as ‘control behaviours’ 
depicting behaviours in which individuals attempted to exert control over their 
symptoms. This included items such as excessive straining or the carrying of extra items 
in case of an accident. It may be that neither of the terms ‘safety’ or ‘control’ behaviour 
are appropriate. It has been suggested that particular actions that may get conceptualised 
as safety behaviours are in fact facilitative of positive adjustment/action and are not 
preventative of disconfirmatory experiences (Rachman, Radomsky, & Shafran, 2008; 
Rachman, Shafran, Radomsky, & Zysk, 2011). It is suggested that some of these 
behaviours may be adaptive rather than inhibiting. Reference to maladaptive behavioural 
responses to symptoms in IBS may instead be better referred to as ‘unhelpful illness 
related behaviour’. In the context of this thesis, this term has been used to identify both 
avoidance and control behaviours collectively. Terminology for ‘control’ behaviours 
specifically, could also be changed to ‘unhelpful illness related control behaviours’.  
9.4.8 The Role of Mediation Analyses in the Development of Treatments 
The utility of mediation analysis in informing the development of treatments has been 
discussed in chapter 3 and in relation to the findings for studies one and two. Such 
discussions have focussed on the importance of mediation analysis however, it is also 
important to contextualise it amongst the other important components of treatment 
development. It has been argued that treatment development research and processes, 
particularly within CBT, has focussed on treatment targets rather than procedures 
(Clark, 2004). For example focus has been on the therapeutic targets of change such as 
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unhelpful cognitions and behaviours, with less focus on the techniques (procedures) 
involved in changing these factors.  Teasing therapy targets apart from therapeutic 
procedures can be hard to conceptualise. Different methodology is used to assess the 
utility of each. Mediation analysis can be used to assess the efficacy of therapy targets. 
This is conducted more commonly than research investigating the efficacy of treatment 
procedures. Clark et al (2004) suggest that procedures may be tested using 
‘decomposition studies’. These include comparison of the efficacy of the ‘full treatment’ 
to the treatment minus a particular procedure. For example, the efficacy of CBT may be 
assessed in its full form and then compared to CBT minus exposure techniques.  
The procedures employed in psychological treatment are arguably key in ensuring the 
targets are effectively changed. As previously discussed, theoretical models can be used 
to identify treatment targets (chapter 3), however, there are additional key processes 
involved in treatment development. This is especially the case where treatment protocols 
are being adapted for different conditions. Key processes involved in treatment 
development include (1) conducting interviews with the target patient population to 
identify core factors to be changed and/or accounted for in treatment (2) formulation 
regarding why and how such factors occur, with consideration of relevant theory/ies (3) 
experimental studies assessing hypotheses formed in formulations (4) development of 
treatments, with procedures aiming to address the identified factors of importance (5) 
RCTs assessing the efficacy of such treatments (Clark, 2004; Holmes et al., 2018). 
Assessment of mechanisms using mediation analysis can occur at multiple points within 
this process to refine hypotheses and treatment design. 
9.5 Conclusions 
The studies in this thesis demonstrate the importance of cognitive and behavioural 
factors in irritable bowel syndrome. Both mediation studies suggest that it is important 
to target GI related cognitions and behaviours in psychological treatment for IBS. 
Cognitive and behavioural factors also appear to be important in the distinction between 
IBS bowel pattern subtypes. Treatment could be targeted to specific responses.   
9.6 Future Research and Implementation Directions 
Two future research directions relate to potential measurement issues arising in the 
present thesis. The BRQ and CS-FBD should be validated in the context of each IBS 
bowel pattern subtype. This would ensure that items relate equally across the different 
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symptom experiences (i.e. constipation, diarrhoea or alternation of them both). 
Furthermore, the relationship between GSA and general anxiety could be examined.  
Ideally the analysis in study two should be replicated in a larger sample. This would 
determine whether avoidance behaviour was a significant mediator in a study with 
sufficient power. In addition future mediation studies might include assessment of GSA, 
as indicated by study one. Another important aspect that future mediation studies may 
address is whether adding directionality to mediation models improves the fit of the 
models to the data. Alternative modelling would involve assessing parallel process 
mediation models, whereby the role of all mediators included in the models are assessed 
concurrently. Such analysis would indicate whether cognitive, behavioural and affective 
processes work in parallel to produce change in outcomes or whether change between 
mediators is sequential. Parallel mediation models can also identify where a variable 
identified as a significant mediator in a simple mediation model becomes insignificant 
when included in a multiple mediation model.  
With regards to subtypes in IBS, the next step would be to identify more multi-
dimensionally defined subgroups in IBS. Cluster analysis is a statistical method that can 
be used to achieve this. It involves using multiple measures as informed by theory and 
research to form ‘clusters’ (i.e. subgroups) that are characterised by the particular 
variables. Based on the existing evidence, recommendations and the studies included in 
the thesis, it would be important to include bowel pattern subtypes, measures of GI 
related cognitions, behaviours, psychological and somatic comorbidities. The 
identification of multidimensional subgroups could help to inform future developments 
of the Rome diagnostic criteria to enhance the provision of positive diagnoses (Spiegel, 
Farid, Esrailian, Talley, & Chang, 2010). 
Subgroups could also be included in moderation analysis to assess whether particular 
subgroups have different responses to particular treatments. There is scope for this 
analysis to be conducted in the context of data set 2.   
Finally, to combine insights gained from all of the studies conducted in the thesis, future 
research may use moderated mediation. This would involve assessing whether either 
bowel pattern subtype or more multidimensional subgroups in IBS, moderate the 
mediated effect of cognitions, behaviours and/or anxiety. All of the future suggestions 
for research would contribute to an empirical basis for personalising treatments and 
modifying treatment approaches. In terms of implementing insights from such research, 
frameworks such as intervention mapping (Bartholomew, Parcel, & Kok, 1998) and the 
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Medical Research Council guidelines for the development of complex interventions 
(Craig et al., 2008) can be used. These guide the process of identifying relevant aspects 
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ACTIB (Assessing Cognitive behavioural Therapy in Irritable Bowel): A randomised 
controlled trial of clinical and cost effectivensss of therapist delivered cognitive 
behavioural therapy and web-based self-management in irritable bowel syndrome 
 
Chief Investigator: Dr Hazel Everitt, Clinical Lecturer in General Practice, University 
of Southampton 
 
Please read this information carefully before deciding to take part in this project. If you 
are happy to participate please return the reply slip in the FREEPOST envelope that is 
enclosed with this letter. 
 
What is the project about? 
We are a group of researchers based at the Department of Primary Medical Care at the 
University of Southampton and the Institute of Psychiatry, at King’s College London 
undertaking studies into the management of Irritable Bowel Syndrome (IBS)  
 
Why have I been chosen? 
You have received this letter because you have consulted your GP in the last 12 months 
about IBS or you are currently seeing a consultant about your symptoms. 
 
Do I have to take part?  
Participation in the project is entirely voluntary.  It is up to you to decide whether to take 
part. You are able to withdraw at any time without giving a reason.  If you decide to 
withdraw or not to take part in this study this will not affect the standard of care you 
receive. 
 
What will happen to me if I take part? 
If you decide you would like to take part we would ask you to return the reply slip at the 
bottom of the attached letter to the study team. You can also email them directly or 
contact them by phone using the details at the end of this sheet.   
 
A member of the team will then go through some questions with you to make sure that 
you are suitable to take part in the study.  If you are eligible to take part you will then be 
asked to have a blood test to make sure you are not anaemic and that there are no signs 




The blood test is a straightforward, safe procedure but may cause some minor 
discomfort and you may notice some slight bruising which should subside in a couple of 
days.  The blood will sent for analysis to the Pathology Laboratory at Southampton 
General Hospital. 
 
As part of this study, you will continue to receive treatment as usual from your doctor as 
you normally do and can continue using any medication that you currently find helpful.  
However, you will also have the opportunity for additional treatment which has been 
shown to reduce IBS symptoms in previous studies.  You won’t be able to choose which 
treatment as a computer system will allocate you to one of three groups at random (see 
box diagram below for details).   People in group 1  will receive a manual about 
managing their IBS as well as six one hour sessions with cognitive behavioural therapist 
(CBT) over the telephone over a 9 week period with two one hour extra telephone 
sessions at 4 and 8 months to see how they are doing.  Sessions will be scheduled at 
times that suit you.  We will endeavour to use the same therapists for you throughout 
your participation in the trial. 
 
 
People in group 2 will have access to a self-management website for IBS consisting of 8 
on-line modules to complete in their own time on the internet over 9 weeks.  In addition, 
they will receive  
three half hour  support sessions with a CBT therapist over the telephone.  These will be 
followed up with two half hour booster telephone sessions at 4 and 8 months to see how 
people are doing.   
 
People in group three will initially just receive an extra information sheet about their 
conditions.  However at the end of the study they will be given access to the IBS self-



















Both the therapy manual and the self-management on-line programme are designed to 
help you manage your IBS and consists of 8 sessions or ‘modules’ to work through over 
a nine week period.   The website group (group 2) will do this largely on their own.  
Each module takes around 30-45 minutes to complete.  The therapy group ( group 1) 
will do this in conjunction with a therapist.   
 
Examples of the type of material covered in the modules are:  
 
Understanding your IBS symptoms 




6 x one hour CBT 
telephone sessions 
over 9 weeks 
+ 
2 x on  hour booster 
telephone sessions 
at 4 and 8 months 
+ 
Usual Treatment 




8 on-line modules 
to be completed via 
the internet over 9 
weeks 
+ 
3 x ½ hour CBT 
sessions 
+ 
2 x ½ hour booster 
telephone sessions 
















Access to the on-
line modules at the 
end of the study 
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Assessing your symptoms,  
Managing Symptoms and Eating, Exercise and Activity 
The role of thoughts and emotions in IBS  
Managing Stress and Sleep 
Managing Flare-ups and  
The Future.  
 
During your participation of the study we will ask you to fill in an on-line questionnaire 
at the start and 3, 6 and 12 months to assess your IBS symptoms and ask you about how 
you are feeling and how you believe your quality of life is.  
 
You will also be asked to keep a simple log of homework tasks to be completed. 
 
At the end of the study, we will also check your GP notes to see how many 
appointments you have had for your IBS in the 12 months before you came into the 
study and for the 12 months that you will be part of the study. 
 
We will also ask a small number of people who enter the study if they would like to take 
part in an interview which should last between 30 and 60 minutes about how it was 
taking part in the study and any useful feedback they can give us about the study.  You 
will have the option to agree to this or not and it is entirely up to you to decide. 
 
Are there any benefits in my taking part? 
Previous studies suggest that your IBS symptoms will be helped by the therapist or the 
self-management programme, however we cannot guarantee change in your symptoms. 
Your information will help us gain more knowledge regarding the website programme 
and the therapist treatment used in the trial, the cost of each and whether we should offer 
either of these routinely to people with IBS. 
 
Will my participation be confidential? 
All information that you provide will be strictly confidential. You will be identified by 
an ID number and the information you provide will be stored in locked filing cabinets or 
a password protected computer. The study will fully comply with the Data Protection 
Act and University policy on conducting research studies.  
Your GP will be informed that you are participating in the study, so that they are aware 
that you receiving additional support for your IBS. The self –management website is a 
secure website and any information you provide on the website is only accessible to you 
and select people in the research team.   
  
Who is organising the funding? 
The study is funded by the NHS as part of the National Institute of Health Research 
(NIHR) Health Technology Assessment (HTA) funding stream.   
 
Who is managing the study?  
The study is being sponsored by the University of Southampton who will monitor the 
study regularly to make sure that everything is being done as agreed at the start.  The 
Berkshire Research Ethics committee has reviewed the study and are happy for it to go 
ahead (Reference:  13/SC/0206). 
 
What happens if something goes wrong? 
If you have complaints about the way your illness was managed, this study will not 
affect your normal rights to pursue a complaint within the NHS in the normal way. 
 
If you were to have any concern or complaint about this project you can contact the head 
of Research Governance at the University of Southampton – Dr Martina Prude, 
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University of Southampton, Highfield Campus, Southampton, SO17 1BJ Telephone: 
023 8059 5058  
email: mad4@soton.ac.uk 
 
Where can I get more information? 
If you have any questions about this research after reading this information sheet please 
















<patient name and address>                                                                     
 
<insert date> 
          
 
ID <insert Study ID> 
 
 
Dear <insert patient name> 
 
ACTIB: Assessing Cognitive behavioural Therapy in Irritable Bowel 
 
We are writing to invite you to take part in a study that is being led by researchers at the 
King’s College London, University of Southampton and hosted by a number of different 
NHS trusts. You have been identified as a suitable participant for this study because you 
have consulted your GP or seen a consultant as you are suffering from IBS. Your 
participation in the study is purely voluntary and you may decide not to take part 
without affecting your care in any way.  
 
We have enclosed an information sheet outlining the study, telling you more about it and 
what you would be asked to do should you decide to take part.  This contains contact 
details if you require any further information. If you are interested in taking part, please 
complete page 2 of this letter and return it directly in the FREEPOST envelope enclosed.     
 
When we receive your reply a member of the research team will contact you to assess 
whether or not you would be eligible to take part. Please note that if you have had access 
to the MIBS (Managing IBS study) website you would not be eligible to participate in 
this study.  
 
If you do not want to participate or you are not eligible please complete page 3 of this 
letter and return it directly in the FREEPOST envelope enclosed.  














Practice Headed paper  
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ID <insert Study ID> 
 
If you wish to take part of our study please fill in the following sheet and send it back 
to us in the FREEPOST envelope. 
I would like to take part in the IBS study and am happy for a researcher to contact me to 
discuss the study further (please tick) 
 
Patient Details Not To Be Entered on MACRO 
 
My name is: ……………………………………………….. 
I am male /female (please circle) 
My date of birth is: ………………………………………… 





My contact telephone number is:  
Home ……………………..  
Mobile ……………………. 
 
My email address is……………………………………………… 
(Please ensure you complete a current email address as we may contact you by email) 
My GP is:   
GP Name………………………………………………………… 
GP Surgery Address……………………………….……..…… 











ID <insert Study ID> 
 
If you do not wish to take part of our study, please fill in the following sheet and send 
it back to us in the FREEPOST envelope. Your responses will help us in the planning 
and design of future research studies. We truly appreciate your time. Thank you.  
I do not wish to take part in this study because:   (tick all that apply) 
 
1. I have had previous access to the MIBS 
(managing IBS study) website and thus am not  
eligible for this study  
 
2. I was involved in the MIBS study, and do not wish to participate 
 
 
3. I do not have time in my daily schedule 
 
 
4. I do not wish to take part in the telephone Cognitive Behavioural  
Therapy  
 




6. My IBS symptoms have improved and I do not currently  
need additional help   
 
7. Any of the previous options do not apply to me  















Consent completed online 
ONLINE CONSENT FORM 
ACTIB (assessing Cognitive behavioural therapy in Irritable Bowel):   A randomized 
controlled trial of clinical and cost effectiveness of therapist delivered cognitive 
behavioural therapy and web-based self-management in irritable bowel syndrome 
 
Chief Investigator:  Dr Hazel Everitt 
Research team email address: actib@soton.ac.uk 
Research team telephone number: 023 80241066 
Patient ID: 
 
Please tick the box(es) if you agree with the statement(s):        
 
 
1.) I have read and understood the information sheet (dated ………………., 
version no. ………….) and have had the opportunity to ask questions about the study       
 
 
2.) I agree to take part in this research project and agree for my data to be used               
for the purpose of this study.                                                                                                         
 
 
3.) I understand that I may be contacted at a later date to take part in an interview  
about my experiences of being involved in the study.                                                              
 
 
4.) I understand that my GP notes will be accessed at the end of the study to gather data  
on GP consultations for IBS.                                                                                                           
 
 
5.) I confirm that I am aware that if I am randomised to the therapist or low intensity  
CBT trial arm that the telephone sessions will be audio recorded.                                         
 
 
6.) I understand that the data I provide may be monitored by a regulatory authority such  
as the University of Southampton or the NHS trust that is hosting the study.                     
 
 
7.) I understand my participation is voluntary and I may withdraw 
at any time without my legal rights being affected                                                                    
 
 
8.) I agree to my GP being told about my participation in the study.                                     
 
 





10.) I agree to have a blood test and for that sample to be analysed at the Pathology      
 





















IBS symptom severity score (IBS-SSS) Questionnaire
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Work and social adjustment scale (WSAS) questionnaire
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Illness Perception Questionnaire adapted for IBS (IPQ)
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Therapy protocols and structures 
































Post hoc power calculations for studies three and four 







Symptom severity 92.65 .13 .42 
Work and social adjustment 7.89 0 .05 
Anxiety 4.01 .08 .18 
Depression 3.47 0 .05 
GI related cognitions 29.02 .13 .43 
GI related avoidance behaviours 17.42 .29 .98* 
GI related safety behaviours 10.23 .32 .99* 
Study four 
Symptom severity 28.40 .08 .35 
Work and social adjustment 8.54 .05 .16 
Anxiety 4.07 .06 .19 
Depression 3.66 .07 .31 
GI related cognitions 33.39 .12 .67 
GI related avoidance behaviours 18.02 .19 .98* 
GI related control behaviours 10.63 .19 .99* 
*denotes sufficient power achieved to detect effect where power  ≥0.80. Effect size 
computed based on mean of each group, pooled standard deviation and number of 
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